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Publications
Davis, K.J., Richardson, C., Beck, J.L., Knowles, B.M., Guédin, A., Mergny, J-L.,
Willis, A.C., and Ralph, S.F., (2015) Synthesis and characterisation of nickel Schiff
base complexes containing the meso-1,2-diphenylethylenediamine moiety:
selective interactions with a tetramolecular DNA quadruplex, Dalton
Transactions, 44:3136-3150.
This manuscript describes the synthesis and characterisation of three
novel complexes, which are numbers (5), (6) and (13) in this PhD thesis, all of
which contain the meso-1,2-diphenylethylenediamine moiety. The interactions
of two of these complexes ((6) and (13)) with different types of DNA molecules,
as examined using ESI-MS, CD spectroscopy, UV thermal denaturation and FRET
melting studies, are also reported. The DNA molecules studied were the dsDNA
molecule D2, the tetramolecular qDNA molecule Q4(5G), and the unimolecular
qDNA molecules Q1 and F21T. This work is described in Chapters 3 and 5 of
this thesis.
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Abstract
A range of structurally diverse novel nickel Schiff base complexes were
synthesised, the synthetic procedures optimised and the resultant complexes
fully characterised by 1D and 2D nuclear magnetic resonance (NMR)
spectroscopy, and in some instances electrospray ionisation mass spectrometry
(ESI-MS) and X-ray crystallography. The binding of these complexes to both
duplex DNA (dsDNA) and several different quadruplex DNA (qDNA) structures
was then examined using a range of techniques, which included ESI-MS, circular
dichroism (CD) spectroscopy, UV-Vis thermal melting profiles, fluorescence
resonance energy transfer (FRET) melting and competition assays, and NMR
spectroscopy. The DNA-binding behaviour of these novel complexes was then
compared to that of some structurally related nickel Schiff base complexes
previously reported in the literature.
The literature complexes (2) and (12), which contain a 1,2phenylenediamine moiety, were found have a high affinity for both dsDNA and
qDNA. In contrast, the novel complexes (6) and (13), both of which differ from
(2) and (12) in having a meso-1,2-diphenylethylenediamine moiety instead of
1,2-phenylenediamine, were found to have little to no affinity for D2, yet were
able to bind to all forms of qDNA, especially the tetramolecular Q4(5G) and
Q4(4G). This result suggests that the presence of a non-planar ligand may
engender selectivity for qDNA over dsDNA upon this class of metal complexes.
The effect of aromatic surface area upon DNA binding affinity was also
examined.

It was found that the presence of a large, planar 9,10-

diaminophenanthrene unit in complex (4) improved affinity for dsDNA, but
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inhibited binding to several qDNA molecules. The positioning of additional
fused aromatic rings within the nickel complexes was also found to be very
important for DNA binding interactions. ESI-MS and CD studies involving the
two asymmetric complexes (15) and (16), both of which contained a single
naphthaldehyde moiety, exhibited little to no binding to dsDNA, as well as
limited binding to qDNA.

This result may also reflect the importance of

electrostatic interactions in the overall binding of this class of molecules to DNA.
This is due to the fact that (15) and (16) only contain one piperidine ring, and
therefore exist as monoprotonated species in aqueous solution, as opposed to
all the other complexes examined which would have been diprotonated under
the same conditions.
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CHAPTER 1 - GENERAL INTRODUCTION
1. 1 Clinical applications of DNA binding drugs
Nucleic acids, along with enzymes and other proteins, are the biological
targets for many chemical compounds which are used clinically to combat a
variety of maladies.1-2

For example, a large number of cancers, bacterial

infections and viruses are treated using drugs which interact in a non-covalent
manner with the above biomacromolecules, although some anticancer agents
exert their activity as a result of covalent binding.2 Many of these drugs exert
their curative effects through interfering with normal DNA synthesis and
replication. This may be a result of causing DNA strand breaks, other lesions, or
interactions with topoisomerases, which are enzymes involved in DNA
transcription and replication.1 In order to minimise the possibility of side
effects through non-specific interactions that affect healthy cells, it is desirable
to develop anticancer agents with the aim of targeting biochemical pathways or
over-expressed molecular targets which occur uniquely in cancer cells. Such
approaches will result not only in more effective treatments, but therapies that
cause less toxicity to the patient owing to non-specific drug/target interactions.2
A number of currently available drugs exert their therapeutic effects as a
result of acting as DNA intercalators. Such molecules contain planar, aromatic
rings which are able to intercalate between the base pairs in DNA (see section
1.3.1), causing a degree of unwinding of the double helix.1-2

These molecules

may also employ additional modes of binding to DNA. For example, many
intercalators

contain

positively

charged

1

groups

which

can

interact

electrostatically with the negatively charged phosphate backbone of DNA.
Examples of DNA intercalators include dactinomycin (also known as
actinomycin D), aminoacridines (including proflavine), bleomycins and
anthracyclines (such as daunorubicin and doxorubicin).1
One simple molecule which acts as an intercalator is the antibacterial
agent proflavine (Figure 1.1), which came into use during World War I as an
antiseptic.1,3-4 This molecule targets bacterial DNA by intercalating between the
base pairs, and forming stabilising interactions between its two primary
ammonium groups and the negatively charged sugar-phosphate backbone of the
nucleic acid.1,5 Incorporation of proflavine into DNA causes a small degree of
unwinding of the double helix, which in turn inhibits normal DNA replication
and transcription.1-2,5

Figure 1.1 – Structure of the antibacterial intercalator proflavine.

Dactinomycin (Figure 1.2) is one member of a family of effective
antibiotics isolated from Streptomyces parvullis, but which has also found
success as an anticancer agent.1,6-7

Dactinomycin is able to intercalate its

aromatic moiety into DNA via the minor groove, and also participates in a
number of stabilising hydrogen bonding interactions via its two cyclic peptide
moieties, which sit externally to the double helix.1-2,6,8-10 The resultant effect is
that mRNA synthesis is inhibited.9,11-12 Dactinomycin is administered intra-

2

venously, and has proven successful against Wilm’s and Ewing’s tumours, which
are both forms of paediatric cancer.1,13-14

Figure 1.2 – Structure of the anticancer agent and naturally occurring antibiotic
dactinomycin, also known as actinomycin D.

The bleomycins (Figure 1.3) are a group of natural products isolated
from Streptomyces verticillus which have proven effective as anticancer agents,
and which use multiple modes of binding to interact with their biological target,
DNA.1-2,15-16 Upon first glance, the structures of the bleomycins may not seem
conducive to an intercalative binding mode, given the most suitable moiety for
such an interaction, namely the bithiazole group, is surrounded by aliphatic
chains. However, both nuclear magnetic resonance (NMR) spectroscopy and Xray crystallography have provided evidence that this unit is able to intercalate,
and that other components of the structure of the bleomycins, namely the
metal-binding domain and the disaccharide moiety, participate in groove
binding interactions with residues in the DNA minor groove.17 The anticancer
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activity of the bleomycins is attributable to their ability to cause single- and
double-stranded DNA breaks, via a series of reactions that involve binding of the
drug to Fe2+, and depend on the presence of O2.1,16-17

Figure 1.3 – Structure of the bleomycins, which are natural products used as
anticancer agents. Bleomycin A2: R = NHCH2CH2CH2SMe2; Bleomycin B2: R =
NHCH2CH2CH2CH2NHC(NH2)=NH. The intercalating region of the molecule is
highlighted in a box.

The two bleomycins are administered in the clinic either intramuscularly
or intravenously, usually as part of a combination chemotherapy regimen, and
are active against some skin cancers, lymphomas, testicular carcinoma and head
and neck tumours.1,15,18 However, treatment with the bleomycins leads to many
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side effects, including accumulation in the skin, damage to mucous membranes
and pulmonary fibrosis.16
Anthracyclines are a group of antibiotics which include the highly
effective anticancer agent doxorubicin and the structurally similar daunorubicin
(Figure 1.4). Daunorubicin was the first of these discovered, being isolated in
1964 from Streptomyces peucetius.19

The isolation of doxorubicin from S.

caesius var. was reported in 1969.20 These compounds are able, unsurprisingly,
to act as intercalators, owing to their extended, planar aromatic moieties, and
presence of a positive charge.1-2,21-22 Their mode of action involves stabilisation
of the DNA-topoisomerase II complex, which leads to inhibition of DNA
replication.21,23 For this reason, although the molecules intercalate with DNA
rather than interacting directly with the enzyme, they are known as
topoisomerase poisons.1,22,24 Doxorubicin is effective against a range of solid
tumours, acute leukaemias, lymphomas and paediatric tumours, whilst
daunorubicin is useful for treatment of acute leukaemias.1,21-22,25-26 Treatment
with both drugs is linked to a range of cardiovascular side effects.21-22,26

Figure 1.4 – Structures of the anthracyclines doxorubicin (left) and
daunorubicin (right).
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Ethidium bromide (EtBr, Figure 1.5) is a widely-used intercalating
molecule, especially in the research laboratory, where it is used as a stain for
detecting nucleic acids in gel electrophoresis experiments.27-29 Similar to the
intercalators described above, EtBr possesses an extended, planar aromatic
moiety as well as a positive charge, which facilitate its interactions with the base
pairs of DNA and phosphodiester backbone.30-34 This interaction results in an
intense orange fluorescence, which allows bands in a gel containing DNA to be
detected.28 The binding of EtBr to DNA inhibits DNA synthesis.30,33,35 There
have been a number of studies into the degree of unwinding induced in the
double helix upon EtBr intercalation. One early study reported an unwinding
angle of 17° for intercalation of a single EtBr molecule;36 however, most studies
report this angle to be between 26° and 29°.27,31-32,37

Figure 1.5 – Structure of the DNA intercalating agent ethidium bromide (EtBr).

The molecules used as examples here are only a small selection of those
which have been investigated and proven to be effective anticancer agents as a
result of their ability to interact with DNA.38-42 Over the last few decades there
has been much interest in designing new drugs that may be added to or replace
those currently used for anticancer therapy. Many different types of chemical
6

compounds have been investigated, ranging from both aliphatic and aromatic
organic compounds through to mono-, di- or even trinuclear metal complexes
coordinated to a wide variety of different types of ligands. Despite the inherent
structural differences between these classes of compounds, a common theme in
these studies has been discovering how the organic compounds or metal
complexes interact with DNA, and how this affects cancer cells.

1. 2 Nucleic acids
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are large
biological macromolecules which carry the genetic information in all
organisms.28,43 These molecules consist of a sequence of nucleotides connected
via phosphodiester linkages, and are involved in specific binding interactions
with a myriad of different proteins.28,38,43-47

Each nucleotide in DNA is

comprised of the sugar deoxyribose, a phosphate group, and a purine or
pyrimidine base.

There are a total of four different bases present in the

nucleotides which make up the structure of DNA. These are the two purines,
adenine and guanine, and the two pyrimidines, cytosine and thymine.1,28,46-47 It
is the sequence of the four different nucleotides along the DNA chain which
encodes the genetic information for an organism.28 In double-stranded DNA
(dsDNA) two polynucleotide chains are wound around each other to form a
double helical secondary structure, with the two strands running in the opposite
direction to one another.43 The two strands are held together by specific
hydrogen bonding interactions between the bases. Two hydrogen bonds occur
between adenine and thymine residues on opposite DNA strands, whilst
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guanine and cytosine are held together by three hydrogen bonds (Figure
1.6).28,43 These bonding interactions help to stabilise the DNA double helix.

Figure 1.6 – Watson-Crick hydrogen bonding interactions for the four bases
found in DNA.

When a cell divides to form two new cells, the DNA content must be
duplicated. This first involves separating the two DNA strands, after which new,
complementary DNA chains are synthesised using the ‘leading’ or ‘lagging’
strands as a template (Figure 1.7). This ultimately results in two new DNA
double helices being created, and preservation of genetic information coded
therein.43
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Figure 1.7 – Schematic overview of DNA strand separation and replication,
leading to the formation of two identical DNA double helices. Adapted from
various references.1,28

The structure of DNA was first elucidated in April 1953 by Watson and
Crick.48 Their structure incorporated specific interactions between purine and
pyrimidine bases, with adenine hydrogen-bonded only to thymine, and guanine
to cytosine. One of the most remarkable aspects of Watson and Crick’s structure
was that it enabled them to propose a plausible scheme for copying of cellular
genetic material.
There were also a number of other important publications in 1953
concerning the structure of DNA.49 In the same April issue of the journal Nature
in which Watson and Crick published their findings, Wilkins, Stokes and Wilson

9

published X-ray diffraction data for nucleic acids, which suggested the existence
of helical structures in biological systems.50 In addition, a paper by Franklin and
Gosling also appeared in which X-ray diffraction was used to demonstrate that
the phosphate backbone of DNA lay on the outside of the structure.51 Just over a
month after their initial publication, Watson and Crick appeared in press again,
this time expanding upon their initial predictions concerning the role of the
base pairs in DNA replication.52 A further two months later in July 1953,
Franklin and Gosling outlined the differences between A and B-form DNA.53
Much of what was put forward in these early publications is still held to be
correct today, and indeed the DNA structure proposed by Watson and Crick has
come to be known by their names.28 Of course, the advent of more advanced
techniques of structure determination over the years has enabled our
understanding of DNA structure to be expanded upon. Today the sequence of
specific genes can be readily determined, and more is known about the role of
proteins in DNA replication and transcription.43 There are several other types
of DNA secondary structure besides the Watson-Crick double helix, all of which
have their own unique and important roles. The most common and stable form
of DNA is the Watson-Crick double helix, which is a right-handed structure, also
called B-DNA.43 In addition, there is A-DNA, which is also a right-handed double
helical structure found to occur in solutions with lower water content, but
which is shorter and wider than B-DNA. In contrast, Z-DNA has a left-handed
double

helical

structure,

and

forms

transformations such as transcription.28,43-44
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during

certain

DNA

structural

1. 3 Duplex DNA drug binding by metal complexes
The importance of nucleic acids, and in particular DNA, as a target for
drug design has been a growing area of research for many years.45 An ideal
DNA-binding drug would be one that binds with high affinity and selectivity to a
specific DNA sequence or structure associated with aberrant DNA replication
and/or transcription.54-56 A wide range of metal complexes that bind to DNA and
interfere with the above biological processes have been investigated. These can
be divided into two main groups: those which bind covalently to DNA, and those
which bind non-covalently. Metal complexes that bind covalently to DNA often
show a preference for interacting with specific sites on a polynucleotide chain,
and do so usually in an irreversible manner.45,57 One of the best known groups
of therapeutic agents that exert their biological activity by binding covalently to
DNA are the platinum complexes illustrated in Figure 1.8. The first of these to
enter clinical use was cis-diamminedichloroplatinum(II), or cisplatin, in 1971.
The platinum complexes in Figure 1.8 are highly effective anticancer agents
chiefly against testicular cancer, but are also used to treat ovarian, lung, bladder,
cervical, colon, head and neck tumours.54-55,58-61 A feature of these platinum
complexes is that they are pro-drugs, which upon entering the cell are
converted into more reactive species that then interact with proteins and
nucleic acids. These interactions often involve binding to specific amino acid
residues or nucleotides.45,55,57-58,62
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JM216

Figure 1.8 - Structures of some platinum anticancer agents.

In contrast, metal complexes that interact non-covalently with
biomacromolecules generally contain only multidentate ligands, preventing
reactions with solvent molecules which lead to more reactive metabolites.45
The strength of non-covalent interactions between metal complexes and nucleic
acids, for example, can vary significantly depending on the nature of the
binding.45,56

However, these invariably consist of reversible binding

interactions.

There is considerable interest in designing and making non-

covalent binding metallodrugs that are sequence or site selective DNA
binders.56,63

This is because metal complexes or organic compounds that

interact with DNA at different locations are more likely to produce different
biological activities, regardless of whether they bind predominantly by a
covalent or non-covalent mechanism. In order to achieve this goal it is essential
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to understand the different ways a metal complex can interact non-covalently
with nucleic acids, and in particular with DNA.

1.3.1 Non-covalent DNA binding
Non-covalent binding of metal complexes to DNA has been shown to
occur by a variety of methods.57 Electrostatic interaction is the simplest of these
and involves, for example, the Coulombic attraction of a positively charged
metal complex to the negatively charged sugar-phosphate backbone of
DNA.38,45-46,56 Minor groove binding is the term used to describe the situation
where a metal complex (or an organic molecule) binds via a combination of
electrostatic, dipole-dipole, hydrogen bonding and hydrophobic interactions, to
functional groups present in the DNA minor groove. The ability of a metal
complex to participate in minor groove binding is dictated by the degree of
structural complementarity between the two binding partners.38-39,56 Metal
complexes may also bind to the major groove of DNA, with the size and shape of
the molecule usually being a defining factor in terms of determining its
preferred site of interaction.45-46
Another binding mode that metal complexes can use to non-covalently
interact with DNA is intercalation, which occurs when a planar aromatic ligand
is inserted between and parallel to the base pairs of DNA.38-39,45,54,56

In this

case, the DNA is stabilised through the overlapping interactions of the π
electron clouds of the DNA bases and those of the aromatic ligand. Further
stabilisation may also result from electrostatic interactions between the
intercalator, which is often positively charged, and the negatively charged
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sugar-phosphate backbone.45-46 As a result of the intercalator being inserted
between the base pairs, the DNA helix unwinds slightly and lengthens in order
to accommodate the intrusion.38-39,64 However, there is a limit to how much the
structure of DNA can alter to accommodate intercalation of other molecules.
This results in a maximum of one intercalating molecule being able to interact
with every two base pairs, an observation which is called the neighbour group
exclusion principle.45-46,56 There are many examples of intercalators, including
small organic molecules, larger naturally occurring natural products, and metal
complexes.38,45,56,63,65 The changes in DNA structure resulting from interactions
with small molecules via binding modes such as intercalation can cause
inhibition of DNA transcription or replication, giving rise to interest in these
molecules as potential anticancer agents.
Metallointercalators are metal complexes coordinated to at least one
planar, aromatic ligand, capable of being inserted into the DNA base stack, and
have been intensely investigated for a variety of potential applications.45,56,63,65
In particular, a significant amount of work has been carried out into the DNA
binding chemistry of metallointercalators containing platinum, ruthenium,
rhodium and other transition metals.54,65-68 Metallointercalators have also been
shown by techniques such as synchrotron radiation X-ray fluorescence (SRXRF)
to localise within DNA-rich regions of cells, strongly suggesting that they are
capable of interacting directly with DNA in vivo.69-71
One of the first studies into metallointercalators was carried out by
Lippard and coworkers, who showed that platinum terpyridine complexes such
as those shown in Figure 1.9 (a) exhibited a degree of binding specificity
towards GC-rich DNA sequences.72-75 The preference of platinum(II) complexes
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for a square planar geometry was stated to be a factor which facilitated
insertion of one of the aromatic rings into the DNA base stack.

(a)

(b)

Figure 1.9 - Metallointercalators investigated by: (a) Lippard and coworkers;72-75
and (b) Barton and coworkers.63

Later research into metallointercalators focussed on octahedral
complexes of ruthenium containing extended aromatic ligands such as
dipyrido[3,2-a:2',3'-c]phenazine (dppz), and 9,10-phenanthrenequinonediimine
(phi). Complexes such as [Ru(phen)2(dppz)]2+ (Figure 1.9 (b)) which contain
the dppz ligand were found to fluoresce in aqueous solution only in the
prescence of duplex DNA, an observation referred to as the “light switch”
effect.76-79 Figure 1.10 illustrates the results of an X-ray structure determination
of the complex formed between ∆-α-[Rh[(R,R)-Me2trien](phi)]3+ and a dsDNA
molecule.56 The structure obtained clearly shows the phi ligand being inserted
between the bases of the double helix.
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Figure 1.10 – Crystal structure of ∆-α-[Rh[(R,R)-Me2trien](phi)]3+ bound to
dsDNA.56

1. 4 Quadruplex DNA
Naturally, the design of new anticancer drugs should include some
consideration as to how to make them interact selectively with their biological
target.80 If the target is a unique feature of a cancer cell then there is greater
likelihood of successfully producing a new drug that produces fewer side-effects
due to interaction with non-target molecules.81-82 It is partially for this reason
that during the last two decades there has been a surge in the number of studies
into the interactions between drug molecules and quadruplex DNA.83 First
described in 1962,84 quadruplex DNA, or qDNA, is formed when DNA strands
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fold to form inter- or intramolecular structures known as G-tetrads or Gquartets (Figure 1.11).83,85-87 A G-tetrad occurs when four guanine residues
arrange themselves in a planar arrangement so that they are able to bond to
each other through Hoogsteen hydrogen bonds.81-83,85-93 In quadruplex DNA
structures, three or more G-tetrads stack upon each other in such a way that the
resulting arrangement is stabilised through π-π stacking interactions involving
the guanine residues. Further stabilising interactions occur between small
metal cations (usually sodium or potassium) located between the G-tetrads and
the carbonyl oxygen atoms of the guanines.82,86,88,93-94 Changing the identity of
the metal cation can significantly affect the final secondary structure of the
quadruplex molecule.86,88,92,95

Figure 1.11 - Structure of a G-tetrad.

QDNA structures are believed to form in the 3′ single-stranded overhang
region present in chromosomes, which are known as telomeres. For humans,
telomeric DNA consists of tandem repeats of the sequence d(TTAGGG).81-83,92,96
Telomeres are non protein-encoding regions which function to protect the ends
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of chromosomes during DNA replication.47,80-81,83,86,88,90,97-99 This function is
required because DNA is gradually lost from the ends of chromosomes as a
result of an inherent problem associated with the DNA replication process as
the replication machinery approaches the ends of linear chromosomes (the “end
replication problem”).81,83 Without telomeres this would quickly lead to the loss
of essential information for the production of proteins that is coded within the
sequence of DNA bases.89,100-102 Once telomeric DNA has shortened to an extent
where it can no longer perform its function, the cell will undergo a sequence of
events leading to apoptosis, or programmed cell death.81-83,86,91,100-101,103-105 It is
for this reason that the progressive loss of telomeric DNA has been linked to the
aging process.96,106 Recently, some of the most convincing evidence for the
presence of quadruplex DNA in chromosomes was obtained using a
fluorescence staining technique which revealed these structures were at their
most prevalent during the DNA replication phase.99
Interest in quadruplex DNA as a drug target stems from a study which
showed that in approximately 85% of cases, the level of the enzyme telomerase
present in cancer cells was elevated compared to normal cells.107

This

heightened activity of telomerase effectively contributes to the immortalisation
of cancer cells, as the length of their telomeric DNA is maintained by the activity
of the enzyme, and so will never become short enough to trigger apoptosis.8182,86,88-89,97

It is also worth noting that the remaining 10-15% of cancer cells

which do not exhibit elevated levels of telomerase use an alternative method of
maintaining telomere length, known as the ALT (alternative lengthening of
telomeres) mechanism.108-109
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The natural substrate for telomerase is the single-stranded overhang
region found at the end of telomeres. These regions are rich in sequences
containing strings of successive guanine residues, which makes them prime
candidates for formation of quadruplex DNA structures. It has been shown that
DNA sequences which have formed DNA quadruplex structures do not function
as effectively as substrates for telomerase.103,110

Therefore, it has been

hypothesised that small molecules which can either stabilise existing DNA
quadruplexes, or induce their formation, may have the ability to inhibit
telomerase, thereby potentially rendering cancer cells more susceptible to
treatment with other chemotherapeutic agents.

The design of new qDNA-

targeting agents must take into account the fact that DNA quadruplexes, at least
in vitro, occur in a multitude of different conformations (Figure 1.12).83
To begin with, quadruplex DNA structures can be formed from one, two
or four polynucleotide strands.86,88,91,94-95,111-113 Typically, tetramolecular DNA
quadruplexes are formed from four parallel strands (Figure 1.12 (a)), although
other structures exist in principle, in which one or more strands become
antiparallel.

In addition to this, when a bimolecular (intermolecular)

quadruplex is formed via alignment of two hairpin structures, two loop regions
are formed which can orient themselves in different ways to give alternative
conformations.90,113 One of these conformations is where the loops connect
adjacent strands to create a parallel conformation (Figure 1.12 (b)), while
others occur when the oligonucleotide chains are antiparallel with either lateral
loops (Figure 1.12 (c)) or diagonal loops (Figure 1.12 (d)). There is also a
diversity of ways in which one strand can fold to create a unimolecular
(intramolecular)

DNA

quadruplex.47,113-114
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These

include

antiparallel

conformations with lateral loops (Figure 1.12 (e)) or a mixture of lateral and
diagonal loops (Figure 1.12 (f)), or a parallel conformation with loops external
to the quadruplex (Figure 1.12 (g)).

(a)

(c)

(b)

(e)

(f)

(d)

(g)

Figure 1.12 – Schematic illustration of different quadruplex DNA conformations:
(a) tetramolecular parallel; (b) bimolecular parallel with external loops; (c)
bimolecular antiparallel with lateral loops; (d) bimolecular antiparallel with
diagonal loops; (e) unimolecular antiparallel with lateral loops; (f) unimolecular
antiparallel with a mix of lateral and diagonal loops; and (g) unimolecular
parallel with external loops. Arrows refer to strand orientation; rectangles
represent guanosine. Adapted from various references.2,115-117

Tetramolecular quadruplexes can arise from the alignment of relatively
short pieces of DNA (e.g. 6-8 nucleotides) containing only one sequence of 3 or 4
consecutive guanine bases.92-93,118 Such qDNA structures are usually parallel
with a slight helical twist, and the bases in an anti conformation.93-94 One
20

example of such a molecule is the tetramolecular structure shown in Figure
1.13, which is formed from the telomeric sequence d(TTGGGGT) found in
Tetrahymena, a single-celled eukaryote often used as a model organism in
experimental biology.119-120 Tetramolecular quadruplexes are also very stable,
with melting temperature (Tm) values usually close to 100 °C.93-94 Some DNA
molecules containing longer sequences of guanines do not form parallel
tetramolecular structures, but rather form a variety of quadruplex structures
where, depending on the length of the G-tract, a traditional unimolecular
quadruplex may be formed, as well as dimers or even trimers.121 When this
happens, the guanines can form part of the loops of the folded DNA molecule,
rather than only thymine or adenine bases. Tetramolecular qDNA molecules are
often used in laboratory investigations owing to their stability, not only with
respect to melting but also interconversion into other types of qDNA
structures.93,122

Figure 1.13 – NMR structure of a parallel tetramolecular quadruplex formed
from the telomeric sequence d(TTGGGGT) found in Tetrahymena.119

21

1. 5 Design of qDNA binding compounds
Many research groups are investigating the ability of organic compounds
or metal complexes, which are collectively often referred to as ligands, to bind
selectively to and stabilise quadruplex DNA structures. This has now resulted in
sufficient data to enable some general structure/activity principles to be
developed.

Typically, an effective qDNA binding ligand possesses a large

aromatic surface area to facilitate π-π stacking interactions between itself and
the G-tetrads. Such interactions are commonplace for molecules that intercalate
between base pairs in dsDNA. An important difference with most qDNA-binding
molecules examined to date, is that they do not act as true intercalators, but
instead stack on the terminal tetrad of a qDNA structure.47,81,83,88,95,123 This
binding mode has been revealed by both NMR spectroscopy and X-ray
techniques, with an example shown in Figure 1.14.124-130 The presence of a
positive charge in an organic compound or metal complex also facilitates
binding to qDNA structures by enabling electrostatic interactions with polar or
charged groups on the DNA.113,123,131-132 For instance, many metal complexes
containing planar aromatic ligands have been shown to be useful qDNA binders,
as a result of possessing both of the above characteristics. In addition, it has
been shown that molecules bearing suitable substituents on their periphery
may also have these groups bind in the grooves of qDNA, or interact with the
loops at their ends.81,86,93,95,113,122,131-133
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(a)

(b)

Figure 1.14 – NMR structure of the ligand TMPyP4 interacting via end-stacking
with a quadruplex DNA molecule:130 (a) side view; (b) top view; and (c)
TMPyP4.

1.5.1 Organic compounds
The first investigation into the binding of an organic compound to qDNA
appeared in 1997, and centred on the derivatised 2,6-diaminoanthraquinone
shown in Figure 1.15 (a).134

This compound was shown through thermal

denaturation studies to stabilise a qDNA molecule d(TTAGGGTTT)4, derived
from the human telomeric sequence, and to inhibit the activity of telomerase.
Since this original study, there have been many more organic compounds found
to stabilise quadruplex DNA structures, inhibit telomerase, or do both. 80-
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81,83,86,132

The range of compounds shown to exhibit these abilities also includes

derivatives of distamycin A (Figure 1.15 (b)),132,135-139 cationic porphyrins such
as TMPyP4 (Figure 1.14 (c)) and natural occurring macrocycles such as
telomestatin (Figure 1.15 (c)).83,92,103,113,135,140-144

Figure 1.15 – Structures of some organic qDNA binding molecules: (a) a
derivatised 2,6-diaminoanthraquinone;134 (b) distamycin A; and (c)
telomestatin.

Telomestatin is a natural product isolated from Streptomyces anulatus,144
which has been shown to selectively bind to qDNA using gel mobility assays and
molecular docking studies.125 In contrast, the substituted porphyrin TMPyP4
(Figure 1.14 (c)) has a high affinity for a range of quadruplex structures, but
unlike telomestatin is not selective and binds to dsDNA.143,145-146 Telomestatin
has also been found to selectively inhibit telomerase in a modified telomerase
repeat amplification protocol (TRAP) assay, but not DNA polymerases,144 and is
effective against several leukaemic cells lines.147
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1.5.2 Metal complexes
Metal complexes have long been investigated for their ability to bind to
dsDNA, but more recently are also being investigated for their ability to bind to
qDNA.82-83,87,132,148 There has been a wide range of different types of metal
complexes which have been explored, including complexes of porphyrin ligands,
mono- and dinuclear complexes of platinum(II), palladium(II), ruthenium(II)
and nickel(II), as well as supramolecular and hybrid structures.82-83,87,113,132
This is not an exhaustive list, as the study of metal complexes that bind to qDNA
is an area of burgeoning interest.
It has become apparent that there is one important difference between
the binding modes used by metal complexes to interact with qDNA and dsDNA.
In the case of qDNA, the metal complex often stacks onto the ends of the
structure, rather than inserting itself between the base pairs. The latter binding
mode is commonly encountered when metal complexes intercalate into
dsDNA.88-89,123 The end-stacking mode of interaction found in many instances
with qDNA results in the metal atom being positioned so that it is in line with
the stabilising K+ or Na+ atoms usually found in the central channel of qDNA
structures.149 Complexes of metal ions such as Ni(II) or Pt(II) have proven to be
particularly useful for binding to qDNA, as they almost exclusively have a square
planar geometry. This ensures that any aromatic ligands bound to the metal ion
are positioned favourably for participating in π-stacking interactions with a Gtetrad.83

In contrast, if a metal complex has a geometry such as trigonal

bipyramidal

or

octahedral,

then

for

disfavoured.150
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steric

reasons

end-stacking

is

A Web of Science literature search for the terms “Quadruplex” and “Metal
Complex” yielded 73 publications between 1998 and 2014, with 68 of these
appearing from 2007 onwards (Figure 1.16). One of the earliest publications
was a 1998 patent that outlined the use of metal complexes of porphyrin ligands
as telomerase inhibitors.151 The complexes were described as being very low in
toxicity, and capable of interacting with telomeric DNA.

In 2001

Tuntiwechapikul and Salazar published their findings on the interaction of
Fe(II)-EDTA complexes with qDNA, which included the ability of such
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complexes to specifically cleave these nucleic acid structures.152
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Figure 1.16 – Yearly publication rates for journal articles focussed on
interactions between quadruplex DNA and metal complexes (Web of Science).

Many other metal complexes whose interactions with qDNA have been
investigated

have

structures

resembling

those

of

traditional

dsDNA

intercalators. For instance, Pierce et al. showed that square planar platinum
complexes containing an extended aromatic ligand (Figure 1.17) were able to
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end-stack onto quaduplex DNA regions, and demonstrated overall better
binding than octahedral ruthenium complexes containing similar ligands.153 As
a result of this preferred end-stacking mode of interaction, they also found that
the conformation of the quadruplex affected the ability of the metal complex to
bind. This suggests that metal complexes with structures different to those
shown in Figure 1.17 might be required in order to facilitate strong bonding
interactions with some types of qDNA structures.

Figure 1.17 – Structures of some square planar platinum(II) complexes shown
to end stack onto qDNA.153

Bonbard and co-workers also suggested that the structure of a metal
complex could affect its preference for certain qDNA topologies.154-156 These
workers investigated the platinum complex shown in Figure 1.18, which
features an intercalating, quinacridine moiety connected to the platinum unit by
a flexible linker. Another noteworthy feature of this complex was that the
platinum had a chlorido ligand, which means the complex could undergo
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hydrolysis reactions, thereby facilitating covalent bond formation between the
metal ion and DNA. It was shown that the complex exhibited a preference for
qDNA structures with antiparallel conformations. This was believed to be due
to platination of guanine, which caused the Hoogsteen hydrogen bonding
network to be disrupted, something that is particularly favourable in
antiparallel qDNA structures.154 An additional means by which a metal complex
could selectively bind to certain qDNA structures has been shown to occur with
chiral nickel and iron complexes.157 The chirality of these complexes resulted in
selective stabilisation of an antiparallel human telomeric (Htelo) DNA sequence,
which in the presence of increased levels of sodium ions converted into a hybrid
structure containing both parallel and antiparallel sets of strands.

Figure 1.18 – Structure of a platinum(II) quinacridine complex shown to prefer
binding to antiparallel qDNA structures.154

It has also been shown that the presence of cyclic amine substituents on
the periphery of the ligands of a metal complex may affect its selectivity for
particular qDNA sequences.90,113,123,135 This is because of the variation in loops
and other structural features between different qDNA structures, which affords
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a range of opportunities for selective molecular interactions.103,112,158

For

example, Vilar and coworkers investigated the qDNA binding abilities of a range
of platinum(II)-terpyridine complexes, where the terpyridine ligand was
functionalised with cyclic amines (Figure 1.19).159

The substituents were

chosen to enable the complexes to participate in a variety of interactions with
the loops and grooves of the quadruplex DNA. Furthermore, it was anticipated
that the cyclic amine substituents would be protonated at pH ~ 7, thereby
increasing the water solubility of the complexes. The Vilar research group had
previously investigated the qDNA binding ability of platinum complexes
containing phenanthroline ligands bearing various substituents.160

These

complexes also showed selectivity for qDNA molecules over dsDNA.

Figure 1.19 – Platinum complexes designed to interact selectively with the loops
and grooves of qDNA structures .159

Over the past several decades a great deal of attention has been devoted
to the exploration of the dsDNA binding properties of octahedral ruthenium
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complexes containing polypyridyl ligands.45,63 Many of these complexes had the
general formula [Ru(La)2(Lb)]2+, where La is either 1,10-phenanthroline (phen)
or 2,2′-bipyridine (bpy), and Lb is an additional bidentate ligand such as dppz,
which features an extended aromatic moiety designed to enhance the
intercalative properties of the molecule. As the larger intercalative aromatic
ligands may, to some extent, also be expected to confer on metal complexes the
ability to bind to qDNA structures, it is not surprising that some reports have
appeared which have investigated this possibility.161-162

A wide range of

techniques has been used to investigate the interactions between these
complexes and qDNA, including circular dichroism spectroscopy (CD),79,163-168
fluorescence resonance energy transfer (FRET) melting and competition
assays,163,166-168 polymerase chain reaction (PCR) stop assays,163,166-167
fluorescent intercalator displacement (FID) assays,164-165 molecular docking
studies,79,164-165,168 UV-visible absorption and fluorescence spectroscopy,79,165-168
telomerase repeat amplification protocol (TRAP) assays163,167 and NMR
spectroscopy.168
The ruthenium complex

[Ru(phen)2(ptpn)]2+ (ptpn

= (3-(1,10-

phenanthroline-2-yl)-as-triazino[5,6-f]1,10-phenanthroline), Figure 1.20), along
with the corresponding analogue containing bpy ligands instead of phen, were
shown to stabilise the Htelo quadruplex. The results of TRAP assays indicated
both complexes were also potential telomerase inhibitors.163 Investigations
involving related

ruthenium complexes

containing bppp

((12-bromo-

pyrido[2′,3′:5,6]pyrazino[2,3-f]1,10-phenanthroline)) or pppp ((12-phenylpyrido[2′,3′:5,6]pyrazino[2,3-f]1,10-phenanthroline)) showed they were both
capable of stabilising qDNA, but exhibited different binding affinities depending
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on the secondary structure of the quadruplex.164-165 For example, whilst both
metal complexes bound a mixed hybrid qDNA molecule with greater affinity
than qDNA with an antiparallel basket conformation, [Ru(phen)2(pppp)]2+
displayed the greater overall binding affinity.165 This complex was also found to
induce a change in conformation from parallel to antiparallel in Htelo qDNA.164

Figure 1.20 – Structures of ruthenium polypyridyl complexes [Ru(phen)2(L)]2+,
used in recent qDNA binding investigations.79,163-167
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There is a long history of investigations into the enantioselectivity of
binding interactions between chiral ruthenium complexes containing three
bidentate ligands and dsDNA.76,169-170 Therefore it is not surprising that similar
studies have been conducted using complexes of this type and qDNA. In one
investigation, the binding of the ∆- and Λ- isomers of [Ru(phen)2(p-HPIP)]2+ (pHPIP = (2-(4-hydroxyphenyl)imidazo[4,5-f]1,10-phenanthroline), Figure 1.20)
to qDNA was investigated.166 Both enantiomers exhibited binding to telomeric
qDNA and antitumour activity against HepG2 cells. However, the Λ isomer
showed a higher level of telomerase inhibition, as well as greater cellular uptake
compared to the ∆ enantiomer.
The qDNA binding ability of [Ru(phen)2(4idip)]2+ (4idip =
thiophenimidazo[4,5-f]1,10-phenanthroline,

Figure

1.20)

as

well

4as

[Ru(bpy)2(4idip)]2+ were examined by Yu and co-workers.167 They found that
both complexes could bind to and stabilise qDNA structures as well as inhibit
telomerase.

However, the phen isomer displayed greater overall binding

affinity and selectivity for qDNA over dsDNA. In view of these results, it is
perhaps not surprising that the qDNA binding properties of closely related
complexes such as [Ru(phen)2(tip)]2+ (tip = 4-indoleimidazo[4,5-f]1,10phenanthroline) have also been studied. This complex was found to display
greater binding affinity towards a human telomeric qDNA than the
corresponding complex containing bpy ligands.168
A potential use of ruthenium polypyridyl complexes may be as sensors
for detecting changes in qDNA structure.79 For example, the fluorescence of
[Ru(phen)2(dppz-idzo)]2+

(dppz-idzo

=

dipyrido[3,2-a:2′,3′-c]phenazine-

imidazole) was found to change significantly when the proportion of
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antiparallel qDNA in solution relative to mixed hybrid qDNA was altered by
changing the pH. These changes are shown in Figure 1.21.

Figure 1.21 – Fluorescence of [Ru(phen)2(dppz-idzo)]2+ in the presence of qDNA
1 = fluorescence in the absence of DNA; 2 = fluorescence in the presence of
qDNA; 3 = fluorescence quenched upon acidification of the solution to pH 1.4;
and 4 = fluorescence reappears when pH readjusted back to 4.5. [Ru] = 5 µM,
[DNA] = 2.5 µM.79

Two optically active dinuclear ruthenium polypyridyl complexes (Figure
1.22) have been investigated by Thomas and coworkers, also as luminescent
DNA probes for quadruplex structural detection. These complexes contained a
linking group of tetrapyrido[3,2-a:2′,3′-c:3′′,2′′-h:2′′′,3′′′-j]phenazine (tpphz),
which connected two ruthenium stereocenters which contained either two phen
or two bpy units. In the first instance, cellular colocalisation studies involving
MCF-7 human breast cancer cells were able to show that these complexes can
act as a ‘light switch’ when they enter cells and bind to quadruplex structures. 171
Subsequently, these workers showed that the enantiomers of these complexes
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interacted to different extents with an antiparallel basket G-quadruplex
structure, with the ΛΛ isomer showing stronger luminescence, as well as
binding 40 times more strongly than the ΔΔ isomer.172 NMR spectroscopy was
used to explore the binding mode of these complexes, and showed that they
interact with the ends of the quadruplex molecules.

Figure 1.22 – Two dinuclear ruthenium polypyridyl complexes synthesised by
the Thomas group.171-172
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Another optically active complex which has shown promise as an optical
switch that turns on or off depending on whether or not qDNA is present, is the
cyclometallated platinum(II) complex shown in Figure 1.23.173 A feature of this
complex is that its binding affinity towards qDNA is 100 times greater than that
for dsDNA. Fluorescence microscopy studies performed using cells exposed to
the platinum complex or DAPI (a widely used dsDNA binding molecule) showed
there was no colocalisation of the two molecules, indicating that they have
different cellular targets (Figure 1.23).

(a)

(b)

Figure 1.23 – (a) Structure of a cyclometallated platinum(II) complex used as an
optical switch for probing qDNA structure.173 (b) Fluorescence image of U20S
cells stained with DAPI (green) and the platinum(II) complex (red), revealing a
lack of colocalisation of the two DNA–binding agents.

Another group of ruthenium complexes that have attracted attention in
recent years for their novel anticancer profiles, feature arene ring systems as
well as a polypyridyl ligand.
MOPIP)Cl]+

(p-MOPIP

=

Two such complexes are [(η6-arene)Ru(p2-(4-methoxyphenyl)-imidazo[4,5f]1,10-phen-

anthroline) and [(η6-arene)Ru(p-CFPIP)Cl]+ (p-CFPIP =

35

2-(4-trifluoromethyl-

phenyl)imidazo-[4,5f]1,10-phenanthroline). The structures of these complexes
are shown in Figure 1.24 (a) and (b). Both have been examined for their ability
to stabilise qDNA, as well as inhibit telomerase.174 The complex with the pMOPIP ligand was found to have a greater overall ability to stabilise qDNA and
inhibit telomerase. This complex causes significant changes in the UV-Vis and
CD spectra of a parallel quadruplex formed from the telomeric sequence
GGG(TTAGGG)3. This was attributed to its ability to induce a conformational
change in this qDNA molecule to an antiparallel structure. When the same
experiments were performed with [(η6-arene)Ru(p-CFPIP)Cl]+ only minimal
changes to both the UV-vis and CD spectra were observed. [(η6-arene)Ru(pMOPIP)Cl]+ was shown to be potent against a range of cancer cell lines including
HepG2, HeLa, A549, SW620 and NIH/3T3.
The ruthenium arene complex [(η6-biphenyl)Ru(en)Cl]+ (Figure 1.24 (c))
has also been investigated for its ability to interact with qDNA.175

These

experiments were performed using ESI-MS, NMR and CD spectroscopy, and the
human telomeric sequence AGGG(TTAGGG)3.

Using LC-ESI-MS to examine

ruthenated fragments, it was shown that binding to the thymine, rather than
the guanine bases in this DNA sequence, was kinetically and thermodynamically
more favourable.
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Figure 1.24 – Structures of ruthenium(II) arene complexes shown to interact
with qDNA. (a) [(η6-arene)Ru(p-MOPIP)Cl]+; (b) [(η6-arene)Ru(p-CFPIP)Cl]+;
(c) [(η6-biphenyl)Ru(en)Cl]+.

Wei and co-workers recently reported on the qDNA binding properties of
platinum complexes featuring derivatised phenanthroline and terpyridine
ligands, such as those shown in Figure 1.25.176-177 Each of the new complexes
were shown to interact with qDNA structures formed from biologically relevant
sequences, such as Htelo, c-kit2 and c-myc. In addition, they all showed a
preference for binding to qDNA over dsDNA. A further interesting feature of the
complexes containing terpyridine ligands was their ability to induce the Htelo
sequence to form an antiparallel structure.
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Figure 1.25 – Structures of qDNA-binding platinum complexes studied by Wei
and co-workers.176-177

The qDNA binding properties of a series of closely related platinum(II)
complexes containing phenanthroimidazole ligands featuring additional
aromatic moieties has also recently been reported.178

Examples of these

complexes are shown in Figure 1.26. The ability of these compounds to inhibit
telomerase was examined using a modified TRAP assay, while preliminary
studies revealed the complex shown in Figure 1.26 (a) exhibited activity against
cancer cell lines, but were not toxic towards normal cells. This highlighted the
potential of the compounds for cancer therapy applications. Interestingly, when
the aromatic moiety appended to the phenanthroimidazole ligand was a
naphthyl group, the resulting complex (Figure 1.26 (b)) exhibited a decreased
ability to bind to qDNA. Increasing the hydrogen bonding capacity of the
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phenanthroimidazole ligand, by adding a phenol group, enhanced the selectivity
of the platinum complex for binding to antiparallel qDNA structures over a
hybrid structure.

Figure 1.26 – Structures of qDNA-binding platinum(II) complexes containing
phenanthroimidazole ligands featuring additional aromatic systems.178

Multinuclear complexes that bind to dsDNA have proven to be a fertile
area of investigation.54,57,68 Therefore, some researchers have turned their
attention to exploring the ability of such complexes to bind to different qDNA
structures. The dinuclear platinum complex shown in Figure 1.27 contains a
tetrakis(pyridine-2-yl)pyrazine (tppz) ligand, and exhibits unique qDNA
recognition properties.179 The ligand is able to exist as two conformational
isomers, also shown in Figure 1.27, which are called the Z and U forms. It was
found that the U isomer binds tightly to qDNA, but the Z isomer does not do so
under normal conditions. Treatment of the Z isomer with guanosine resulted in
its conversion into the U form, thereby enabling binding to Htelo.

39

Figure 1.27 – Structure of the dinuclear platinum complex [[Pt(2,2′bpy)]2(tppz)]4+ as well as schematic illustrations of its two conformational
isomers.179

Both the dinuclear zinc(II) complex shown in Figure 1.28 and the
corresponding free ligand were shown to bind to two different hybrid qDNA
molecules.180 It was proposed that the central naphthalene diimide moiety
would confer the ability to π-stack with qDNA, as previously reported for
similar molecules.131,181-182 In addition, in the case of the metal complex, the two
Zn2+ ions in the side chains would enable additional electrostatic interactions
with the negatively charged DNA. The zinc complex showed a higher qDNA
binding affinity than the ligand alone, confirming that the two zinc ions, which
together confer an overall 4+ charge on the molecule, do provide additional
binding affinity. Both the free ligand and zinc complex were shown to inhibit
telomerase.
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Figure 1.28 – Structure of a highly flexible dinuclear Zn(II) complex shown to
bind to hybrid qDNA structures.180

Another novel type of selective qDNA binder was described by Zheng and
co-workers, who designed the tetranuclear platinum square, shown in Figure
1.29.183 This complex was comprised of four platinum moieties joined by 4,4′bipyridine units, so that the platinum atoms are at the four ‘corners’ of the
square. Overall the structure of this complex is similar to that of complexes
investigated by Kieltyka and co-workers.184 The complex shown in Figure 1.29
was found to display a preference for binding to parallel qDNA over dsDNA. A
noteworthy feature of the experiments conducted was that they showed the
drug:qDNA binding stoichiometry for these complexes was 6:1, which indicates
that they are able to interact with qDNA using more than just an end stacking
binding mode. Isothermal titration calorimetry (ITC) was used to determine
both a binding constant for the overall interaction with qDNA and the number of
binding sites.135,183

It was proposed that the size of the platinum square

matched closely that of the grooves within qDNA structures. The selectivity for
parallel quadruplexes was proposed to originate from the position of the loops
with respect to the grooves in parallel structures, which permitted binding of
the complex.

In contrast, the position of grooves in antiparallel hybrid

structures would prohibit binding by these complexes.
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Figure 1.29 – Structure of a platinum(II) square shown to exhibit strong binding
interactions with parallel qDNA structures.183

To date there have only been a relatively small number of studies which
have investigated the effect of changing the metal ion present in a complex on
its ability to bind to qDNA. One such study focussed on the complexes shown in
Figure

1.30,

which

contain

both

a

phenanthroline

ligand

and

ethylenediaminediacetate (edda).185 Significant differences in qDNA binding
affinity between complexes containing Co(II), Zn(II) and Cu(II) were revealed by
CD spectroscopy. Addition of the zinc complex caused the greatest increase in
ellipticity of the CD signal arising from qDNA, whilst the cobalt complex only
caused a minor decrease, suggesting it interacted much more weakly. Each of
the metal complexes were also shown to bind to dsDNA.
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Figure 1.30 – Structure of metal complexes [M(phen)(edda)]2+ (M = Co2+, Cu2+,
Zn2+) shown to bind to qDNA.185

1,10-Phenanthroline has proven to be a very popular building block for
synthesising new ligands to be incorporated into metal complexes used for DNA
binding studies. For example, the two complexes shown in Figure 1.31 feature a
unique tridentate ligand consisting of a phenanthroline linked to a pyridine unit
via a thioether bond.186 Both metal complexes were found to interact with
quadruplex DNA, with the copper complex binding to a greater extent.

Figure 1.31 – Structures of Ni(II) and Cu(II) complexes containing a modified
phenanthroline ligand featuring an appended thiopyridine moiety.186
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An

example

of

a

nickel(II)

complex

featuring

two

modified

phenanthroline ligands is shown in Figure 1.32. Each phenanthroline was
functionalised with an N,N-dimethylaminoethylamino unit. Having shown the
selective binding ability of this and similar complexes for qDNA, 187 Musetti et al.
subsequently discovered that altering experimental conditions such as
temperature could change the binding site of the metal complex.188 These
changes to the conditions demonstrate the impact they could have on the
affinity of metal complexes for qDNA.

Figure 1.32 – Structure of a Ni(II) qDNA-binding complex featuring two
modified phenanthroline ligands.187-188

Terpyridine is another ligand commonly found in metal complexes that
bind to DNA.72-73,75 However, Feng and co-workers developed a novel method
for probing the interactions with qDNA of some modified copper(II) and zinc(II)
terpyridine complexes (Figure 1.33).189

First, they functionalised gold

nanoparticles with guanine-rich single-stranded DNA.

The purpose of the

nanoparticles was to function as a biosensor that scattered light when qDNA
formation was promoted by a drug binding event.

Figure 1.34 shows the

aggregation of the nanoparticles caused by addition of 1 µM metal complex, and
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the resulting change in colour of the solution. Using this new method, it was
determined that the complex with the greatest qDNA stabilising ability was the
copper(II) complex with the methylthiophenyl substituent.

Figure 1.33 – Structures of Cu(II) and Zn(II) complexes (R = NO3- or Cl-)
designed to interact with modified gold nanoparticle biosensors.189

Figure 1.34 – TEM images of DNA-functionalised gold nanoparticles: (a) in the
absence of any metal complex; and (b) in the presence of 1 µM Cu(II)
complex.189 The inserts demonstrate the colour of each solution.
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The use of porphyrins as DNA quadruplex stabilising molecules is well
documented.94,103,123,143 In addition, metalloporphyrins have been investigated
for their ability to bind to and stabilise qDNA. For example, Zhao and coworkers investigated the Cu(II), Zn(II) and Co(II) complexes of the modified
porphyrin shown in Figure 1.35, and found the Cu(II) complex was the most
effective at stabilising qDNA.190 Each of the porphyrin complexes were shown
to

end

stack

onto

the

antiparallel

telomeric

quadruplex

molecule

AGGG(TTAGGG)3.

Figure 1.35 – Structures of metal porphyrin complexes shown to bind to qDNA
by Zhao and co-workers.190 M = Cu2+, Zn2+ or Co2+.

Another group of metal complexes that has been investigated recently
for their ability to bind to qDNA are copper complexes of derivatised
salicylaldehyde dibenzyl semicarbazones.191 Of the initial complexes examined,
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only those shown in Figure 1.36 showed significant affinity for the Htelo qDNA
molecule, and selectively bound to qDNA in preference to dsDNA. Replacement
of the chloride ligand with pyridine yielded new complexes that displayed both
greater affinity and improved selectivity for the same qDNA molecule. All metal
complexes displayed toxicity against MOLT-4 human leukaemia cells, but were
not toxic towards normal cells, indicating they possess some therapeutic
potential in this area.

Figure 1.36 – Structures of substituted copper salicylaldehyde dibenzyl
semicarbazones shown to bind to the Htelo qDNA molecule.191

1.5.3 Nickel salen complexes
As described above, there have now been a number of different types of
metal complexes whose interactions with qDNA have been examined, including
complexes of nickel, ruthenium and platinum. In addition, there has been a
significant amount of investigation into the qDNA binding ability of metal
complexes of Schiff base ligands. One such group of molecules examined is the
platinum(II) complexes shown in Figure 1.37.192 The ligands examined featured
a wide range of functional groups appended to the Schiff base core.

The

complexes which showed the greatest qDNA stabilisation were the two variants
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of Figure 1.37 (d), with the piperidine-substituted complex exhibiting a ten-fold
higher degree of inhibition of the c-myc promoter in HepG2 cells than the
complex with R = H.

Figure 1.37 – Structures of some platinum(II) Schiff base complexes whose
interactions with qDNA have been explored.192

Complexes of derivatised salphen ligands with a variety of other metal
ions including Ni(II), Cu(II), Zn(II) and V(II) have proven especially attractive to
researchers interested in developing selective qDNA binding reagents.113,149150,193

The precursor to many of the nickel complexes is N,N'-Bis-4-

(hydroxysalicylidine)phenylenediamine)nickel(II) (Ni(salphen), Figure 1.38
(a)), which is synthesised from 1,2-phenylenediamine, 2,4-dihydroxy-
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benzaldehyde, and nickel(II) acetate. The hydroxyl groups at the 4' positions
are readily amenable to functionalisation by various haloalkylated piperidines.
An example of one such derivative is N,N'-Bis[4-[[1-(2-ethyl)piperidine]oxy]salicylidine]phenylenediaminenickel(II), shown in Figure 1.38 (b).150,193

Figure 1.38 – Structures of: (a) Ni(salphen); and (b) a derivative of Ni(salphen)
shown to bind selectively to qDNA.

The complex shown in Figure 1.38 (b) was shown by a FRET assay, as
well as CD and UV-visible spectroscopies, to be an effective qDNA binding
agent.149-150,193 Importantly, it also displayed good selectivity for binding to
quadruplex over duplex DNA. The strong affinity of the molecule for qDNA was
suggested to be due to the following factors: (i) the square planar geometry of
the metal complex, which is ideal for interacting with a G-tetrad, (ii) the cationic
metal, which when positioned at the centre of a quadridentate ligand such as a
Schiff base, can align itself with the centre of the G-tetrad onto which the
complex is end-stacked, thereby allowing the nickel ion to mimic the potassium
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or sodium ion normally present in qDNA structures, and (iii) the electron
withdrawing nature of the metal ion, which enhances π-π stacking interactions
between its ligands and the guanine bases of the G-tetrad. Computer modelling
studies confirmed that the aromatic rings of the Schiff base could effectively
overlap with those of the guanines in a G-tetrad, and suggested that the
piperidine substituents, which would be protonated under physiological pH
conditions, could interact with the grooves of qDNA (Figure 1.39).149-150
Ultimately, however, the most important factor in determining the effectiveness
of this complex as a qDNA binding agent was its square planar geometry. This
was supported by work which showed that analogous square pyramidal zinc(II)
and vanadium(II) complexes, which contained both the same quadridentate
Schiff base and a fifth ligand in an axial coordination site, were not able to
interact and stack as well with qDNA as the rigorously square planar nickel
complexes.150

Figure 1.39 - Computer model of the interaction between the nickel(II) Schiff
base complex shown in Figure 1.38 (b) and a G-tetrad.193
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Recently, the first ever X-ray structures of metal complexes bound to
qDNA were reported.149 The structures of these complexes are shown in Figure
1.40. They were crystallised with a parallel bimolecular qDNA formed from two
strands

of

d(AGGGTBrUAGGGTT)

(BrU

=

5-bromo-2′-deoxyuridine-5′-

monophosphate). This sequence is based on the human telomeric sequence,
with the prescence of BrU aiding the process of solving the crystal structure. In
the structure, the metal complexes are end-stacked on the 3′ ends of the
quadruplex (Figure 1.41). It was also revealed that the TTA loop of the qDNA
molecule was sufficiently flexible to accommodate additional binding
interactions with the nickel complexes.

Figure 1.40 – Structures of the two nickel Schiff base complexes crystallised
with qDNA.149
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Figure 1.41 – Two views of the X-ray structure of the copper Schiff base complex
in Figure 1.40 (b) bound to the bimolecular quadruplex d(AGGGTBrUAGGGTT).
The structure on the left depicts one complete qDNA molecule, where two
copper complexes are end-stacked on the 3′ end of the quadruplex. The
structure on the right is a half-molecule, depicted for clarity, where the
alignment of the copper complex over the central channel of the qDNA molecule
can be seen.149

There has also been a number of studies into the biological properties of
Schiff base complexes. For instance, work by Ansari et al. centred on the
antitumour properties of some manganese salen compounds.194-195

These

complexes were found to be active against MCF7 malignant breast cancer cells,
but non-toxic towards the MCF10 non-malignant cell line. Copper Schiff base
complexes were also shown by Ma and coworkers to inhibit growth of the same
breast cancer cell line.196 Hybrid copper salen-oligonucleotide base complexes
were investigated by Kaul et al. for their ability to be included as a base pair in a
DNA chain, and therefore as a potential DNA crosslinker.197
Some metal salen complexes have also been tested as potential
antibiotics. For example, the effects of copper salen complexes on bacterial
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strains have been studied.198

They were found to act as antibiotics, but

exhibited only about 50% of the activity of the clinically used antibiotic
chloramphenicol. Similarly, a variety of Cu(II), Ni(II), Co(II) and Zn(II) Schiff
base complexes derived from 4-aminoantipyrine, benzaldehyde and ophenylenediamine were examined by Raman and co-workers for antimicrobial
activity and their ability to cleave calf thymus DNA (CT-DNA).199 They were
found to photocleave pBR211 DNA, and displayed antibacterial activity against
five different bacterial strains. Yang et al. also examined some copper Schiff
base complexes for their ability to cleave DNA, and act as antimicrobial agents
against two bacterial strains.200 In addition to these studies of the biological
properties of metal complexes of Schiff base ligands, there have been numerous
other reports describing the synthesis and spectroscopic properties of this class
of compounds.201-222

Overall, however, there have been relatively few

systematic investigations of the DNA binding behaviour and biological activity
of this promising class of qDNA-binding metal complexes.

1. 6 Thesis aims and synopsis
The aim of this project was to evaluate the effect of modifying the
structure of the complex shown in Figure 1.38 (b) on its ability to bind to dsDNA
and a range of different qDNA molecules. This complex was chosen as the “lead”
in this investigation because of the promising selectivity it has already exhibited
in DNA-binding studies, and owing to the ease with which it appeared possible
to alter its structure in order to enhance these properties. Figure 1.42 shows
the structures of all molecules investigated as part of this work. Of these,
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complexes (1), (2), (7), (8), (9), (11) and (12) have been reported previously,
and in some instances their qDNA-binding properties partially explored.149150,193

The following paragraphs summarise the investigations described in the

remaining chapters of this thesis.

Figure 1.42 – Structures of all nickel Schiff base complexes prepared in this
study.
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Chapter 2 provides general information about the chemicals used in all
experiments, as well as standard procedures used for performing various
spectroscopic measurements, including those used to assess the affinity of the
nickel complexes for different types of DNA
Chapter 3 presents the synthetic procedures used to prepare all nickel
Schiff base complexes made during the course of this study, as well as data
obtained during their characterisation by microanalysis, NMR spectroscopy,
mass spectrometry and, in some instances, X-ray crystallography. The chapter
also includes discussion of issues that arose during attempts to synthesise some
complexes, as well as the methods used to overcome these obstacles.
Chapter 4 describes the results of DNA-binding studies performed using
the group of nickel Schiff base complexes which were prepared by changing the
identity of the diamine used in the synthetic procedure.

These binding

investigations were performed using ESI-MS, CD, UV-Vis melting curve
measurements and FRET techniques, and involved a 16mer duplex DNA and
both unimolecular and tetramolecular G-quadruplexes. It was hoped that these
modifications would result in either/both greater affinity for qDNA and lower
affinity for dsDNA.
Chapter 5 describes the results of similar DNA-binding studies performed
using nickel Schiff base complexes where the identity of the side chain was
changed from ethyl piperidine to either propyl piperidine or ethyl morpholine.
Results from investigations performed using both dsDNA and qDNA are
included and discussed. It was hoped that changes to the side chains might
significantly modify affinity of the nickel complexes for qDNA in particular, as a
result of varying their ability to interact with the grooves in such structures.
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Chapter 6 focusses on the DNA-binding properties of two asymmetric
nickel Schiff base complexes with both dsDNA and different types of qDNA. It
was hoped that these molecules might prove superior to those described above
for binding to DNA quadruplexes, in view of the additional aromatic ligand they
possess which could interact with G-quartets.
Chapter 7 provides an overall summary of the relative effectiveness of the
different strategies outlined in this thesis for developing new nickel Schiff base
complexes with higher affinity and selectivity for qDNA over dsDNA.

In

addition, it also suggests areas which are worthy of further investigation in
order to achieve this objective.
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CHAPTER 2 - MATERIALS AND METHODS
2. 1 Materials
All chemical reagents and solvents used were of the highest grade
commercially available. MilliQTM water from Millipore (Molsheim, France) was
used in all experiments. All reagents used in the synthesis of nickel Schiff base
complexes were purchased from Sigma Aldrich (Castle Hill, Australia), except for
methanol (MeOH), ethanol (EtOH), anhydrous diethyl ether (Et2O), and
dichloromethane (DCM) which were purchased from Ajax Finechem (Seven Hills,
Australia). Deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform
(CDCl3), deuterated DMF (DMF-d7) and caesium iodide (Fluka) were also
purchased from Sigma Aldrich (Castle Hill, Australia).

Ammonium acetate

(NH4OAc), acetic acid, ammonia, and acetonitrile (ACN) which were used in DNAbinding studies were purchased from Ajax Finechem (Seven Hills, Australia).

2. 2 Characterisation of nickel Schiff base compounds
Elemental analyses were performed by staff of the Microanalytical Units at
either the Research School of Chemistry at the Australian National University, or
the Chemistry Department at the University of Otago, New Zealand.

X-ray

diffraction studies were carried out by Dr Anthony Willis, also of the Research
School of Chemistry, Australian National University.
In-house NMR characterisation of all compounds was performed using a
Varian Inova-500 NMR spectrometer using solutions prepared with DMSO-d6,
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DMF-d7 or CDCl3. Assignment of resonances observed in 1H and 13C NMR spectra
was accomplished in part through the use of COSY, NOESY and HSQC 2D
methods. All spectra were referenced to either the solvent peak or TMS.

13C-

NMR spectra were recorded using a relaxation time of 1 s, unless otherwise
stated. Mass spectra of the alkylated complexes were obtained using a Waters
Quattro ESI mass spectrometer, using solutions prepared in 50% H 2O : 50%
MeOH.

2.2.1 Crystallography
For complexes (5), (6) and (13), X-ray data were collected at 200 K using a
Nonius Kappa CCD diffractometer with Mo Kα radiation at a wavelength of
0.71073 Å, and COLLECT software.223 Data reduction and cell refinement were
performed using DENZO/SCALEPACK.224 Structures were solved with SIR92,225
and refined by full-matrix least squares analysis using teXsan and CRYSTALS.226227

Molecular graphics were prepared using ORTEP-II.228
For complexes (4) and (14), X-ray data were collected at 150 K using a

SuperNova EosS2 diffractometer using Cu Kα radiation at a wavelength of
1.54180 Å, and CrysAlis Pro software.229 Data reduction was also accomplished
using the latter software, while the structures were solved with SIR92,225 and
refined using CRYSTALS.227 Molecular graphics were prepared using PLATON.230
In the structures of (5), (6) and (13) the H atoms attached to C atoms were
included at calculated positions. Difference electron density maps were used to
locate the H atoms of water molecules and alcohol groups in the structure of (5).
Initial refinement of H atoms was done with soft restraints on the bond lengths
58

and angles to regularise their geometry (C-H = 0.93 - 0.98 Å and O-H = 0.82 Å)
and with Uiso(H) in the range 1.2 - 1.5 times Ueq of the parent atom. The
coordinates of the H atoms bonded to O were refined without restraints or
constraints, but H atoms bonded to C were refined with riding constraints.
Refinement of (6) resulted in two, overlapping positions for a
dimethylsulfoxide molecule, whose position was disordered in the structure.
Two sites were used for each atom and restraints were imposed on bonded
distances and angles as well as upon the displacement parameters. During
refinement of (13), a difference electron density map obtained after location of
the nickel Schiff base moiety showed a number of positions of electron density.
It was concluded that these most likely indicated the presence of a highly
disordered molecule of dimethylsulfoxide. Since a suitable model could not be
determined for the molecule of DMSO, the program SQUEEZE, within PLATON,
was used to account for the electron density within this region of the unit cell. 231
This program identified solvent accessible voids totalling 636.9 Å3, and 118
electrons per unit cell were recovered. The formula weight, density etc. reported
here for this complex does not include any corrections for the missing solvent
molecules(s).
For the structures of (4) and (14), all H atoms were located in a difference
map, but were repositioned geometrically. The H atoms were initially refined
with soft restraints on the bond lengths and angles to regularise their geometry
(C-H in the range 0.93 - 0.98 Å) and with Uiso(H) in the range 1.2 - 1.5 times Ueq of
the parent atom. After this, the positions for complex (4) were refined with
riding constraints, whereas the positions for complex (14) were refined without
riding constraints.
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2. 3 Oligonucleotides
2.3.1 Purification of single-stranded oligonucleotides
Oligonucleotides were obtained from Geneworks (South Australia), and
were of PCR grade and obtained as ‘trityl off’ derivatives. The sequences of all
oligonucleotides used in this study are listed in Table 2-1.
The

method

for

purifying

oligonucleotides

has

been

reported

previously,232-235 but is outlined here. Single-stranded DNA (ssDNA) obtained
from Geneworks was dissolved in 1 mL of 10 mM ammonium acetate (NH4OAc).
Aliquots (200 µL) of the resulting solution were purified by HPLC using a Waters
1525 Binary HPLC pump equipped with a Rheodyne injector, and a C18
octadecylsilyl column (8 × 100 mm Waters Delta Pak Radial Cartridge). The
ssDNA was eluted using a linear gradient (0 – 60 %) consisting of ACN in 10 mM
NH4OAc, over 35 min, at a flow rate of 1 mL min-1. After each injection the
column was allowed to equilibrate in 10 mM NH4OAc for 5 min. The peaks in the
chromatogram corresponding to ssDNA were collected, combined and freeze
dried using a Savant SpeedVac (Selby-Biolab, Australia). Once dried, the ssDNA
was redissolved in 500 µL Milli-QTM, and stored in a freezer (-20 °C).
The concentration of ssDNA in the above solutions was determined by
measuring the A260 and using the molar absorption coefficient for each sequence
(Table 2-1).236 Typically, final ssDNA concentrations were within the range 0.8 –
1.2 mM. The oligonucleotide sequences used for fluorescence resonance energy
transfer (FRET) and NMR binding experiments are reported in sections 2.7 and
2.8, respectively.

60

Table 2-1 - DNA sequences used throughout this study.
Annealed
sequence
name

ssDNA
name

4786.2
4977.3

Molar
absorption
coefficient
(M-1 cm-1)
159370
177370

GGG (TTA GGG)3

6653.4

240120

q4(5G)

TTG GGG GT

2496.7

85250

q4(4G)

TTG GGG T

2467.5

73240

D2

d2A
d2B

Q1

q1

Q4(5G)
Q4(4G)

Base sequence
5′-3′

Mass (Da)237

GCT GCC AAA TAC CTC C
GGA GGT ATT TGG CAG C

2.3.2 Preparation of double-stranded DNA
In order to prepare a solution of double-stranded DNA (dsDNA),
appropriate volumes of stock solutions containing the ssDNA sequences d2A and
d2B were added together to give the required final concentration of dsDNA, and
the solvent then removed using the Savant SpeedVac. The DNA was redissolved
in sufficient 100 mM NH4OAc (pH 7.4) to give a solution in which the final
concentration of each strand was 1 mM. This solution was then heated at 56°C
(the melting temperature of the DNA plus 10°C)236 for 15 min and allowed to
slowly cool to room temperature overnight. The annealed DNA was then stored
in a freezer at -20 °C.

2.3.3 Preparation of quadruplex DNA
The three types of quadruplex DNA (Q1, Q4(5G) and Q4(4G)) were
prepared by freeze-drying an appropriate volume of ssDNA to make a 1 mM
stock solution. The number of strands required to form the quadruplex was
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taken into consideration when calculating the required volume. In the case of
the unimolecular Q1 only a single strand of DNA was required, while for the
tetramolecular Q4(5G) or Q4(4G) a total of four strands was necessary. Dried
ssDNA samples containing q4(5G) or q4(4G) were redissolved in 150 mM
NH4OAc (pH 7.4), and annealed by heating to 90°C for 15 min, then slowly
allowing the solution to cool to room temperature. In the case of Q1, two
different conformations of the quadruplex were obtained, depending on how the
sample was cooled after being heated to 95 °C for 15 min. If the sample was
immediately placed in ice, an antiparallel quadruplex was obtained; however, if it
was allowed to cool slowly to room temperature at a rate no greater than 10
°C/hr, a parallel conformation was instead observed (see section 4.4). The
annealed DNA for all sequences was stored in the freezer at -20 °C.

2. 4 Preparation of metal complex stock solutions for
binding studies
Stock solutions of metal complexes were prepared at 1 mM concentration,
in 150 mM NH4OAc (pH 7.4). Since not all metal complexes were completely
soluble in the aqueous NH4OAc alone, some methanol was added to ensure that
total solubility was achieved. Generally, the initial 1 mM stock solution was
prepared as 80:20 v/v water:MeOH, except for complexes (9), (10) and (11)
(complexes alkylated with a morpholine group), which required greater volumes
of methanol (50:50 v/v for (10) and (11), 30:70 v/v for (9)), as well as the two
asymmetric complexes (15) and (16), which each required 100% MeOH. It has
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previously been noted that the nickel Schiff base complexes containing pendant
morpholine groups are not as soluble in water as their piperidine
counterparts.149

2. 5 Mass spectrometry studies
2.5.1 Conditions used for ESI mass spectrometric analysis
2.5.1.1 Analysis of metal complexes
Electrospray ionisation (ESI) mass spectra of the metal complexes
synthesised as part of this thesis were obtained using a Waters Quattro Micro ESI
mass spectrometer (Milford, Massachusetts, USA). Spectra were obtained in
positive ion mode. Typical conditions used to obtain mass spectra of the metal
complexes are presented in Table 2-2.

Table 2-2 – ESI-MS conditions for analysing metal complexes.
Parameter
Capillary (kV)
Cone (V)
Source Temperature (°C)
Desolvation Temperature (°C)

Value
2.5
10
40
120

2.5.1.2 ESI-MS analysis of solutions containing metal complexes and DNA
All ESI mass spectra of solutions containing metal complexes and DNA
reported in this thesis were obtained using a Waters Q-TOF UltimaTM ESI mass
spectrometer (Manchester, UK). This instrument has an extended mass range in
the quadrupole for tandem mass spectrometry.238 However, this adaption was
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not required for the experiments described in this thesis.

The conditions

employed for obtaining optimal spectra of the solutions have been previously
reported and are presented in Table 2-3.233-235,239 All ESI mass spectra were
acquired in negative ion mode, after the instrument had been calibrated using a
solution containing 1 mg/mL caesium iodide in 70:30 isopropanol:water.
Samples were injected into the spectrometer at a flow rate of 10 µL/min using a
Harvard Model 22 syringe pump (Natick, USA).

Table 2-3 - ESI-MS conditions used for analysing solutions containing metal
complexes and either dsDNA or qDNA.
Parameter
Capillary (kV)
Cone (V)
Source Temperature (°C)
Desolvation Temperature (°C)
RF Lens Energy (V)
Desolvation Gas Flow (L/h)

Value
2.5
100
25
80
70
100

2.5.2 Preparation of DNA/metal complex solutions
Stock solutions containing 1 mM of annealed dsDNA or qDNA were
prepared in 100 mM or 150 mM NH4OAc (pH 7.4), respectively. Solutions
containing DNA and metal complexes were prepared using appropriate volumes
of stock solutions of both components so that the final DNA concentration was
10 µM, and the DNA:metal complex ratios were 1:1, 1:3, 1:6 and 1:9 (Table 2-4).
The total volume of these solutions was 100 µL.
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Table 2-4 – Volumes of stock solutions employed to prepare samples for ESI-MS.
Ratio DNA:metal complex
Vol DNA (µL) (1 mM stock)
Vol metal complex (µL) (1 mM stock)
Vol buffer (µL) (NH4OAc)

1:1
1
1
98

1:3
1
3
96

1:6
1
6
93

1:9
1
9
90

2. 6 Circular dichroism studies
2.6.1 Instrumental conditions
Circular dichroism (CD) spectra (200 – 400 nm) were obtained using a
Jasco J-810 spectropolarimeter and a 0.1 cm pathlength quartz cell. For the
acquisition of all spectra, the following parameters were used: sensitivity
(standard), scanning speed (100 nm/min), response (4 s), bandwidth (1 nm),
accumulation (6 scans) and temperature (25 °C).

2.6.2 Preparation of DNA/metal complex solutions for CD
studies
The method of preparing samples containing metal complexes and either
dsDNA or qDNA only differed so that solutions containing dsDNA were prepared
in 100 mM NH4OAc, while those involving qDNA contained 150 mM NH4OAc.
Once the samples were prepared, CD spectra were obtained immediately.
Measurements taken on selected samples containing metal complexes and DNA
immediately after preparation, and after the sample had been allowed to stand
for 10 min, showed no discernible differences.
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Prior to analysing samples by CD spectroscopy, a stock solution (350 µL)
containing both the metal complex (0.6 mM) and DNA (20 µM) was prepared.
The required volumes of this stock solution were then added to another solution
containing DNA alone (300 µL, final DNA concentration 20 µM) to give samples
with metal complex:DNA ratios of 1:1, 3:1, 6:1 and 9:1. The calculated volumes
of these aliquots are outlined in Table 2-5.

Table 2-5 – Volumes of DNA/metal complex stock solution required to prepare
samples for CD experiments.
Ratio DNA:metal
complex
1:1
1:3
1:6
1:9

Volume DNA/metal
complex stock added (µL)
10.4
23.0
41.7
53.6

In some experiments solutions containing other ratios of DNA:metal
complex were used and are stated in the relevant sections of text.

These

solutions were prepared in a similar manner to that outlined above.

2. 7 Absorption spectrophotometry
All UV-Vis measurements of solutions containing DNA and metal
complexes

were

obtained

using

a

Varian

Cary

500

UV-Vis-NIR

spectrophotometer, and quartz cuvettes. Absorption spectra were obtained at
25 °C, and the reference cuvette contained the same concentration of NH4OAc
(100 mM for dsDNA) as that present in the sample cuvette.
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2.7.1 DNA melting experiments
DNA melting curves were obtained by monitoring the absorbance of
solutions containing DNA at 260 nm over the temperature range 25 – 90 °C. Data
were collected at 0.3 °C intervals, using a temperature ramping rate of 1 °C / min
and a filter size of 101. A small volume (750 µL), 1 cm pathlength quartz cuvette
was used, which was covered to minimise solvent evaporation at higher
temperatures. Solutions containing either a DNA:metal complex ratio of 1:3 or
1:6 were used, and the concentration of D2 in the solution was always 1 µM.
Melting temperature (Tm) values were calculated using the instrumental
software, and the melting curves themselves were normalised using Microsoft
Excel.

2. 8 FRET melting
Fluorescence resonance energy transfer (FRET) melting studies of
solutions containing oligonucleotides and selected nickel Schiff base complexes
were carried out at the Institut Européen de Chimie et Biologie, Université de
Bordeaux, France, in the laboratory of Dr. Jean-Louis Mergny. All equipment and
materials were supplied by the Mergny group and the experiments carried out as
previously described.240-241 Some properties of the oligonucleotides used in
FRET assays are presented in Table 2-6.
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Table 2-6 – DNA sequences used in FRET melting studies
Oligo
Name
F21T

ssDNA Base Sequence (5′-3′)a
FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA

FdxT

FAM-TAT AGC TAT A - hexa ethylene glycol T ATA GCT ATA-TAMRA

ds26

CAA TCG GAT CGA ATT CGA TCC GAT TG

Annealed DNA
conformation
Quadruplex (mainly
antiparallel)
Hairpin duplex

Self-complementary
duplex
a FAM is 6-carboxyfluorescein; TAMRA is tetramethyl-6-carboxyrhodamine.240-241

2.8.1 FRET melting assays
In FRET melting assays, the fluorescence emission of the fluorescentlytagged oligonucleotides F21T and FdxT (Table 2-6) at 515 nm was monitored as
the temperature was gradually increased by 1°C / min, over the range 25 – 96 °C.
Melting assays were carried out on an MX3005P-Stratagene QuantitativePolymerase Chain Reaction (Q-PCR) device. All 96-well plates and caps used in
these experiments were fluorescence-capable and obtained from Agilent
Technologies (USA), while the salts and buffers employed were sourced from
Sigma (USA). The oligonucleotides (HPLC purified) used in the FRET melting
assays were obtained from Eurogentec (Belgium). The temperature ramping
program, as well as data recording and processing were controlled using MxPro
software.

There were two replicate wells for each sample and the results

obtained from these wells were averaged only during final data processing and
normalisation. The fluorescence data generated from the melting assay were
then normalised using Microsoft Excel so that the fluorescence values were
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between 0 and 1, with the melting temperature (Tm) determined to be that which
corresponds to a normalised emission of 0.5.
The final volume of solution in each well was 25 µL (20 µL stock
oligonucleotide mix, and 5 µL metal complex). The stock oligonucleotide mixture
was prepared containing lithium cacodylate (LiCaco, 10 mM), sodium chloride
(NaCl, 100 mM), and oligonucleotide (F21T or FdxT, 0.2 µM), sufficient for 20 µL
per required well. Each stock sample was heated to 90 °C for 2 min, and cooled
immediately on ice. Aliquots of the mix were then added to the plate (20 µL per
well).
Solutions containing metal complexes were prepared initially as 1 mM
stock solutions in 20:80 MeOH:H2O.

From these solutions a series of

intermediate stock solutions of metal complex were prepared in which the final
concentration of the metal complex was 200 µM. This was achieved by diluting
the original 1 mM stock using H2O. The final metal complex concentrations in
the wells were 0 µM, 1 µM, 2 µM, 4 µM, 5 µM, and 10 µM (5 µL per well, with
additional stock solutions prepared in advance so that the addition was a 5×
dilution directly into the well).

2.8.2 Competition assays
Competition assays were carried out in a manner similar to the FRET
melting assays (above), with the only difference being the addition of a nonfluorescent competitor duplex sequence. The final volume of solution in each
well was 25 µL: 15 µL of stock oligonucleotide mix, 5 µL of metal complex (1 µM
or 5 µM), and 5 µL of competitor ds26 (0 µM, 3 µM or 10 µM). Both the metal
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complex and ds26 solutions were a direct 5 × dilution into the well (as for FRET
melting assays).

The stock oligonucleotide mix for the competition assay

contained LiCaco (10 mM), NaCl (100 mM) and F21T (0.2 µM), and was of
sufficient volume for 15 µL per required well.

2. 9 NMR
The binding of selected metal complexes to the antiparallel qDNA molecule
22AG (AGG GTT AGG GTT AGG GTT AGG G) was examined.

The solution

structure of this qDNA molecule has been previously determined using NMR
spectroscopy.242

1H-NMR

studies of 22AG in the presence of the nickel

complexes were carried out on a Bruker 800 MHz Ultrashield NMR
spectrometer, located at the Institut Européen de Chimie et Biologie, Université
de Bordeaux, France. All equipment and materials were supplied by the Mergny
group, and the NMR spectra were acquired by Dr Samir Amrane.243-244
An aqueous stock solution of 22AG (1 mM) was prepared in sodium
phosphate (10 mM) and NaCl (90 mM). This DNA stock solution was heated at
95 °C for 5 min, and then allowed to cool slowly overnight. Initial stock solutions
containing 13 mM metal complex were prepared in CD3OD. A combined stock
solution was then prepared which contained 22AG (90 µM) and metal complex
(9 mM). The required volumes of this combined stock were added to a solution
containing 22AG alone (90 µM, 495 µL final volume of which 50 µL was D2O) to
give final NMR samples with DNA:metal complex ratios of 1:1, 1:1.5, 1:2, 1:4 and
1:6. The calculated volumes of the combined stock solution required to give
these DNA:metal complex ratios in the NMR samples are shown Table 2-7.
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Table 2-7 - Volumes of combined DNA/metal complex stock solution added to
DNA control to give final samples for NMR analysis.
Ratio DNA:metal
complex
1:1
1:1.5
1:2
1:4
1:6

Volume DNA:metal complex
stock added (µL)
5.1
2.6
2.6
10.7
10.1
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CHAPTER 3 - SYNTHESIS AND
CHARACTERISATION OF NICKEL SCHIFF
BASE COMPLEXES
3. 1 Introduction and scope of this chapter
This chapter presents the synthesis and characterisation of the nickel Schiff base
complexes used in DNA-binding experiments described in later chapters. For
selected novel complexes, the solid state structure was determined by X-ray
crystallography.

In other instances, a comprehensive range of NMR

spectroscopic methods was used to confirm the identity of the compound. A
discussion of the issues encountered when developing synthetic procedures for
novel complexes is also included.

3. 2 Synthetic methods
N,N′-Bis-4-(hydroxysalicylidine)phenylenediamine nickel(II) (1)
This compound was prepared using the
method described by Reed et al.193

1,2-

Phenylene-diamine (564 mg, 5.21 mmol) and
2,4-dihydroxybenzaldehyde (1390 mg, 10.1
(1)

mmol) were dissolved in MeOH (100 mL) to

give a transparent yellow solution which was subsequently heated under reflux
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for 30 min, with stirring. Ni(OAc)2·4H2O (2530 mg, 10.2 mmol) was then added
to the mixture, and immediately resulted in the formation of a deep red
precipitate. This mixture was subsequently refluxed for a further 3 h, and
afterwards slowly cooled to room temperature. The solid was then isolated
using a sintered glass frit and vacuum filtration, washed with MeOH (100 mL),
diethyl ether (50 mL) and water (50 mL), and then dried further under vacuum
for several hours. The complex was thus isolated as a red solid (1130 mg, 55.5
%). Microanalysis calc. for C20H14N2NiO4·2H2O: C = 54.46, H = 4.11, N = 6.35, Ni =
13.31. Found: C = 54.25, H = 4.04, N = 6.22, Ni = 13.04.

1H

NMR (δ 500 MHz,

DMSO-d6): 6.20 (s, 2H, H10), 6.22 (d, J = 9.28 Hz, 2H, H8), 7.20 (dd, J = 3.7 and
6.11 Hz, 2H, H1), 7.40 (d, J = 8.55 Hz, 2H, H7), 7.99 (dd, J = 3.18 and 5.87 Hz, 2H,
H2), 8.54 (s, 2H, -CH=N-), 10.2 (br s, 2H, -OH).

13C

NMR (δ 125MHz, DMSO-d6):

103.53 (C10), 107.80 (C8), 114.53 (C6), 115.51 (C2), 126.45 (C1), 135.90 (C7),
142.49 (C3), 154.22 (C5), 164.42 (C11), 167.30 (C9).

N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)salicylidine)phenylenediamine nickel(II)
(2)
This compound was also
prepared as outlined by Reed et al.193
Compound (1) (133 mg, 0.327 mmol)
was dissolved in anhydrous DMF (10
mL), along with 1-(2-chloroethyl)(2)

piperidine hydrochloride (226 mg,
1.23 mmol) and K2CO3 (290 mg, 2.10
mmol), and stirred for 72 h under N2.

During this time, an orange precipitate appeared, and the K2CO3 disappeared,
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indicating it was being consumed. The orange solid was then slowly filtered
through a sintered glass funnel under gravity, and washed with a small amount
of DMF and diethyl ether. A vacuum was briefly applied to dry the solid, which
was subsequently dissolved in DCM, washed with water four times, and dried
using MgSO4. The DCM was then removed under vacuum, the resulting solid redissolved in a small amount of DCM and allowed to slowly evaporate, yielding an
orange product (79.46 mg, 79.5 %). ESI-MS calc: [M+H]+ = 628.4, [M+2H]2+ =
314.5.

Found: [M+H]+ = 627.2, [M+2H]2+ = 314.3.

Microanalysis calc. for

C34H40N4NiO4: C = 65.09, H = 6.43, N = 8.93, Ni = 9.36. Found: C = 64.71, H = 6.12,
N = 8.73, Ni = 9.05. 1H-NMR (δ 500MHz, CDCl3): 1.45 (br s, 4H, H19), 1.61 (q, J =
5.61 Hz, 8H, H18), 2.50 (br s, 8H, H17), 2.78 (t, J = 5.90 Hz, 4H, H15), 4.11 (t, J =
5.90 Hz, 4H, H14), 6.32 (dd, J = 2.24 and 8.89 Hz, 2H, H8), 6.59 (d, J = 1.68 Hz, 2H,
H10), 7.15 (m, 2H, H1), 7.17 (d, J = 8.71 Hz, 2H, H7), 7.63 (dd, J = 3.37 and 6.18
Hz, 2H, H2), 8.05 (s, 2H, -CH=N-).

13C-NMR

(δ 125 MHz, CDCl3): 24.21 (C19),

25.92 (C18), 54.95 (C17), 57.65 (C15), 65.96 (C14), 103.12 (C10), 109.09 (C8),
114.67-114.64 (C2 and C6), 126.50 (C1), 134.15 (C7), 142.85 (C3), 152.27 (C5),
165.05 (C11), 168.37 (C9).

N,N′-Bis-4-(hydroxysalicylidine)diaminophenanthrene nickel(II) (3)
This synthesis was carried out using
phenanthrene-9,10-diamine purchased from
Ark Pharm Inc (Libertyville, IL, USA) as
opposed to Sigma Aldrich, which was the
(3)

regular supplier of reagents.

Phenanthrene-

9,10-diamine (520 mg, 2.50 mmol) and 2,4-dihydroxybenzaldehyde (691 mg,
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5.00 mmol) were suspended in MeOH (50 mL). Upon the addition of MeOH, the
solution changed from olive green, through to a brown-yellow colour and finally
orange-red within the space of approximately 30 s. The reaction mixture was
stirred at reflux for 30 min. Ni(OAc)2·4H2O (1262 mg, 5.07 mmol) was added to
the solution, resulting in an immediate dark red colour change, and the mixture
stirred at reflux for a further 3 h. A red solid was isolated using a sintered glass
funnel, and was washed with MeOH (100 mL), diethyl ether (50 mL) and water
(50 mL), before being dried under vacuum for several hours. The final product
was a red powder (492 mg, 38.9 %). Microanalysis calc. for C28H18N2NiO4.3H2O:
C = 60.15, H = 4.33, N = 5.01, Ni = 10.50. Found: C = 60.74, H = 3.88, N = 4.80, Ni
= 10.5. 1H-NMR (δ 500 MHz, DMF-d7): 6.33 (d, J = 8.26 Hz, 2H, H12), 6.40 (s, 2H,
H14), 7.53 (d, J = 8.58 Hz, 2H, H11), 7.75 (m, 4H, H3 and H4), 8.19 (m, 2H, H5),
8.54 (s, 2H, -CH=N-), 8.92 (m, 4H, H2).

13C-NMR

(δ 125 MHz, DMF-d7): 104.01

(C14), 108.16 (C12), 115.05 (C10), 124.26 (C6), 124.49-124.75 (C2 and C5),
126.90 (C3 or C4), 128.21 (C3 or C4), 130.80 (C1), 135.57 (C7), 136.49 (C11),
158.74 (C9), 165.73 (C15), 168.81 (C13).
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N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)salicylidine)diaminophenanthrene
nickel(II) (4)
Compound (3) (149 mg, 0.296
mmol),

1-(2-chloroethyl)piperidine

hydrochloride (246 mg, 1.34 mmol)
and K2CO3 (403 mg, 2.91 mmol) were
suspended in DMF (anhydrous, 10 mL)
and stirred at room temperature for 72

(4)

h under N2. During this time, a red
precipitate formed in the reaction
mixture, which was isolated using a sintered glass funnel and then washed with
DMF (50 mL) and diethyl ether (25 mL) before being dried under vacuum. The
resulting solid was dissolved in DCM, washed seven times with water, then dried
using MgSO4 before being filtered under gravity and the filtrate subsequently
allowed to evaporate slowly, resulting in a red-orange product (92.4 mg, 43.0 %).
ESI-MS calc: [M+H]+ = 727.5, [M+2H]2+ = 364.8.

Found: [M+H]+ = 727.2,

[M+2H]2+ = 364.1. Microanalysis Calc. for C42H44N4NiO4·H2O: C = 67.66, H = 6.22,
N = 7.52, Ni = 7.9. Found: C = 68.17, H = 6.22, N = 7.46, Ni = 7.8. Crystals suitable
for X-ray diffraction were obtained using a DCM/PET spirit solvent mixture. 1H
NMR (δ 500MHz, CDCl3): 1.46 (m, 4H, H23), 1.62 (q, J = 5.52, 8H, H22), 2.52 (br s,
8H, H21), 2.80 (t, J = 5.85, 4H, H19), 4.14 (t, J = 5.85, 4H, H18), 6.35 (dd, J = 2.28
and 8.77 Hz, 2H, H12), 6.66 (d, J = 1.95 Hz, 2H, H14), 7.16 (d, J = 9.10 Hz, 2H,
H11), 7.64 (m, 4H, H3 and H4), 7.99 (d, J = 7.48 Hz, 2H, H5), 8.22 (s, 2H, -CH=N-),
8.67 (dd, J = 1.30 and 7.47 Hz, 2H, H2).

13C-NMR

(δ 125 MHz, CDCl3): 24.34

(C23), 26.06 (C22), 55.08 (C21), 57.79 (C19), 66.13 (C18), 103.32 (C14), 109.06
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(C12), 114.76 (C10), 123.75 (C5), 124.14 (C2), 124.54 (C6), 126.64-127.78 (C3
and C4), 130.83 (C1), 134.33 (C11), 135.57 (C7), 157.41 (C9), 165.46 (C15),
168.54 (C13).

N,N′-Bis-4-(hydroxysalicylidine)meso-diphenylethylenediamine nickel(II) (5)
Meso-1,2-diphenylethylenediamine (550
mg,

2.57

mmol)

and

2,4-dihydroxy-

benzaldehyde (693 mg, 5.01 mmol) were
dissolved in methanol (50 mL) and heated
under reflux for 30 min. After approximately 10
(5)
min a bright yellow solid precipitated. Ni(OAc)2·4H2O (1270 mg, 5.09 mmol)
was then added, which resulted in a brown precipitate starting to appear. The
solution was refluxed for a further 3 h, over which time a red-orange coloured
precipitate deposited. This solid was then collected by vacuum filtration before
being washed with methanol (100 mL), diethyl ether (50 mL) and water (50 mL),
and then dried further under vacuum for several hours. The final product was
isolated as an orange solid (1050 mg, 82.8%).

Crystals suitable for X-ray

diffraction were obtained from a MeOH/DMSO mixture, where the complex was
suspended in MeOH, and DMSO added until it just became dissolved.
Microanalysis calc. for C28H20N2NiO4·2.5H2O: C = 60.91, H = 4.56, N = 5.07, Ni =
10.63. Found: C = 61.04, H = 4.67, N = 4.97, Ni = 10.45.

1H

NMR (δ 500 MHz,

DMSO-d6): 4.91 (s, 2H, H7), 5.98 (dd, J = 1.8 and 8.29 Hz, 2H, H12), 6.11 (d, J =
2.16 Hz, 2H, H14), 6.88 (d, J = 8.65 Hz, 2H, H11), 7.22 (m, 6H, H1, H3 and H5),
7.27 (s, 2H, -CH=N), 7.36 (s, 4H, H2 and H4), 9.85 (br s, 2H, -OH).

13C

NMR (δ 125

MHz, DMSO-d6): 75.78 (C7), 103.61 (C14) 105.99 (C12), 114.05 (C10), 128.1477

128.21 (C1, C2, C4 and C5), 129.09 (C3), 134.53 (C11), 136.25 (C6), 160.82
(C15), 163.16 (C13), 166.05 (C9).

N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)salicylidine)meso-diphenylethylenediamine
nickel(II) (6)
A suspension of (5) (165 mg,
0.324

mmol),

1-(2-chloroethyl)-

piperidine hydrochloride (221 mg, 1.20
mmol) and K2CO3 (291 mg, 2.11 mmol)
in anhydrous DMF (25 mL) was stirred
for 72 h under N2. The resulting pale(6)

coloured solids obtained were then
removed by filtration and washed with

small amounts of DMF and diethyl ether. The DMF from the combined filtrate
and washings was removed under low pressure, and the resulting red product
dissolved in DCM, which was subsequently washed six times with water, dried
with MgSO4 and the DCM allowed to evaporate. The product was obtained as a
red solid (80.0 mg, 33.6 %). ESI-MS calc: [M+H]+ = 732.5, [M+2H]2+ = 366.8.
Found: [M+] = 731.1, [M2+] = 366.3. Microanalysis calc. for C42H48N4NiO4·H2O: C =
67.30, H = 6.72, N = 7.47. Found: C = 66.88, H = 6.66, N = 6.95. Crystals suitable
for X-ray diffraction were formed in a deuterated DMSO solution used for NMR
experiments.

1H-NMR

(δ 500 MHz, DMSO-d6): 1.36 (br s, 4H, H23), 1.47 (d, J =

4.81 Hz, 8H, H22), 2.40 (br s, 8H, H21), 2.61 (t, J = 5.62 and 11.50 Hz, 4H, H19),
4.01 (t, J = 5.61 and 11.23 Hz, 4H, H18), 4.96 (s, 2H, H7), 6.08 (dd, J = 2.14 and
8.56 Hz, 2H, H12), 6.23 (d, J = 2.14 Hz, 2H, H14), 6.98 (dd, J = 2.14 and 8.82 Hz,
2H, H11), 7.24 (m, 6H, H1, H3 and H5), 7.37 (br s, 6H, H2, H4 and –CH=N).
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13C-

NMR (δ 125 MHz, DMSO-d6): 23.91 (C23), 25.54 (C22), 54.34 (C21), 57.08 (C19),
65.54 (C18), 75.83 (C7), 101.79 (C14), 105.76 (C12), 114.51 (C10), 128.16 (C1
and C5), 128.24 (C3), 129.05 (C2 and C4), 134.10 (C11), 136.07 (C6), 161.09
(C15), 163.60 (C13), 166.08 (C9).

N,N′-Bis-4-(hydroxysalicylidine)ethylenediamine nickel(II) (7)
This complex was prepared using a
method adapted from that previously reported
by Arola-Arnal et al.150 Ethylenediamine (171

(7)

mg, 2.85 mmol) and 2,4-dihydroxybenzaldehyde (694 mg, 5.02 mmol) were
dissolved in methanol (50 mL), forming a yellow solution which was heated at
reflux for 30 min.

Over the course of the reflux, a bright, canary-yellow

precipitate formed. To this mixture was added Ni(OAc)2·4H2O (1270 mg, 5.08
mmol), resulting in the immediate formation of a bright red precipitate. The
reaction mixture was heated at reflux for a further 3 h, and the precipitate
isolated by filtration on a sintered glass frit, washed with methanol (100 mL),
diethyl ether (50 mL) and water (50 mL), before being dried further under
vacuum for several hours. The final product isolated was a red-orange solid (782
mg, 87.3 %). Microanalysis calc. for C16H14N2NiO4.2H2O: C = 48.90, H = 4.62, N =
7.13. Found: C = 49.68, H = 4.58, N = 7.10. 1H-NMR (δ 500 MHz, DMSO-d6): 3.27
(s, 2H, H1), 6.04 (s, 4H, H8 and H6), 7.04 (d, J = 7.63 Hz, 2H, H5), 7.60 (s, 2H, CH=N), 9.71 (br s, 2H, -OH).

13C-NMR

(δ 125 MHz, DMSO-d6): 57.68 (C1), 103.69

(C8), 105.54 (C6), 114.06 (C4), 134.07 (C5), 160.97 (C9), 162.58 (C7), 165.78
(C3).
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N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)salicylidine)ethylenediamine nickel(II) (8)
This complex was prepared
using a method adapted from that
previously reported by Arola-Arnal et
al.150
0.326
(8)

A suspension of (7) (116 mg,
mmol),

1-(2-chloroethyl)-

piperidine hydrochloride (226 mg, 1.23
mmol) and K2CO3 (288 mg, 2.08 mmol)

in DMF (anhydrous, 10 mL) was stirred for 72 h under N2. A cream coloured
solid was isolated by filtration, and washed using small amounts of DMF and
diethyl ether. The combined red coloured DMF filtrate and washings were
removed using low pressure and heat. This yielded a red solid which was
subsequently dissolved in DCM, washed five times with water, then dried with
MgSO4, before the DCM was allowed to evaporate, giving the target product as a
dark red solid (150 mg, 79.5 %). ESI-MS calc: [M+H]+ = 580.4, [M+2H]2+ = 290.7.
Found: [M+] = 579.2, [M2+] = 290.3. Microanalysis calc. for C30H40N4NiO4.2H2O: C
= 58.55, H = 7.21, N = 9.10. Found: C = 58.22, H = 7.09, N = 9.05. 1H-NMR (δ 500
MHz, DMSO-d6): 1.36 (br m, 4H, H17), 1.48 (m, 8H, H16), 2.39 (br s, 8H, H15),
2.60 (t, J = 5.67 and 11.47 Hz, 4H, H13), 3.31 (m, partly obscured by water signal,
J = 5.75 Hz, 4H, H1), 3.99 (t, J = 5.67 and 11.33 Hz, 4H, H12), 6.13 (d, J = 8.71 Hz,
2H, H6), 6.17 (s, 2H, H8), 7.12 (d, J = 8.70 Hz, 2H, H5), 7.69 (s, 2H, -CH=N-).

13C-

NMR (δ 125 MHz, CDCl3): 23.89 (C17), 25.52 (C16), 54.33 (C15), 57.14 (C13),
57.71 (C1), 65.40 (C12), 101.95 (C8), 105.37 (C6), 114.53 (C4), 133.70 (C5),
131.08 (C9), 163.10 (C7), 165.80 (C3).

80

N,N′-Bis-(4-((1-(2-ethyl)morpholine)oxy)salicylidine)phenylenediamine nickel(II)
(9)
A procedure for synthesising
this compound had been previously
reported,150

which

involved

the

reactants being heated overnight to
yield the product.

However, the

method employed here was similar to
(9)

that used for the piperidine analogue,
where the reactants were stirred over

a period of 72 h in an inert atmosphere.193 The product was still isolated from
the filtrate, as reported in the literature.
Compound (1) (133 mg, 0.330 mmol) was suspended in DMF (anhydrous,
25 mL) along with 4-(2-chloroethyl)morpholine hydrochloride (223 mg, 1.20
mmol) and K2CO3 (298 mg, 2.15 mmol) and stirred for 72 h under N2. After this
time the yellow-coloured solid that had deposited was removed by filtration, and
washed with DMF (5 mL), followed by diethyl ether (5 mL). The DMF filtrate and
washings were then evaporated to dryness under low pressure, and the resultant
solid dissolved in DCM and washed with water twelve times. The DCM was dried
using MgSO4 and subsequently allowed to evaporate, yielding red needles (167
mg, 80.3 %). ESI-MS calc: [M+H]+ = 632.4, [M+2H]2+ = 316.7. Found: [M+H]+ =
631.1, [M+2H]2+ = 316.3. Microanalysis calc for C32H36N4NiO6·2H2O: C = 57.59, H
= 6.04, N = 8.40, Ni = 8.8. Found: C = 57.63, H = 6.04, N = 8.49, Ni = 9.4. 1H NMR
(δ 500 MHz, CDCl3): 2.57 (m, 8H, H17), 2.80 (t, J = 5.45 and 11.19 Hz, 4H, H15),
3.74 (t, J = 4.30 and 11.19 Hz, 8H, H18), 4.10 (t, J = 5.74 and 11.19 Hz, 4H, H14),
6.30 (dd, J = 6.60 and 8.61 Hz, 2H, H8), 6.56 (d, J = 1.73 Hz, 2H, H10), 7.14 (partly
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obscured dd, J = 2.87 and 6.02 Hz, 2H, H1), 7.15 (d, J = 8.89 Hz, 2H, H7), 7.62 (dd,
J = 2.58 and 6.02 Hz, 2H, H2), 8.02 (s, 2H, -CH=N-).

13C-NMR

(δ 125 MHz, CDCl3):

54.15 (C17), 57.45 (C15), 65.87 (C14), 67.02 (C18), 103.11 (C10), 109.15 (C8),
114.56 (C2), 114.86 (C6), 126.72 (C1), 134.40 (C7), 142.90 (C3), 152.42 (C5),
164.95 (C11), 168.34 (C9).

N,N′-Bis-(4-((1-(2-ethyl)morpholine)oxy)salicylidine)-meso-diphenylethylenediamine nickel(II) (10)
A suspension of (5) (164 mg,
0.323

mmol),

4-(2-chloroethyl)-

morpholine hydrochloride (224 mg,
1.20 mmol) and K2CO3 (289 mg, 2.09
mmol) was prepared in anhydrous
DMF (10 mL), and stirred under N2 for
72 h. The solution was then filtered
(10)

and the precipitate washed with a small

amount of DMF. The DMF filtrate and washings were then evaporated under low
pressure, and the resulting solid dissolved in DCM.

A small amount of

undissolved material was removed by gravity filtration before the filtrate was
washed four times with water. The DCM solution was dried using MgSO4 before
being allowed to evaporate. This afforded a dark red solid (36.8 mg, 15.5 %
yield). ESI-MS calc: [M+H]+ = 736.5, [M+2H]2+ = 368.8. Found: [M+H]+ = 735.3,
[M+2H]2+ 368.3. Microanalysis calc. for C40H44N4NiO6·H2O: C = 63.93, H = 5.90, N
= 7.46, Ni = 7.8. Found: C = 63.22, H = 6.31, N = 7.73, Ni = 7.7.

1H-NMR

(δ 500

MHz, CDCl3): 2.57 (br s, 8H, H22), 2.81 (br s, 4H, H19), 3.75 (br s, 8H, H21), 4.09
(br s, 4H, H18), 4.73 (s, 2H, H7), 6.14 (dd, J = 2.01 and 8.62 Hz, 2H, H12), 6.53 (d, J
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= 1.44 Hz, 2H, H14), 6.79 (d, J = 8.62 Hz, 2H, H11), 7.14 (s, 2H, -CH=N-), 7.21 (d, J
= 7.47 Hz, 4H, H1 and H5), 7.27 (m, 4H, H2 and H4), 7.37 (br s, 2H, H3).

13C-NMR

(δ 125 MHz, CDCl3): 54.09 (C22), 57.45 (C19), 65.58 (C18), 66.89 (C21), 76.9077.47 (C7, obscured by CDCl3 signal), 103.42 (C14), 107.25 (C12), 114.75 (C10),
128.53 (C1 and C5), 128.85 (C2 and C4), 129.63 (C3), 133.64 (C11), 135.50 (C6),
161.07 (C15), 164.00 (C13), 167.00 (C9).

N,N′-Bis-(4-((1-(2-ethyl)morpholine)oxy)salicylidine)ethylenediamine nickel(II)
(11)
A suspension of (7) (137 mg,
0.386

mmol),

4-(2-chloroethyl)-

morpholine hydrochloride (234 mg, 1.25
mmol) and K2CO3 (352 mmol, 2.55
mmol) was suspended in anhydrous
(11)

DMF (10 mL), and stirred under N2 at 90

°C overnight. The suspension was then filtered and the precipitate washed with
DMF and diethyl ether, before the combined DMF filtrate and washings were
evaporated to dryness under low pressure, yielding a sticky, orange residue. The
residue was redissolved in DCM and washed four times with water, before the
DCM layer was dried with MgSO4, filtered and the DCM allowed to slowly
evaporate, giving a red-orange solid (324 mg, 83.8 %). ESI-MS calc: [M+H]+ =
584.2, [M+H]2+ = 292.1. Found: [M+H]+ = 583.2, [M+H]2+ = 292.2. Microanalysis
calc. for C28H36N4NiO6·3H2O: C = 52.77, H = 6.64, N = 8.79, Ni = 9.2. Found: C =
52.83, H = 6.40, N = 8.69, Ni = 9.0.

1H-NMR

(δ 500 MHz, DMSO-d6): 2.44 (br s

obscured by DMSO signal, 8H, H16), 2.65 (t, J = 5.59 Hz, 4H, H13), 3.32 (br s
obscured by water signal, H1), 3.56 (t, J = 4.28 Hz, 4H, H15), 4.02 (t, J = 5.59 Hz,
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4H, H12), 6.14 (dd, J = 1.98 and 8.72 Hz, 2H, H6), 6.18 (s, 2H, H8), 7.12 (d, J = 8.72
Hz, 2H, H5), 7.69 (s, 2H, -CH=N-).

13C-NMR

(δ 125 MHz, DMSO-d6): 53.41-53.58

(C15), 56.81 (C13), 57.75 (C1), 65.15 (C12), 65.99-66.29 (C16), 101.90 (C8),
105.28 (C6), 114.60 (C4), 133.67 (C5), 161.37 (C9), 163.05 (C7), 165.811 (C3).

N,N′-Bis-(4-((1-(3-propyl)piperidine)oxy)salicylidine)phenylenediamine nickel(II)
(12)
A suspension of (1)
(131 mg, 0.324 mmol), 1(3-chloropropyl)piperidine
hydrochloride

(236

mg,

1.19 mmol) and K2CO3 (298
mg,
(12)

2.16

prepared

mmol)
in

was

anhydrous

DMF (10 mL), and stirred
under N2 for 72 h. A pale yellow solid was filtered off, washed with small
amounts of DMF and diethyl ether, and the combined DMF filtrate and washings
removed under low pressure, yielding a red-orange solid which was
subsequently dissolved in DCM. The DCM solution containing the product was
then washed five times with water, dried with MgSO4 and the DCM allowed to
evaporate slowly to give the product as an orange solid (157 mg, 74.1 %). ESIMS calc: [M+H]2+ = 328.7. Found: [M+H]2+ = 328.2.

Microanalysis calc: for

C36H44N4NiO4·H2O: C = 64.20, H = 7.00, N = 8.10. Found: C = 64.05, H = 6.83, N =
8.31. Crystals suitable for X-ray diffraction were obtained from a deuterated
DMSO solution used for NMR experiments. 1H-NMR (δ 500 MHz, CDCl3): δ 1.44
(m, 4H, H20), 1.60 (m, 8H, H19), 1.97 (m, 4H, H15), 2.41 (br s, 8H, H18), 2.46 (t, J
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= 7.24, 4H, H16), 3.99 (t, J = 6.29, 4H, H14), 6.27 (dd, J = 6.61 and 8.82 Hz, 2H,
H8), 6.57 (d, J = 1.89 Hz, 2H, H10), 7.12 (dd, J = 2.84 and 6.30 Hz, 2H, H1), 7.15 (s,
2H, H7), 7.61 (dd, J = 2.84 and 6.30 Hz, 2H, H2), 8.01 (s, 2H, -CH=N-).

13C-NMR

(δ

125 MHz, CDCl3): 24.62 (C20), 26.07-26.16 (C19), 26.78 (C15), 54.83 (C18),
56.08 (C16), 66.84 (C14), 103.24 (C10), 109.12 (C8), 114.57 (C6), 114.77 (C2),
126.64 (C1), 134.35 (C7), 143.35 (C3), 152.37 (C5), 165.45 (C11), 168.54 (C9).

N,N′-Bis-(4-((1-(3-propyl)piperidine)oxy)salicylidine)meso-1,2-diphenylethylenediamine nickel(II) (13)
A suspension of (5)
(167

mg,

0.329

mmol),

K2CO3 (315 mg, 2.28 mmol),
and

1-(3-chloropropyl-

piperidine

hydrochloride

(239 mg, 1.21 mmol), in
(13)

anhydrous DMF (10 mL),
was stirred for 72 h at room

temperature.

After this time undissolved salts and excess reactants were

removed by filtration under gravity, and the DMF filtrate evaporated to dryness
under low pressure. The red solid obtained was dissolved in DCM and washed
with water three times, after which the DCM layer was dried with MgSO4 and
then allowed to slowly evaporate, giving the product as an orange solid (198 mg,
78.9 %). ESI-MS calc: [M+H]+ = 759.6, [M+H]2+ = 380.8. Found: [M+H]+ = 759.3,
[M+H]2+ = 380.4. Microanalysis calc. for C44H52N4NiO4·2H2O: C = 66.42, H = 7.09,
N = 7.04. Found: C = 66.29, H = 7.02, N = 7.09. 1H-NMR (δ 500 MHz, CDCl3): 1.44
85

(d, J = 4.16 Hz, 4H, H24), 1.60 (q, J = 5.55 Hz, 8H, H23), 1.94 (m, 4H, H19), 2.41
(br s, 8H, H22), 2.45 (t, J = 7.21 Hz, 4H, H20), 3.93 (m, 4H, H18), 4.78 (s, 2H, H7),
6.08 (dd, J = 6.38 and 8.60 Hz, 2H, H12), 6.51 (d, J = 1.94 Hz, 2H, H14), 6.71 (d, J =
8.87 Hz, 2H, H11), 7.05 (s, 2H, -CH=N-), 7.19 (t, J = 7.77, 4H, H1 and H5), 7.25 (t, J
= 5.26 Hz, 4H, H2 and H4), 7.35 (br s, 2H, H3).

13C-NMR

(δ 125 MHz, CDCl3):

24.50 (C24), 26.00 (C23), 26.64 (C19), 54.70 (C22), 56.03 (C20), 66.53 (C18),
76.91-77.41 (C7, obscured by CDCl3 signal), 103.28 (C14), 107.09 (C12), 114.59
(C10), 128.44 (C1 and C5), 128.71 (C2 and C4), 129.68 (C3), 133.58 (C11),
135.74 (C6), 160.95 (C15), 164.41 (C13), 166.97 (C9).

(Hydroxysalicylidine)(2-hydroxy-1-naphthalene)phenylenediamine nickel(II) (14)
The method employed for the
synthesis of this complex was based upon
that described by Barwiolek et al.207 1,2Phenylenediamine (1730 mg, 16.0 mmol)
(14)

and 2-hydroxy-1-naphthaldehyde (2750

mg, 16.0 mmol) were heated under reflux in MeOH (200 mL) for 30 min, giving a
bright yellow solution initially, but which turned bright orange over the course of
the reflux. 2,4-Dihydroxybenzaldehyde (2210 mg, 16.0 mmol) was then added to
the reaction mixture, and heated under reflux overnight. The solution was
subsequently allowed to cool, and the orange product isolated using a sintered
glass frit, washed with MeOH (100 mL) and small amounts of diethyl ether and
water, and dried under vacuum (5.15 g, 84.2 %). Owing to the lack of solubility
of this ligand in any solvent, it was not characterised.

86

The ligand (1000 mg, 2.62 mmol) was then refluxed in MeOH (75 mL) and
Ni(OAc)2·4H2O (782 mg, 3.14 mmol) added, which immediately gave a red
precipitate. The resultant suspension was heated under reflux for 3 h, after
which it was cooled, and the red product isolated using a sintered glass frit
before being washed with MeOH (150 mL), diethyl ether (150 mL) and water
(150 mL), then dried under vacuum for several hours (1010 mg, 95.2 %).
Recrystallisation was achieved by suspending the complex (505 mg) in
MeOH (75 mL), and then stirring the suspension with gentle heating applied.
DMSO (250 mL) was added to the suspension, causing the product to dissolve.
After several days, the recrystallised product had precipitated and was isolated
using a sintered glass frit. It was washed with large quantities of MeOH, diethyl
ether and H2O, then dried under vacuum for several hours, giving a red product
(527 mg, 95.9 %). Some crystals suitable for X-ray diffraction were obtained
from this mixture. Microanalysis calc. for C24H16N2NiO3·H2O: C = 63.06, H = 3.97,
N = 6.13, Ni = 12.8. Found: C = 63.20, H = 4.04, N = 5.97, Ni = 12.6. 1H-NMR (δ
500 MHz, DMF-d7): 6.35 (dd, J = 1.89 and 8.69 Hz, 1H, H15), 6.39 (d, J = 1.89 Hz,
1H, H10), 7.08 (d, J = 9.44 Hz, 1H, H16), 7.30 (dd, J = 3.03 and 6.05 Hz, 2H, H1 and
H28), 7.34 (t, J = 7.18 Hz, 1H, H18), 7.53 (d, J = 8.68 Hz, 1H, H8), 7.56 (t, J = 7.18
Hz, 1H, H21), 7.82 (dd, J = 9.07 and 15.49 Hz, 2H, H20 and H21), 8.14 (dd, J = 3.40
and 6.04 Hz, 1H, H27), 8.48 (dd, J = 3.40 and 6.04 Hz, 1H, H2), 8.58 (d, J = 8.31 Hz,
1H, H7), 8.75 (s, 1H, -CH(24)=N-), 9.50 (s, 1H, -CH(5)=N-).

13C-NMR

(δ 125 MHz,

DMF-d7): 103.96 (C10), 108.42 (C8), 111.85 (C6), 115.30 (C23), 115.64-116.47
(C15 and C21), 120.78 (C19), 123.38-123.49 (C2 and C27), 126.77 (C20), 127.13127.25 (C1 and C28), 128.25 (C20), 129.31 (C17), 134.30 (C16), 136.17-136.28
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(C7 or C22), 143.40-143.70 (C3 or C26), 149.47 (C14), 145.48 (C11), 165.70 (C9),
168.00-168.53 (C5 and C24).

1((N-piperidyinyl)ethoxy)salicylidine-2-(2-hydroxylnaphthyl)phenylenediamine
nickel (II) (15)
A suspension of (14) (154 mg,
0.323 mmol), 1-(2-chloroethyl)piperidine
hydrochloride (220 mg, 1.19 mmol) and
K2CO3 (301 mg, 2.18 mmol) was prepared
in anhydrous DMF (10 mL), and stirred at
room temperature under N2 for 72 h. The

(15)

suspension was then filtered using a
sintered glass frit, washed with diethyl
ether (10 mL), and dried under vacuum.

The resulting red solid was

subsequently dissolved in DCM (150 mL) and washed ten times with water to
remove any remaining DMF and salts from the product. The DCM solution was
then dried with MgSO4, filtered under gravity, and the solvent allowed to slowly
evaporate, giving the product as a red solid (94.9 mg, 53.4 %). ESI-MS calc:
[M+H]+

=

549.1.

Found:

[M+H]+

=

550.3

Microanalysis

calc.

for

C31H29N3NiO3·H2O: C = 65.52, H = 5.50, N = 7.39, Ni = 10.3. Found: C = 65.25, H =
5.39, N = 7.28, Ni = 10.6. Some problems were encountered while attempting to
acquire acquiring good quality NMR spectra of this compound; this will be
discussed in section 3.3. Assignments of spectra run in multiple solvents are
presented below.
1H-NMR

(δ 500 MHz, DMSO-d6): 1.40 (br s, 2H, H35), 1.53 (br s, 4H, H34),

2.4 (br s, obscured by DMSO, H33), 2.6 (br s, obscured by DMSO, H31), 4.14 (br s,
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2H, H30), 6.35 (d, J = 8.81 Hz, 1H, H8), 6.44 (s, 1H, H10), 7.06 (d, J = 9.10 Hz, 1H,
H16), 7.29 (dd, J = 3.52 and 6.44 Hz, 2H, H1 and H28), 7.33 (t, J = 6.95 Hz, 1H,
H19), 7.50 (d, J = 9.10 Hz, 1H, H7), 7.54 (t, J = 7.93 Hz, 1H, H20), 7.78 (d, J = 7.34
Hz, 1H, H18), 7.81 (d, J = 9.10 Hz, 1H, H15), 8.07 (dd, J = 3.52 and 6.17 Hz, 1H,
H2), 8.41 (dd, J = 3.23 and 6.46 Hz, 1H, H27), 8.51 (d, J = 8.52 Hz, 1H, H21), 8.72
(s, 1H, -CH(5)=N-), 9.33 (s, 1H, -CH(24)=N-).

13C-NMR

(δ 125 MHz, DMSO-d6):

101.73 (C10), 107.68 (C8), 111.10 (C6), 114.95 (C23), 115.51 (C2), 116.42 (C27),
120.61 (C21), 122.88 (C16), 123.08 (C19), 126.35 (C22), 126.70-126.79 (C1 and
C28), 127.78 (C20), 128.84 (C18), 133.36 (C17), 135.28 (C7), 135.91 (C15),
142.27 (C3 and C26), 142.85 (C14), 149.27 (C24), 154.54 (C5), 166.87 (C11),
167.27 (C9).
1H-NMR

(δ 500 MHz, CDCl3): 1.46 (br s, 2H, H35), 1.64 (br s, 4H, H34),

2.54 (br s, 4H, H33), 2.82 (br s, 2H, H31), 4.16 (br s, 2H, H30), 6.36 (dd, J = 2.20
and 8.81 Hz, 1H, H8), 6.62 (d, J = 1.89 Hz, 1H, H10), 7.24 (m, 3H, H1, H7 and H28),
7.31 (m, 2H, H18 and H19), 7.52 (t, J = 7.87 Hz, 1H, H20), 7.68 (m, 3H, H2, H15
and H16), 7.82 (d, J = 7.86 Hz, 1H, H27), 8.05 (d, J = 8.18 Hz, 1H, H21), 8.14 (s, 1H,
-CH(5)=N-), 9.16 (s, 1H, -CH(24)=N-).

13C-NMR

(δ 125 MHz, CDCl3): 24.28 (C35),

25.97 (C34), 55.06 (C33), 57.75 (C31), ~65 (C30), 103.25 (C10), 109.67 (C8),
111.41 (C23), 114.62-114.82 (C2, C6 and C27), 119.06 (C21), 123.34 (C18 and
C19), 124.66 (C22), 126.71-126.78 (C1 and C28), 127.28 (C20), 128.01 (C17),
129.49 (C16), 133.68 (C7), 134.41 (C3 or C26), 136.93 (C15), 142.94 (C3 or C26),
143.78 (C14), 147.64 (C24), 152.45 (C5), 165.35 (C11), 168.35 (C9).
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1-((N-piperidinyl)propyloxy)salicylidine-2-(2-hydroxynaphthyl)phenylenediamine
nickel(II) (16)
A suspension of (14) (154 mg,
0.323

mmol),

1-(3-chloropropyl)-

piperidine hydrochloride (237 mg,
1.19 mmol) and K2CO3 (305 mg, 2.21
mmol) was stirred in anhydrous DMF
(16)

(10 mL) for 72 h under N2.

The

product was then filtered using a
sintered glass frit, washed with diethyl
ether (50 mL), and dried under vacuum. The red product was then dissolved in
DCM (150 mL), and washed six times with water before the DCM layer was dried
with MgSO4, filtered under gravity and the filtrate allowed to evaporate to
dryness, giving a red solid (62.3 mg, 34.21 %).

Microanalysis calc. for

C31H29N3NiO3.H2O: C = 65.52, H = 5.50, N = 7.39, Ni = 10.3. Found: C = 65.08, H =
5.66, N = 7.35, Ni = 10.1. ESI-MS calc: [M+H]+ = 563.2. Found: [M+H]+ = 564.3.
Owing to some difficulties encountered while attempting to acquire good quality
NMR spectra of this compound, assignments of spectra run in multiple solvents
are presented below. 1H-NMR (δ 500 MHz, CDCl3): 1.45 (br s, 2H, H36), 1.58 (m,
partially obscured by H2O, 4H, H35), 1.99 (t, J = 7.26 Hz, 2H, H31), 2.43 (br s, 4H,
H34), 2.48 (t, J = 6.95 Hz, 2H, H32), 4.02 (t, J = 6.32 Hz, 2H, H30), 6.34 (dd, J =
2.21 and 8.53 Hz, 1H, H8), 6.62 (d, J = 1.90 Hz, 1H, H10), 7.22 (m, 3H, H1, H7 and
H28), 7.31 (m, 2H, H18 and H19), 7.52 (t, J = 7.89 Hz, 1H, H20), 7.68 (m, 3H, H2,
H16 and H15), 7.82 (d, J = 7.27 Hz, 1H, H27), 8.05 (d, J = 8.53 Hz, 1H, H21), 8.13
(s, 1H, -CH(5)=N-), δ 9.16 (s, 1H, -CH(24)=N-).
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1H-NMR

(δ 500 MHz, DMF-d7): 1.41 (br d, J = 5.09 Hz, 2H, H36), 1.54 (t, J =

5.77 Hz, 4H, H35), 1.93 (q, J = 6.78 Hz, 2H, H31), 2.37 (br s, 4H, H34), 2.43 (t, J =
7.00 Hz, 2H, H32), 4.10 (t, J = 6.45 Hz, 2H, H30), 6.38 (dd, J = 2.04 and 8.82 Hz,
1H, H8), 6.45 (d, J = 2.03 Hz, 1H, H10), 7.12 (d, J = 9.16, 1H, H15), 7.32 (m, 2H, H1
and H28), 7.36 (t, J = 7.12 Hz, 1H, H19), 7.57 (m, 2H, H7 and H20), 7.83 (d, J =
7.81 Hz, 1H, H18), 7.87 (d, J = 9.16, 1H, H16), 8.16 (m, 1H, H2), 8.51 (m, 1H, H27),
8.60 (d, J = 8.49 Hz, 1H, H21), 8.82 (s, 1H, -CH(5)=N-), 9.52 (s, 1H, -CH(24)=N-).
13C-NMR

(δ 125 MHz, DMF-d7): 25.61 (C36), 27.17 (C35), 27.70 (C31), 55.64

(C34), 56.45 (C32), 67.55 (C30), 102.67 (C10), 109.03 (C8), 112.68 (C23), 116.37
(C2), 116.56 (C27), 117.36 (C21), 124.63 (C16), 124.45 (C19), 127.84-128.08
(C1, C28 and C22), 129.11 (C20), 130.14 (C18), 135.09 (C17), 136.41 (C7),
137.14 (C15), 144.06-144.61 (C3 and C26), 150.42 (C14), 155.56 (C24), 166.40
(C5), 168.82 (C11), 169.37 (C9).

3. 3 Discussion of synthetic methods
3.3.1 Precursor nickel Schiff base complexes
Syntheses of all nickel Schiff base complexes were based on literature
methods.150,193 These methods were modified and improved as the synthesis of
novel complexes was accomplished. The first step on each occasion was to
produce hydroxylated Schiff base complexes by the reaction of different
diamines with 2,4-dihydroxysalicylaldehyde, and subsequently adding nickel
acetate. This is summarised in Figure 3.1 using complex (1) as an example.
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These reactions yielded the desired complexes as microcrystalline powders in
good yields and purity (Table 3-1).

Figure 3.1 – Reaction scheme for the synthesis of nickel Schiff base complex (1).

Table 3-1 – Yields of nickel Schiff base complexes (1), (3), (5) and (7).
Nickel complex
(1)

Structure of diamine

Yield
56 %

(3)

39 %

(5)

83 %

(7)

87 %

Full assignment of 1H- and

13C-NMR

spectra of (1), (3), (5) and (7) was

achieved using 2D techniques including COSY, NOESY and HSQC. Examples of
the process of assigning the spectra of the hydroxylated nickel Schiff base
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complexes is outlined below for complexes (1) and (3). Similar procedures were
employed for assignment of the spectra of the other nickel Schiff base complexes.
Figure 3.2 shows the 1H-NMR spectrum of (1). The complete assignment
of all the resonances in this spectrum has not been previously reported, although
the spectrum has been described in a paper by Reed et al.193 Specific signals in
the spectrum were assigned based on their characteristic appearance and
chemical shifts. For example, the imine proton (H5) is more deshielded than the
other C-H groups in the complex, and is at least four bonds away from another H
atom. It therefore appears as a singlet at 8.54 ppm. Further downfield is the
hydroxyl proton signal, which in all complexes was found to be very broad. The
only other singlet expected in this complex was H10, which was observed at 6.20
ppm, overlapping slightly with another doublet.
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Figure 3.2 – 1H-NMR spectrum of complex (1), with the structure and atom
numbering scheme for the complex shown in the inset.
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One distinctive pattern was the appearance of two signals at 7.20 and
7.99 ppm, which are assigned to H1 and H2 and resemble what is observed in the
1H-NMR

spectrum of 1,2-phenylenediamine alone. Another two doublets at 7.40

and 6.22 ppm are assigned to either H7 or H8.

Definitively assigning the

individual resonances within these pairs of signals (H1/H2 and H7/H8) required
the use of 2D NMR techniques. Therefore, COSY (Correlation Spectroscopy) and
NOESY (Nuclear Overhauser Effect Spectroscopy) NMR spectra were obtained.
The COSY spectrum of complex (1) (Figure 3.3) showed two strong sets of
couplings involving H1/H2 and H7/H8. This confirmed that the protons of each
pair were located in close proximity to one another, and that each pair was on
separate ring systems within the nickel complex.

However, separately

identifying the individual resonances within these pairs of protons was still not
possible at this stage.
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Figure 3.3 – COSY spectrum of complex (1), with observed three-bond couplings
highlighted.
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NOESY identifies through space correlations between protons in close
proximity, and is often able to show correlations that COSY spectra cannot
identify.

A NOESY spectrum of complex (1) (Figure 3.4) was required to

completely assign signals due to H1/H2 and H7/H8 in this complex. The key
starting point for assigning these signals was the imine proton, which appears as
a downfield singlet at 8.54 ppm. This proton is located quite close to H2 and H7
within the structure of (1), and was therefore expected to show strong cross
peaks to these protons. These correlations were observed with the proton
signals at 7.99 ppm and 7.40 ppm, allowing these to be assigned to H2 and H7,
respectively. There were also correlations between H1 and H2, as well as H7 and
H8, which were expected owing to the close proximity of these coupled protons.
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Figure 3.4 – NOESY NMR spectrum of complex (1), with key couplings
highlighted.
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The

13C-NMR

spectrum of complex (1) contained the correct number of

resonances (Figure 3.5), many of which could be assigned directly to specific
carbons in complex (1) by inspection. However, in order to fully assign the
spectrum, additional information was required. An HSQC (Heteronuclear SingleQuantum Correlation Spectroscopy) spectrum was obtained and is also shown in
Figure 3.5. This 2D technique gives information regarding directly coupled
heteronuclei 1JCH. Since the 1H-NMR spectrum of this complex had now been
fully assigned, the C-H correlations in the HSQC spectrum could be used to assign
the resonances in the

13C-NMR

spectrum.

For brevity, only the key C-H

correlations in the HSQC spectrum that enabled assignment of the

13C

signals

shall be discussed here.
The two most upfield signals in the

13C-NMR

spectrum appear at 103.53

ppm and 107.80 ppm. In the HSQC spectrum, these signals correlated with the
two most upfield 1H-NMR signals, which had very similar chemical shifts. Since
one of the latter signals, at 6.20 ppm, had already been assigned to H10, it was
then possible to assign the 13C resonance at 103.53 ppm to C10. In addition, the
signal for H8 at 6.22 ppm correlated to the carbon at 107.80 ppm, allowing
definitive assignment of the latter signal to C8. Two close

13C

signals at 114.53

and 115.51 ppm required careful examination of the HSQC spectrum to facilitate
their assignment. The most downfield of these was identified as arising from C2,
owing to the strong correlation with the proton assigned to H2. Assignment of
the

13C

signal at 114.53 ppm, as well as other carbon resonances which did not

shown any correlations with proton signals in the HSQC spectrum, was
accomplished through comparison with the
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13C

spectrum of the reactant

molecules. For instance, the signal at 114.53 ppm was the most upfield of the
remaining carbon atoms, and was assigned to C6.
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Figure 3.5 – 13C- and HSQC NMR spectra of complex (1), with selected protoncarbon correlations highlighted.

It also proved difficult to fully assign the NMR spectra of the novel
complex (3), as there were a number of signals in its 1H- and
with very similar chemical shifts.

13C-NMR

spectra

The 1H-NMR spectrum of (3) is shown in

Figure 3.6. The characteristic downfield singlet at 8.54 ppm was assigned to the
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imine proton, and the broad –OH signal appeared at 10.5 ppm. There was also a
singlet and doublet at 6.40 and 6.33 ppm, respectively, as well as several
multiplets appearing further downfield which arise from H2, H3, H4 and H5.
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Figure 3.6 – 1H-NMR spectrum of complex (3), with the structure and atom
numbering scheme for the complex shown in the inset.

In order to assign the signals in the spectrum, COSY and NOESY 2D NMR
were again used. The COSY spectrum of complex (3) (Figure 3.7) shows three
strong couplings. One of these was the coupling between the two doublets at
6.33 ppm and 7.53 ppm, which are attributable to H11 and H12, or vice versa.
This is the same pattern that was observed in the 1H spectrum of complex (1),
which was to be expected as this component of the structure of the nickel
complex had not changed.
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Figure 3.7 – COSY-NMR spectrum of complex (3), with three-bond proton
couplings highlighted.

The remaining correlations between 1H resonances are a result of the
phenanthrene moiety. The key signal is that at 7.75 ppm, which integrates as
four protons, and shows couplings to the multiplets at 8.19 and 8.82 ppm. Owing
to the structure of the phenanthrene unit, the signal at 7.75 ppm is most likely
due to both H3 and H4, as these two protons are present in very similar
electronic environments. These protons would exhibit through-bond coupling to
two other protons: H3 to H2, and H4 to H5. A NOESY experiment was used to
confirm specific assignments of all of these protons. The resulting spectrum is
shown in Figure 3.8.
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Figure 3.8 – NOESY NMR spectrum of complex (3), with selected key proton
couplings highlighted.

The imine proton at 8.54 ppm showed through space correlations to
signals at 8.19 ppm and 7.53 ppm that could be assigned to H5 and H11,
respectively. There were also similar patterns within this NOESY spectrum
compared to those observed for complex (1), owing to the identical
salicylaldehyde unit. However, the key correlation in this spectrum was between
the imine proton and the multiplet at 8.19 ppm. Since this signal was within the
the phenanthrene unit, it could be assigned as H5. This signal then exhibited a
coupling to the large multiplet at 7.75 ppm, which itself further correlated to the
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multiplet at 8.92 ppm, allowing the assignment of these three signals as H5,
H3/H4 and H2, respectively.
The 13C-NMR spectrum of complex (3) (Figure 3.9) contained the correct
number of signals. There were several similarities between the spectrum of this
complex and that of complex (1), owing to the salicylaldehyde unit present in
both complexes. However, the signals associated with carbon atoms within the
phenanthrene moiety required the use of HSQC spectra in order to make
definitive assignments. For example, the 1H-NMR signal at 7.75 ppm, which
arises from H3 and H4, gave a strong cross-peak with two carbon signals at
126.90 and 128.21 ppm, allowing their assignment to C3 and C4. Similarly, the
two carbon signals at 124.49 and 124.75 ppm exhibited correlations to proton
signals at 8.92 and 8.19 ppm, allowing assignment of these two carbon signals as
C2 and C5. Owing to their very similar chemical shifts, it was not possible to
definitively assign these signals as arising from specifically C2 or C5.
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Figure 3.9 – 13C- and HSQC NMR spectra of complex (3), with selected protoncarbon correlations highlighted.

3.3.2 Alkylation of the precursor nickel Schiff base complexes
The final step towards producing complexes which could be used for
DNA binding studies was to react the hydroxylated nickel Schiff base compounds
with

various

alkylating

agents,

such

as

1-(2-chloroethyl)piperidine

hydrochloride. These reactions were performed in the presence of a significant
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excess of base (K2CO3) and yielded alkylated nickel Schiff base complexes as
orange solids. This is summarised in Figure 3.10 using complex (2) as an
example.

Figure 3.10 – Reaction scheme for the synthesis of nickel Schiff base complex (2),
using (1) as the starting material.

Initial attempts to synthesise (2) as per the literature method193 yielded
the product in 40 – 45 % yield, with good purity. In order to allow more of the
starting materials to react, the volume of DMF used was decreased from 25 mL to
10 mL.

As a result, the yield obtained from this method was significantly

improved, increasing to almost 80 %. Once this improvement was discovered,
the volume of DMF used for all subsequent alkylation reactions was also
decreased. The yields obtained for each of the alkylated complexes produced
during the course of this thesis research are summarised in Table 3-2.

103

Table 3-2 – Yields of alkylated nickel Schiff base complexes.
Nickel complex

Structure of alkyl
group

Structure of
diamine

Yield

(2)

80 %

(4)

43 %

(6)

34 %

(8)

80 %

(9)

80 %

(10)

16 %

(11)

84 %

(12)

74 %

(13)

79 %

Typically, the target alkylated nickel Schiff base complex precipitated as
an orange solid, which could be directly isolated by filtration. However, some
complexes required a slightly different isolation method. For example, filtration
of solutions containing complexes (6), (8) or (13) did not give the desired
product, which was instead present in the highly coloured filtrates. Therefore,
the DMF was removed using heat and very low pressure, allowing the alkylated
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complexes to be successfully isolated. Any unreacted starting material was
removed during the washing stage, as it was not soluble in the DCM solvent.
The morpholine-containing complexes (9), (10), and (11), as well as the
piperidine complex (12) were isolated in very low yields, despite decreasing the
volume of DMF solvent used.

Therefore, both the residue obtained by

evaporating the filtrate and any filtered solid were combined in the washing
step.

Any unreacted starting nickel Schiff base complex was subsequently

removed during this process. This enabled satisfactory yields of all complexes
except (10) to be obtained. In the case of the latter complex, a large amount of
unreacted starting material remained in the solution, which was removed by
gravity filtration.
Full assignment of 1H- and

13C-NMR

spectra of all alkylated complexes

was achieved using various 2D NMR techniques. An example of this process
using complex (2) is described below. The full assignment of all the 1H- and 13CNMR signals for this complex has not previously been described, although the
spectra themselves have been reported.193
The fully assigned 1H-NMR spectrum of complex (2) is presented in
Figure 3.11, with expansions of both the aromatic and aliphatic regions also
shown separately for greater clarity. Since the aromatic portion of the structure
of (2) is identical to the structure of (1), discussion of this part of the 1H-NMR
spectrum will not be detailed here. The 1H-NMR signals for the piperidine
groups all appear in the upfield region of the spectrum, owing to their aliphatic
nature. Most notable are the two triplets at 2.78 and 4.11 ppm. The splitting
pattern and relative integration allowed their assignment to either H14 or H15.
Further upfield in the spectrum, however, the splitting of the remaining proton
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signals was not as clear. Nevertheless, the signal at 1.45 ppm was assigned to
H19, owing both to the smaller relative integration of this signal as well its
chemical shift.
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Figure 3.11 – 1H-NMR spectra of complex (2), with the structure and atom
numbering of the complex shown in the inset.
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The exact assignment of the remaining aliphatic signals again required
the use of 2D techniques, including COSY NMR spectroscopy (Figure 3.12). In the
aromatic portion of the molecule, the same coupling patterns were observed as
for the corresponding hydroxylated complex (1). This meant that protons in the
phenylenediamine moiety (H1 and H2) showed coupling to one another, and the
two doublets in the salicylaldehyde moiety (H7 and H8) were also coupled
together. Within the alkylating moiety, coupling within both the ethylene chain
and the piperidine group was clearly seen. For example, the multiplet at 1.61
ppm exhibited cross-peaks with the broad singlet at 2.50 ppm. This coupling, as
well as the integration of these signals, allowed their assignment to H17 or H18.
Figure 3.12 also shows that the two triplets at 2.78 ppm and 4.11 ppm, arising
from the CH2 groups in the ethylene linker moiety, are coupled together. No
coupling between the piperidine ring and ethylene linker was observed,
however.
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Figure 3.12 – COSY spectrum of complex (2), showing three bond couplings
between selected protons.

NOESY (Figure 3.13) was required to fully assign the 1H-NMR spectrum of
this complex. Similar through-space couplings within the aromatic portion of the
complex were observed to what was reported for the hydroxylated precursor
complex (1). In particular, the coupling of the imine proton to both H2 and H7
was used to make final assignments of these protons. Another key NOESY
correlation in this complex was that observed between the doublet at 6.59 ppm
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(H10) and the triplet at 4.11 ppm. This enabled the triplet to be assigned as H14,
and also confirmed that complex (2) had indeed been formed. In addition, it was
now possible to definitively identify the triplet at 2.78 ppm as arising from H15.
Further NOESY couplings between the signals at 2.78 ppm and 2.50 ppm enabled
identification of the latter as being due to H17. By using both the COSY spectrum
and the remaining NOESY correlations, all proton resonances were subsequently
successfully assigned.
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Figure 3.13 – NOESY spectrum of complex (2), with selected correlations
highlighted.

The

13C-NMR

spectrum of complex (2) is shown in Figure 3.14, and

contained the expected number of signals. Whilst some assignments could be
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made by comparing the observed chemical shifts to those of

13C

resonances in

the spectra of the starting materials, an HSQC spectrum was required to
complete this task (also shown in Figure 3.14). Of note in the 13C-NMR spectrum
were two signals at 25.92 ppm and 54.95 ppm, which were of greater intensity
than all other 13C resonances. These signals were therefore assigned to C17 and
C18, owing to the fact that there are twice as many of these carbon atoms within
the structure of (2).
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Figure 3.14 – 13C-NMR and HSQC spectra of complex (2). Selected proton-carbon
correlations are highlighted.
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C-H correlations were used to assign most of the remaining signals in the
13C

spectrum. Assignment of the aromatic carbon atoms was accomplished in a

very similar fashion to that described earlier for the precursor hydroxylated
complex (1). For example, the two signals at 114.64 and 114.67 ppm correlated
to only one proton signal, meaning that one was a tertiary carbon (in this case,
C2), whereas the other was a quaternary carbon. Owing to its chemical shift, it
was assigned to C6. With respect to the aliphatic signals, C-H correlations
observed in the HSQC enabled assignments of most of the remaining carbon
atoms.
ESI mass spectrometry also proved to be a valuable tool for confirming
that the alkylated complexes had been successfully obtained. This was possible
as the nitrogen atoms of the piperidine rings undergo protonation in protic
solvents, enabling positive ion ESI mass spectra to be obtained. Typical mass
spectra of complexes (4) and (13) are shown in Figure 3.15. In each case, the
most abundant ions observed were from the protonated complex, i.e. [M + 2H]2+
(m/z 364.8 and 380.4 for (4) and (13), respectively).
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Figure 3.15 – Positive ion ESI mass spectra of selected alkylated complexes: (a)
(13); and (b) (4).

3.3.3 Asymmetric nickel Schiff base complexes
The synthesis and characterisation of the asymmetric nickel Schiff base
complexes provided additional challenges.

The synthesis method used was

centred upon a literature procedure for a similar, but not identical complex, 207
and is outlined for complex (14) in Figure 3.16. The first step was to react one
equivalent of 2-hydroxynaphthaldehyde with 1,2-phenylenediamine to generate
a ligand with only one imine. Subsequently, one equivalent of this intermediate
was reacted with 2,4-dihydroxybenzaldehyde in order to obtain the full Schiff
base ligand. It was not possible to obtain an NMR spectrum of this ligand, as its
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solubility was too low in all common deuterated solvents. The ligand was then
reacted overnight in the presence of excess nickel acetate to produce a fine,
powder-like solid.

Figure 3.16 – Reaction scheme for the synthesis of the asymmetric nickel Schiff
base complex (14).

Since this solid was shown to contain the desired product and some
unreacted starting material, a recrystallisation procedure was developed to
separate the two components. Since the ligand itself was not soluble in any
common solvents, and the nickel Schiff base complexes only readily dissolved in
DMSO or DMF, this left very few options. However, by first suspending the solid
in MeOH, and then adding DMSO, it proved possible to selectively dissolve the
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nickel complex. This mixture was filtered, thereby separating the ligand as a
solid, and leaving the asymmetric nickel Schiff base complex dissolved in the
methanol/DMSO mixture. The complex eventually precipitated and was isolated,
giving a pure product which was suitable to be alkylated, as per the procedure
shown in Figure 3.10.
Complete characterisation of the alkylated asymmetric complexes (15)
and (16) using NMR spectroscopy proved to be difficult, owing to a number of
factors. These included overlap of signals arising from the complex and the
solvent, as well as significant variations in relaxation times for signals in
different regions of the spectrum. The latter issue meant that in some spectra
there were well resolved resonances in one region of the spectrum, but not in
other parts. For example, the 1H-NMR spectrum of (15) dissolved in DMSO-d6
(Figure 3.17) shows many sharp signals in the aromatic proton region, but
exhibits broad signals further upfield in the aliphatic region, some of which
overlapped with strong signals from DMSO and water.
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Figure 3.17 – 1H-NMR spectrum of complex (15), obtained in DMSO-d6, with the
structure and atom numbering scheme of the complex shown in the inset.

Assignment of the 1H-NMR spectrum of complex (15) in DMSO-d6 was
possible after acquisition of the corresponding COSY (Figure 3.18) and NOESY
(Figure 3.19) spectra. The COSY spectrum allowed many of the proton signals
associated with individual ring systems to be identified. For example, the two
most upfield aromatic signals at 6.35 and 6.44 ppm, strongly resembled those at
6.32 and 6.59 ppm in the spectrum of the symmetrical complex (2) (Figure 3.11),
which were assigned to the salicylaldehyde ring protons H8 and H10. Therefore
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the signals at 6.35 and 6.44 ppm in Figure 3.17 were also assigned to these two
protons. The observation of a cross-peak between the signal at 6.35 ppm and a
doublet at 7.50 ppm in the COSY spectrum allowed assignment of the latter
doublet to H7, which is the only remaining proton in this ring.
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Figure 3.18 – COSY NMR of complex (15), dissolved in DMSO-d6.

The protons within the phenylenediamine moiety gave rise to a more
complex pattern of resonances than in otherwise similar complexes such as (2),
owing to the asymmetric nature of (15). A total of three sets of signals were
observed which could be assigned to H1, H2, H27 and H28. H1 and H28 were
observed as a large multiplet at 7.29 ppm with an integral of two. This multiplet
showed strong cross-peaks with signals at 8.07 ppm and 8.41 ppm in the COSY
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spectrum, indicating that these were attributable to the two remaining protons
in this ring system, H2 and H27.
The remaining signals in the 1H spectrum consisted of two groups of
coupled resonances, and arose from protons in the naphthaldehyde moiety. Two
doublets at 7.06 and 7.18 ppm exhibited cross-peaks with each other in the COSY
spectrum, but no other 1H resonances. These were therefore assigned to H15
and H16. The remaining four protons in the naphthaldehyde ring, H18-H21,
exhibited several cross-peaks in the COSY spectrum which facilitated their
assignment. The two central protons, H19 and H20, were assigned to the two
triplets at 7.33 ppm and 7.54 ppm. These triplets showed cross-peaks with each
other in the COSY spectrum, as well as with the doublets at 7.78 ppm and 8.51
ppm. These were therefore assigned to either H18 or H21.
A NOESY spectrum (Figure 3.19) was required to complete the
assignment of all signals in the 1H-NMR spectrum. Once again the observation of
correlations between the imine proton signal and that of adjacent protons was
critical to this process. First, the two imine resonances at 8.72 and 9.33 ppm
needed to be definitively assigned to either the salicylaldehyde or
naphthaldehyde imine groups. The signal at 8.72 ppm showed a NOESY crosspeak with the doublet at 7.50 ppm, which was already assigned to a proton in the
salicylaldehyde ring using the COSY spectrum. This imine singlet was therefore
assigned to H5. This assignment was confirmed by the observation of a crosspeak between the remaining imine singlet at 9.33 ppm and a doublet at 8.51
ppm, which had already been assigned to an as yet unidentified proton in the
naphthaldehyde ring. This correlation meant that these two signals could be
assigned to H24 and H21, respectively.
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Figure 3.19 – NOESY NMR spectrum of complex (15), with selected key couplings
highlighted.

Two additional NOESY correlations were also useful in assigning the
remaining 1H signals. The first of these was between the imine (H5) resonance
at 8.72 ppm and the doublet at 8.07 ppm, which meant that the latter could be
assigned to H2. The second was the correlation between two doublets at 7.06
ppm and 7.78 ppm. The former doublet was identified previously as arising from
either H15 or H16, as it exhibited only one cross-peak in the COSY spectrum.
This signal exhibited a NOESY correlation with its COSY-coupled doublet at 7.81
ppm, as well as another with the doublet at 7.78 ppm. This meant that the 7.06
ppm signal could be assigned to H16, as this proton would be expected to show
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NOESY correlations with both H15 and H18. Therefore, the signals at 7.78 ppm
and 7.81 were assigned to H18 and H15, respectively.
The 1H-NMR spectrum of (15) in CDCl3 (Figure 3.20) differed significantly
from that obtained in DMSO-d6, as it contained many well-resolved resonances
from aliphatic protons. This enabled assignment of signals to individual protons
within the single piperidine moiety, something which was not possible for the
spectrum obtained in DMSO-d6. Whilst there were some differences in the
chemical shifts of resonances attributable to aromatic protons in the spectra
obtained in different solvents, the same types of COSY and NOESY correlations
were observed. Therefore, for brevity they will not be discussed in detail here.
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Figure 3.20 – 1H-NMR spectrum of complex (15), obtained in CDCl3, with the
structure and atom numbering scheme for the complex shown in the inset.

The COSY spectrum of complex (15) (Figure 3.21) showed correlations
between resonances attributable to the sole piperidine moiety that were similar
to those observed in the corresponding spectra of other complexes containing
120

the same alkyl group and ring system. Whilst the resolution of these signals in
Figure 3.20 was not as great as in the spectra of other alkylated complexes, the
chemical shifts of resonances attributable to the same protons were always very
similar, if not identical.
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Figure 3.21 – COSY spectrum of complex (15), obtained in CDCl3.

One of the most important pieces of information required to assign all of
the spectral features of this complex was observed in the NOESY spectrum
(Figure 3.22). This was the observation of a cross-peak between the singlet at
6.62 pm (H10) and the broad singlet at 4.16 ppm (H30). This enabled the
assignment of the signal due to the latter methylene group, and also proved that
(15) had been obtained as an intact molecule. Furthermore, assignment of H30
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subsequently enabled signals due to the other methylene group in the ethylene
linker, and the piperidine group, to also be made.
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Figure 3.22 – NOESY NMR spectrum of complex (15), obtained in CDCl3. The key
through-space correlation for this complex is highlighted.

Acquisition of suitable quality 13C-NMR spectra of complex (15) was even
more problematic. Spectra were obtained using different relaxation times in
order to facilitate assignment of signals in both the aromatic and aliphatic
regions. For example, for both complexes (15) and (16),

13C

spectra acquired

using a 1 s delay between pulses did not give spectra of sufficient quality in any
solvent, even after a total accumulation time of 8 h. For complex (15), spectra
acquired in DMSO-d6 using a 2 s pulse delay yielded satisfactory signals in the
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aromatic carbon region, but there were no signals apparent in the aliphatic
region. When the solvent was changed to CDCl3,

13C

spectra acquired using

either a 1 or 2 s pulse delay did not give suitable spectra, as only some signals
were apparent, even though HSQC correlations indicated where other peaks
should appear. When a 5 s pulse delay was implemented, the spectrum was of
sufficient quality that almost all assignments could be made, with the exception
of C30, which did not appear in the

13C

spectrum but was indicated by HSQC to

be present at approximately 65 ppm. In view of the problems encountered
obtaining a single spectrum containing signals attributable to all carbon atoms in
complex (15), the assignments reported here had to be obtained using more
than one solvent. For complex (16), 1H-NMR spectra obtained in CDCl3 were of
acceptable quality, however this was not true for

13C-NMR

spectra obtained

using pulse delays of 1 s, 2 s and 5 s. However, a suitable spectrum was obtained
using a solution of (16) dissolved in DMF-d7 and a 1 s pulse delay.
The 13C and HSQC spectra of complex (15) dissolved in DMSO-d6 are shown
in Figure 3.23. Whilst there were some poorly resolved, broad signals in the 1HNMR spectrum for the aliphatic protons, no
correlations were observed for this region.

13C-NMR

signals or HSQC

However, there were strong

correlations between the aromatic proton and carbon signals in the HSQC
spectrum. The resolution of these signals and overall signal:noise ratio of the
spectrum was sufficient to allow all aromatic signals in the
assigned.
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Figure 3.23 – 13C-NMR and HSQC spectra of complex (15) in DMSO-d6, with
selected key correlations highlighted.

The 13C resonances for both C2 and C27 were expected to appear at similar,
though not identical, chemical shifts, owing to the asymmetric nature of (15).
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Since the signals for the corresponding protons in the 1H-NMR spectrum were
definitively assigned as described previously, their HSQC correlations were used
to identify the signal at 115.51 ppm as C2, and the signal at 116.42 ppm as C27.
Conversely, on other occasions some protons which had very similar chemical
shifts exhibited HSQC correlations which indicated that their corresponding

13C

signals had well separated chemical shifts. For example, H15 and H18 both
appeared as doublets in the

1H-NMR

spectrum at 7.81 and 7.78 ppm,

respectively. However, HSQC correlations indicated that C15 and C18 appeared
at 135.91 ppm and 128.84 ppm, respectively. Furthermore, C18 was in an area
of the spectrum where carbon signals from five carbon atoms were closely
grouped, all appearing between 126.35 ppm and 128.84 ppm. Using these HSQC
correlations, therefore, allowed separation and subsequent assignment of all
these signals.
The

13C-NMR

spectrum of complex (15) in CDCl3 (Figure 3.24) showed

carbon signals attributable to all but one carbon atom in the aliphatic portion of
the molecule. Whilst it is not clear why this signal was not observed, the HSQC
spectrum showed a strong cross-peak between the missing

13C

signal and the

corresponding proton signal for H30. This indicated that the signal for C30
should occur at approximately 65 ppm.
correlations between the 1H and

13C

Figure 3.24 shows many other

spectra which enabled assignment of the

remaining carbon signals in both the aliphatic and aromatic regions.
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Figure 3.24 - 13C and HSQC NMR spectra of complex (15), obtained in CDCl3. For
clarity, the solvent signal in the 13C-NMR spectrum has been suppressed using
processing software.

Despite the problems encountered with obtaining full-scale, high quality
1H-

and 13C-NMR spectra of complexes (15) and (16), their successful synthesis

was eventually confirmed using a combination of NMR techniques, as well as ESIMS and microanalysis. The positive ion ESI mass spectra of (15) and (16) are
shown in Figure 3.25. Owing to the presence of a nitrogen atom in the piperidine
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ring, these complexes can become protonated in protic solvents, allowing spectra
to be obtained which indicated the synthetic procedures had been successful.
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Figure 3.25 – Positive ion ESI mass spectra of asymmetric, alkylated complexes:
(a) (15); and (b) (16).

3.3.4 Crystallographic data
X-ray data collection and structure determinations were performed by Dr.
Anthony Willis, of the Research School of Chemistry, Australian National
University. Crystals of complexes (5), (6), (13) and (14) suitable for single
crystal X-ray analysis were grown from MeOH/DMSO solvent mixtures.

In

contrast, crystals of complex (4) which were used for crystallographic analysis
were obtained from a DCM/PET spirit mixture. The results of crystallographic
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data collection and structure refinement performed on the five complexes are
summarised in Table 3-3. Figure 3.26 shows the ORTEPs of these complexes,
which show the numbering systems for the non-hydrogen atoms.
Complex (5) crystallised in the monoclinic space group P21/c, with one
metal complex and two water molecules of crystallisation in the asymmetric unit.
The phenolic groups in the nickel Schiff base complex participate in hydrogen
bonding interactions with the oxygen atoms of the lattice water molecules. The
asymmetric unit of complex (6) belongs to the monoclinic space group C2/c, and
consists of one full metal complex and one highly disordered molecule of DMSO.
Complex (13) also has an asymmetric unit consisting of a single metal complex
and a region containing highly disordered solvent molecules, which could not be
modelled satisfactorily. Similar to the previous two complexes, the structure of
(13) belongs to a monoclinic crystal system, but with a space group of P21/n.
The diaminophenanthrene complex (4) crystallised as a monoclinic system,
with a space group of P21/c. No solvent molecules were present in the crystal
lattice of this complex, owing to it being crystallised from a far more
hydrophobic combination of solvents than that used for the other complexes.
The asymmetric complex (14) crystallised in the monoclinic P21/n space group
with one molecule of DMSO in the crystal lattice. The phenolic groups in the
nickel Schiff base complex are involved in hydrogen bonding interactions with
the oxygen atom of the DMSO molecule.
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Table 3-3 – Summary of crystallographic data.
(5)

(6)

(13)

(4)

(14)

Formula

C28H22N2NiO42(H2O)

C42H48N4NiO4C2H6

C44H52N4NiO4

C42H44N4NiO4

C24H16N2NiO3.C2H6

M

545.23

759.63

727.55

Crystal system

Monoclinic

809.71
OS
Monoclinic

Monoclinic

Monoclinic

517.25
OS
Monoclinic

Space group

P21/c

C2/c

P21/n

P21/n

P21/n

a (Å)

8.3098(1)

31.9069(3)

20.0562(7)

8.1684(1)

15.2582(2)

b (Å)

28.7045(6)

15.0731(2)

10.1772(2)

20.6438(3)

5.6873(1)

c (Å)

10.4088(2)

20.8035(2)

22.9552(7)

21.0440(3)

26.0174(3)

 (˚)

91.0868(12)

125.4699(6)

112.4092(13)

99.3335(14)

102.6233(12)

V (Å3)

2482.35(8)

8148.40(17)

4331.7(2)

3501.60(8)

2203.16(6)

Dx (Mg m-3)

1.459

1.320

1.165

1.380

1.559

Z

4

8

4

4

4

Number of unique
reflections
Refinement

4362

9323

7680

6875

4294

R[F2 > 2σ(F2)] = 0.036

0.041

0.051

0.035

0.033

wR(F2) = 0.093

0.112

0.148

0.091

0.089

1017431

1017432

1017433

-

-

CCDC number
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Figure 3.26 – Molecular structures of (5), (6), (13), (4) and (14).
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The nickel ion in all five crystal structures was observed to possess a
square planar coordination geometry. The Ni-N and Ni-O bond distances, as well
as angles around the central nickel atom (Table 3-4) are close to standard
values.150,206,208 The meso-1,2-diphenylethylenediamine groups in (5), (6) and
(13) are arranged to minimise steric interactions. This results in one phenyl ring
being in an equatorial position, with the face of its ring perpendicular to the
plane of the molecule, whilst the other phenyl ring is in an axial position. This is
illustrated in Figure 3.27 for complex (6). Such an arrangement results in
torsion angles (N2-C9-C8-N1) for (5), (6) and (13) of 41.8 (2)°, 36.6 (2)° and
29.8 (3)°, respectively. For comparison, the torsion angle of these same atoms in
complex (4) is only 16.0 (2)°, whereas complex (14) has no torsion through
these bonds. Additionally, the 9,10-diaminophenanthrene unit in (4) is not coplanar with the rest of the nickel Schiff base molecule (Figure 3.28).

Table 3-4 – Selected bond lengths (Å) and angles (°) for nickel Schiff base
complexes.

Ni-O1
Ni-O2
Ni-N1
Ni-N2
O1-Ni-O2
O1-Ni-N1
O2-Ni-N1
O1-Ni-N2
O2-Ni-N2
N1-Ni-N2

(5)
1.8403 (17)
1.8607 (17)
1.862 (2)
1.838 (2)
83.63 (7)
95.53 (8)
177.09 (9)
176.00 (9)
94.74 (8)
86.28 (9)

(6)
1.8400 (13)
1.8404 (14)
1.8515 (16)
1.8419 (15)
83.47 (6)
95.23 (6)
176.48 (7)
177.18 (7)
94.39 (7)
87.01 (7)

(13)
1.849 (2)
1.849 (2)
1.851 (3)
1.836 (3)
85.28 (10)
95.25 (11)
179.11 (12)
176.43 (12)
93.78 (11)
85.73 (12)
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(4)
1.8447 (11)
1.8378 (11)
1.8557 (13)
1.8659 (13)
82.72 (5)
95.78 (5)
176.84 (5)
176.43 (5)
96.22 (5)
85.43 (6)

(14)
1.8460 (12)
1.8430 (12)
1.8563 (15)
1.8508 (14)
84.38 (5)
95.20 (6)
178.73 (6)
178.45 (6)
94.07 (6)
86.35 (6)

Figure 3.27 – Crystal structure of complex (6).

Figure 3.28 – Crystal structure of complex (4), viewed from the 9,10diaminophenanthrene moiety towards the nickel ion.

In the crystal lattice of (5), the nickel Schiff base molecules are arranged
in a slipped co-facial manner, and are related by a crystallographic inversion
centre (Figure 3.29). The closest intermolecular distance is 2.62 Å, and is found
between the phenolic oxygen (O4) and the hydrogen atom of the diamine (H81,
which is bonded to C8).
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Figure 3.29 – Crystal packing of two molecules of (5).

The crystal structure of complex (6) also possesses a crystallographic
inversion centre, however in this instance the metal complexes sit neatly on top
of one another, with a separation of 3.4 Å. Owing to this new configuration, H81
now makes contact with both oxygen atoms coordinated to the nickel atom, with
the distances for O1-H81 and O2-H81 being 2.38 and 2.69 Å, respectively.
Complex (13), on the other hand, does not exhibit the same arrangement as the
previous two complexes also containing the meso-1,2-diphenylethylenediamine
moiety. Instead, there are contacts between the H atoms on the phenyl groups
and the oxygen atoms coordinated to the nickel. The distances of these contacts
are 2.46 and 2.64 Å. A further notable aspect of the structure of this complex is
that it is distinctly bowed (Figure 3.30). This results in a C1-O1-O2-C14 torsion
angle of 16 (2)°, and a C10-N2-N1-C7 torsion angle of 15 (2)°.
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Figure 3.30 – Crystal structure of complex (13), viewed from the meso-1,2diphenylethylenediamine moiety towards the nickel ion.

The crystal structure of complex (4) also possesses a crystallographic
inversion centre, and again the nickel complexes are sitting directly on top of one
another (Figure 3.31). There are contacts between C-H groups of the benzylic
moieties of both complexes, as well as a close contact of 2.53 Å between O1 and
H271, which is bonded to C27 in the phenanthrene moiety.
In contrast to what is illustrated in Figure 3.31 for complex (4), the nickel
molecules in the crystal structure of (14) are not packed together to form a cofacial arrangement (Figure 3.32). Instead, the molecules assemble in such a way
as to result in contacts between carbon atoms on the benzylic and
phenylenediamine moieties (C3-C22 = 3.35 Å), as well as between H221
(attached to C22) and both the phenolic O3 and C3 (2.61 and 2.75 Å,
respectively).
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Figure 3.31 – Arrangement of nickel molecules in the crystal lattice of complex
(4).

C3
H221 O3

Figure 3.32 – Arrangement of nickel molecules in the crystal lattice of complex
(14). The contacts between H221 and both O3 and C3 are highlighted.
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CHAPTER 4 - DNA-BINDING PROPERTIES OF
NICKEL SCHIFF BASE COMPLEXES: EFFECT OF
VARYING THE DIAMINE MOIETY
4. 1 Introduction and scope of this chapter
The mechanism by which metallointercalators interact with dsDNA has
been long understood to principally involve the π-π stacking of planar, aromatic
ligands between the bases of the DNA. As a result, increasing the size of aromatic
ligands on a metal complex often leads to an increase in the extent and/or
strength of binding interactions with DNA.45-46,54,56,63 The presence of suitably
positioned aromatic ring systems in the coordination sphere on nickel Schiff base
complexes has also been shown to be an important factor in determining their
ability to bind to DNA quadruplexes.149,193

It was therefore decided to

systematically explore the effect of replacing the aromatic diamine moiety in the
“top” of one such well-studied nickel Schiff base complex (2) by other structural
units, to see what effect this might have on affinity towards dsDNA as well as
both unimolecular and tetramolecular DNA quadruplexes. The structures of the
four complexes whose binding properties are described in this chapter are
shown in Figure 4.1.
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Figure 4.1 – Structures of nickel Schiff base complexes whose binding to dsDNA
and qDNA are explored in this chapter.

4. 2 DNA binding experiments using duplex DNA
As a first line of investigation, ESI mass spectra were obtained of solutions
containing different ratios of each nickel Schiff base complex and the dsDNA D2
(Table 2-1) in order to compare their binding ability. Figure 4.2 shows the ESI
mass spectra of D2 alone, and solutions containing D2:(2) ratios of 1:1, 1:3, 1;6
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and 1:9. Ions at m/z 1626.4 and 1952.0 in the spectrum of D2 alone (Figure 4.2
(a)) correspond to [D2 - 6H]6- and [D2 - 5H]5-, respectively. When one equivalent
of the nickel complex was also present in solution, the resulting spectrum
(Figure 4.2 (b)) also displayed ions of high abundance from free DNA, as well as
ions of very low abundance at m/z 1731.0, and with an overall charge of 6-,
which can be assigned to non-covalent complexes containing one nickel molecule
bound to D2. These non-covalent complexes are represented as “{D2 + (2)}”. In
the spectrum of the solution containing a 1:3 ratio of DNA:(2) (Figure 4.2 (c)),
these ions now had the greatest abundance observed. Also present were ions
with an overall charge of 5- at m/z 2077.5, which are attributable to the same
non-covalent complex(es). This spectrum also contained peaks from ions of low
abundance at m/z 1835.5, which are attributable to non-covalent complexes
containing two nickel molecules bound to DNA, i.e. {D2 + 2(2)}. After increasing
the amount of (2) in solution further, the spectra shown in Figure 4.2 (d) and (e)
were obtained. Ions from free DNA decreased in abundance as the amount of (2)
was increased, whilst those from {D2 + (2)} remained the most abundant. Ions
attributable to D2 with two nickel Schiff base molecules attached non-covalently
increased further in abundance. In addition, ions of low abundance at m/z
1940.3 and 2328.1 were also observed, attributable to {D2 + 3(2)}.
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Figure 4.2 – Negative ion ESI mass spectra of solutions containing different ratios
of (2) and D2. (a) free D2; (b) D2:(2) = 1:1; (c) D2:(2) = 1:3; (d) D2:(2) = 1:6; (e)
D2:(2) = 1:9.  = free D2;  = {D2 + (2)};  = {D2 + 2(2)};  = {D2 + 3(2)}.

Overall, the results in Figure 4.2 show that as the ratio of DNA:(2) was
increased, ions attributable to non-covalent complexes with greater numbers of
nickel molecules bound to the dsDNA increased in abundance. Similar trends
were observed for solutions containing D2 and either complex (4) or (8). The
mass spectral results therefore confirmed the ability of each of these three nickel
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complexes to bind to this dsDNA molecule, most likely in a non-covalent fashion.
Having demonstrated that binding does occur, the next objective was to
ascertain whether complexes (2), (4), (6) and (8) vary significantly in the extent
to which they bind to D2. In order to address this aim, it was necessary to
compare spectra having the same ratio of D2 and each of the nickel complexes.
For example, Figure 4.3 shows the ESI mass spectra of solutions
containing D2 and one of (2), (4), (6) or (8) at a DNA:nickel complex ratio of 1:6.
In each spectrum, ions at m/z 1626.4 and 1952.0 are present which are
attributable to free dsDNA.

However, the abundances of these ions varies

depending on the extent to which the different nickel complexes bind to the DNA.
For instance, in Figure 4.3 (d), which is a spectrum of a solution containing D2
and (6), the ions at m/z 1626.4 are of high abundance, and the only ions present
which are attributable to non-covalent complexes (at m/z 1748.0) are of
extremely low abundance. Together these results suggest that complex (6),
containing the meso-1,2-diphenylethylenediamine moiety, has a very low affinity
for D2. Figure 4.3 (b) and (e) both show ions of medium to high abundance from
free D2, along with ions of similar or lower abundance which indicated that noncovalent complexes containing between one and three nickel molecules bound to
DNA are also present. This indicates that complexes (2) and (8) have a markedly
greater affinity for D2, compared to that exhibited by (6). It is important to note
that in this context, affinity refers to the overall extent to which nickel Schiff base
complexes are bound to the dsDNA. Since there are several binding sites on D2,
they may not be equivalent. In addition, as a greater number of molecules bind
to the 16 base pair dsDNA, further binding will be limited by steric hindrance.
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Figure 4.3 – Negative ion ESI mass spectra of solutions containing different
nickel Schiff base complexes and D2 at a 1:6 ratio. (a) free D2; (b) D2 + (2); (c)
D2 + (4); (d) D2 +(6); (e) D2 + (8).  = free D2;  = {D2 + (Ni)};  = {D2 +
2(Ni)};  = {D2 + 3(Ni)};  = {D2 + 4(Ni)}.

Inspection of Figure 4.3 (c) reveals there is little free DNA remaining in
solution, and that non-covalent complex formation has been more extensive in
the case of complex (4) than for any of the other nickel complexes. This result
may be rationalised by proposing that the greater aromatic surface area of (4)
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will enable it to bind more extensively to dsDNA than any of the other nickel
complexes, possibly by an intercalative binding mode.
One of the most interesting results shown in Figure 4.3 is the almost
complete absence of non-covalent complex formation when (6) was added to a
solution containing D2. This indicates that the introduction of the meso-1,2diphenylethylenediamine moiety into the nickel complex has had a significant,
and negative, impact on affinity towards dsDNA. Inspection of the X-ray crystal
structure of (6), as well as the precursor molecule (5) and the analogue (13)
(shown and discussed in section 3.3.4), shows that the two aromatic rings of this
structural unit are not co-planar with respect to each other, or the other two
aromatic rings in the Schiff base ligand. Such an arrangement is likely to restrict
the manner with which (6) can approach dsDNA, and is likely to strongly inhibit
intercalation as a mode of binding.
Inspection of Figure 4.3 readily leads to the conclusion that complex (4)
has the highest affinity of the four nickel complexes for D2, and complex (6) the
lowest affinity. It is also apparent that complexes (2) and (8) have affinities for
this DNA molecule that lie somewhere between those of these aforementioned
complexes; however, it is very difficult to determine which of complexes (2) and
(8) binds more avidly. Under these circumstances it is useful to compare relative
abundances of ions. Relative ion abundances are calculated by adding together
the abundances of ions from either free DNA or a specific non-covalent complex,
and dividing this by the sum of the abundances of all ions present in the
spectrum.
Figure 4.4 presents the relative abundances of ions from free D2 and each
of the different types of non-covalent complexes giving rise to the ions in the
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spectra shown in Figure 4.3. Using this method of presenting the mass spectral
data, it can still be seen that complex (4) binds the most extensively to D2, as the
relative abundances of ions from non-covalent complexes corresponding to one,
two and three nickel molecules bound to D2 are higher than for any of the other
nickel complexes. This proposal assumes that the response factors for each
complex are similar.

The response factor refers to the ability of the mass

spectrometer to detect an analyte and involves intrinsic factors of the analyte
and the ionisation source (e.g. ionisation efficiency), and transmission through
the focussing and mass analysis regions of the instrument. It is reasonable to
assume similar response factors for the nickel Schiff base complexes ((2), (4), (6)
and (8)) given their chemical similarity and likely binding modes to dsDNA.
Similar assumptions have previously been made for other DNA ligands.115,245-248
Figure 4.4 also shows that the relative abundances of ions from noncovalent complexes consisting of one or three nickel molecules bound to DNA is
almost identical for (2) and (8). The relative abundance is higher for complex
(2) in the case of ions from non-covalent complexes containing two nickel
molecules bound to D2, suggesting that the affinity of this nickel complex may be
slightly greater than that of (8). Quantifying the mass spectral data in this
manner therefore supports that the order of binding affinity for these four
complexes is (4) > (2) ~ (8) > (6), but also suggests that (2) may have a slightly
higher binding affinity for this specific dsDNA than complex (8).
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Figure 4.4 – Relative abundances of ions from free DNA and different noncovalent complexes in spectra of solutions containing a 1:6 ratio of D2 and
different nickel complexes.

As described in Chapter 1, the use of circular dichroism (CD) spectroscopy
for analysing nucleic acids and the binding of small molecules to DNA is well
known. Therefore, this technique was chosen to probe the binding interactions
of the four nickel complexes with D2. Chiral molecules such as DNA have
distinctive CD spectra that vary with changes in their secondary structure, and
which are affected by the binding of organic molecules or metal complexes. For
example, the binding of small molecules like spermine or [Co(NH3)6]3+ to B-DNA
results in a change of conformation to Z-DNA, and is accompanied by marked
changes to the CD spectrum.46 In addition, an organic molecule or metal complex
which is achiral may give rise to an induced CD signal upon binding to a chiral
molecule such as DNA.46 CD spectroscopy can therefore be used to probe the
interactions of different small molecules with DNA, in order to provide
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information about the relative strengths of their binding and/or the nature of the
binding interaction. The mass spectral results presented above allowed some
preliminary conclusions to be reached concerning the effects of changing the
structure of the nickel Schiff base complexes on their binding to the dsDNA D2.
Therefore, the effects of adding increasing amounts of the nickel complexes on
the CD spectrum of D2 were examined. Of particular interest was whether or not
those nickel complexes which gave rise to high abundances of ions attributable
to non-covalent complexes in ESI mass spectra, also had large effects on the CD
spectra of the DNA molecules.
Figure 4.5 shows the effect on the CD spectrum of D2 of adding increasing
amounts of the four nickel complexes. The CD spectrum of the DNA alone shows
a major positive CD band with maximum ellipticity at 279 nm, and a negative CD
band with maximum ellipticity at 247 nm. These values are typical for B-form
DNA.249 As the metal complexes were added to the DNA, the ellipticity of the CD
bands changed, and there were shifts in their positions. These changes are
summarised in Table 4-1.
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Figure 4.5 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and D2. (a) D2 +(2); (b) D2 + (4);
(c) D2 + (6); and (d) D2 + (8)

The most substantial changes to the CD spectrum of D2 occurred when
complex (4) was added. Addition of 9 equivalents of this complex resulted in a
blue shift of 7.5 nm for the major, positive CD signal, as well as an increase in
ellipticity of 4.5 mdeg, which was by far the largest observed. These results are
qualitatively similar to those observed previously when octahedral ruthenium
and nickel complexes of the general formula [M(phen)2L]2+ (L = phen, dpq, dpqC,
dppz) were added to a 16mer dsDNA molecule.161,239 Therefore it would appear
that (4) is also capable of participating in intercalative binding interactions with
D2. The magnitude of the changes to the CD spectrum of dsDNA caused by
addition of the octahedral ruthenium and nickel complexes was much larger in
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some instances, indicating that complex (4) is perhaps not capable of inserting
its phenanthrene ligand as deeply into the dsDNA base stack as, for example, a
complex such as [Ni(phen)2(dppz)]2+ can with its dppz ligand. Furthermore,
complexes such as [Ni(phen)2(dppz)]2+ also caused other large changes to the CD
spectrum of dsDNA, including the appearance of a new, negative CD signal above
280 nm. In contrast, addition of (4) to D2 resulted in a new positive band above
300 nm. This indicates that the binding mode of (4) with dsDNA is distinct from
that of the above octahedral complexes.

Table 4-1 – Effect on the CD spectrum of D2 of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 279 nm
Negative CD band at 247 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
-1.9
0.36
-0.1
2.5
(4)
-7.5
4.5
1.0
0.32
(6)
0.8
1.6
-0.7
2.0
(8)
-5.8
0.29
0.4
0.29
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:9. Negative ∆λ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

Addition of complexes (2) and (8) to solutions containing D2 produced
only minor changes to the CD spectrum of the latter (Figure 4.5 (a) and (d),
respectively). For example, the maximum change in position of the positive CD
band was only 1.9 nm in the case of complex (2), while the effects on the
negative CD band were even smaller. If the size of the effects on the positive CD
band is considered to reflect the extent of interaction of the metal complexes
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with D2, then the order of binding affinity of the nickel complexes is either (4) >
(8) > (2) > (6) or (4) > (6) > (2) ~ (8), depending on whether the size of the
change in position of the major positive CD band, or its ellipicity, is considered.
In both cases the CD spectral results suggest complex (4) interacts most strongly
and/or extensively with D2; a conclusion in accord with the results of the ESI-MS
experiments presented earlier.
Despite this apparent concordance between the results obtained from the
two techniques, there are also some noteworthy differences. Most significantly,
addition of complex (6) to D2 resulted in significantly larger changes to both CD
signals of the latter, than that caused by addition of (8). This is in contrast with
results of the ESI-MS studies, where it was found that (6) had essentially no
ability to form non-covalent complexes with D2, whilst complex (8) did exhibit
this ability. This apparent contradiction can be rationalised by proposing that
complex (6), as a result of the meso-1,2-diphenylethylenediamine moiety,
interacts with D2 in a different manner to (8) or the other nickel complexes.
It is also worth noting that addition of (6) resulted in a small shift to
longer wavelengths for the positive CD band of D2, whereas the other three
nickel complexes caused much larger blue shifts. Furthermore, the ellipticity of
this band decreased when (6) was added, as opposed to an increase observed
with the other three nickel complexes. Enhanced ellipticity of this CD band is
typically associated with stronger π-π stacking interactions, which occur when
small molecules intercalate between the DNA base pairs.250-251

These

interactions are very unlikely to occur in solutions containing D2 and (6), owing
to the steric hindrance of the meso-1,2-diphenylethylenediamine moiety. The
changes to the CD spectrum of D2 upon addition of complex (6) may therefore be
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the result of weak interactions (e.g. groove binding), possibly facilitated by the
two side chains bearing the piperidine groups.
Further credence to the concept that ESI-MS and CD spectroscopy assess
different aspects of the metal complex/DNA interaction is provided by
examination of the results obtained using complex (2). This nickel complex
showed a significant ability to form non-covalent complexes that could be
detected by ESI-MS, yet its addition resulted in changes to the CD spectrum of D2
that were at best only equal to these caused by the addition of (6). It could be
argued that the binding shown by ESI-MS is the result of entirely non-specific
interactions of the positively charged nickel complexes with the negatively
charged phosphodiester backbone of the DNA.

If that were the case to a

substantial degree, then the ESI mass spectra of mixtures of (2), (4), (6) or (8)
with the dsDNA would be expected to be the same. The very different ESI-MS
results (Figure 4.3) suggest that the more specific binding modes (e.g.
intercalation and/or groove interactions) occur.
Absorption spectrophotometry can be used, under certain circumstances,
to measure the effect of binding of small molecules to DNA on its stability
towards thermal denaturation.

This is most readily accomplished through

measurement of the melting temperature, or Tm, of either a dsDNA or qDNA
molecule. The premise of this technique is that small molecules which can bind
to and stabilise a particular DNA secondary structure will lead to an increase in
Tm (or positive value for ΔTm). Furthermore, small molecules which bind more
extensively and/or effectively than others will generally lead to higher values of
ΔTm. This technique was used to probe the ability of the four nickel Schiff base
complexes to stabilise D2.

Figure 4.6 shows representative melting curves
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obtained for solutions containing a 1:3 ratio of D2 and the various nickel
complexes, whilst Figure 4.7 presents graphically the values of Tm obtained at
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two different D2:Ni ratios.
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Figure 4.6 – DNA melting curves obtained using solutions containing a 1:3 ratio
of D2 with different nickel Schiff base complexes.

There are a number of interesting trends to emerge from the results
presented in Figure 4.6 and Figure 4.7. First, only complexes (2) and (4) have a
substantial effect on the melting temperature of D2, with the magnitude of this
effect increasing slightly at the higher DNA:Ni ratio. These observations may
point to key differences between how complexes (2) and (4) interact with D2 on
the one hand, and (6) and (8) on the other. Only complexes (2) and (4) possess
at least one planar aromatic ring in the “top” portion of the molecule, which was
derived from the diamine used in the original synthesis. These aromatic rings
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may be in suitable positions for participating in intercalative interactions with
D2 which are well known to stabilise dsDNA, and increase measured values of
Tm.162,252-255 On the other hand, complexes (6) and (8), by virtue of not having
this structural unit, are incapable of forming these types of stabilising
interactions which lead to increases in Tm.

Instead they may bind by a

combination of other modes of interaction involving the grooves of the nucleic
acid, which do not lead to overall stabilisation.

Adding credence to this

argument, the complex containing the largest planar group in the “top” portion of
the molecule, (4), produced the largest increases in Tm for the solutions with a
1:3 and a 1:6 DNA:Ni ratios. These increases in Tm were 9.9 and 11.4 °C,
respectively.
Complex (2), which contains only one aromatic ring derived from the
original diamine used to synthesise the Schiff base complex, still showed a
reasonable ability to stabilise D2, giving ∆Tm values of 4.4 and 5.1 °C for the
solutions containing a 1:3 and 1:6 DNA:metal complex ratio, respectively. The
remaining two complexes, (6) and (8), were unremarkable in their ability to
stabilise DNA. For example, the Tm for a solution containing a 1:3 ratio of D2:(8)
was, within experimental error, the same as that for D2 alone. This is somewhat
surprising, as ESI-MS showed evidence of formation of non-covalent complexes
with (8). On the other hand, the absence of an effect of complex (6) on the Tm of
D2 at either ratio is not surprising and is consistent with ESI mass spectra, given
the lack of ions attributable to non-covalent complexes in ESI mass spectra in
these solutions.
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Figure 4.7 – Mean melting temperatures (Tm) of solutions containing either a 1:3
or 1:6 ratio of D2 and different nickel complexes: (a) 1:3 ratio and (b) 1:6 ratio.
Error bars are standard errors.

Overall, the results of the melting temperature experiments indicate that
the relative binding affinities of the nickel complexes towards the dsDNA
molecule D2 follow the sequence (4) > (2) > (8) ~ (6). This order is generally
similar to those derived from ESI-MS and CD studies, and reinforces the view
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that the size of the aromatic group derived from the original diamine used to
synthesise the nickel Schiff base complex plays a significant role in determining
the binding interactions with dsDNA.
FRET experiments were also undertaken to probe the ability of the nickel
Schiff base complexes to bind to and stabilise dsDNA, using the fluorescentlytagged oligonucleotide FdxT (Table 2-6). Examples of normalised melting curves
obtained using FdxT, and increasing concentrations of (2) are shown in Figure
4.8. As the concentration of (2) was increased, the melting curve shifted to
higher temperatures, indicating that interactions with the nucleic acid were
taking place which resulted in stabilisation of the nucleic acid secondary
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structure. Similar results were obtained with the other nickel complexes.
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Figure 4.8 – Effect of increasing amounts of (2) on the FRET melting curve for
FdxT.
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The values of ΔTm derived from FRET melting curves obtained using
solutions containing the nickel complexes and FdxT are presented in Table 4-2.
Complex (4) was not examined as part of these studies, which were performed in
the laboratory of Dr. Jean-Louis Mergny, as no sample was available during the
time when these experiments were carried out. The ∆Tm values are the
difference between the Tm for FdxT in the presence of a nickel complex, and the
Tm of FdxT alone (63.5 ± 1.2 °C). The ΔTm values obtained when the three nickel
complexes were present at a low concentration were all very small and, within
experimental error, identical to each other. When the concentration of (8) was
increased there was no change in the value of ΔTm. This strongly suggests that
there is very little interaction with this DNA molecule. This result is consistent
with the lack of binding evident from ESI-MS and conventional DNA melting
experiments performed with this nickel molecule and the dsDNA D2. At a nickel
complex concentration of 10 µM, both (2) and (6) resulted in larger values of
∆Tm compared to that caused by the addition of (8). This indicates that the
former nickel complexes have a greater ability to stabilise FdxT, presumably
because of more extensive and/or stronger binding interactions.

Table 4-2 – Values of ΔTm derived from FRET melting experiments performed
using solutions containing different concentrations of nickel complexes and FdxT
(0.2 μM, Tm = 63.5 ± 1.2 °C).
∆ Tm (°C)
4 µM
1.8 ± 0.1
2.4 ± 0.2
1.5 ± 0.6

1 µM
2 µM
(2)
1.0 ± 0.5
1.4 ± 0.7
(6)
1.3 ± 0.8
1.5 ± 0.6
(8)
1.7 ± 0.7
1.6 ± 0.8
Error values are standard errors.
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5 µM
1.9 ± 0.5
1.8 ± 0.4
1.3 ± 0.5

10 µM
4.0 ± 0.9
4.5 ± 0.5
1.4 ±0.6

4. 3 DNA binding experiments using tetramolecular qDNA
Having investigated the binding of the nickel complexes to the dsDNA
molecule D2, a similar series of experiments were performed with the
tetramolecular quadruplex DNA molecule Q4(5G). Figure 4.9 shows ESI mass
spectra of solutions containing a 1:3 ratio of Q4(5G) and different nickel
complexes.
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Figure 4.9 – Negative ion ESI mass spectra of solutions containing Q4(5G) and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q4(5G); (b) Q4(5G)
+ (2); (c) Q4(5G) + (4); (d) Q4(5G) + (6); (e) Q4(5G) + (8).  = free Q4(5G);  =
{Q4(5G) + (Ni)};  = {Q4(5G) + 2(Ni)};  = {Q4(5G) + 3(Ni)}.
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The spectrum of a solution containing Q4(5G) alone (Figure 4.9 (a))
contains ions of medium and high abundance at m/z 1674.9 and 2010.9, which
are assigned to [Q4(5G) + 4NH4+ – 10H]6- and [Q4 + 4NH4+ – 9H]5-, respectively.
Since Q4(5G) contains sufficient contiguous guanines to enable formation of five
G-quartets, and the mass spectra were obtained using solutions containing
ammonium acetate, the presence of four ammonium cations in these structures
is not surprising. This is because univalent ions are known to stabilise the
structure of DNA quadruplexes by inserting themselves in between the Gquartets. Therefore, the presence of four ammonium cations provides strong
evidence in support of the quadruplex structure having been retained during
acquisition of the ESI mass spectra.256-258
After addition of the nickel Schiff base complexes, the only spectrum to
show ions from free DNA is that shown in Figure 4.9 (c), which is of a solution
containing a 1:3 ratio of Q4(5G) and (4). This observation, combined with the
much lower abundance of ions from non-covalent complexes consisting of
{Q4(5G) + 2(Ni)}, compared to the other spectra, indicates that (4) has the
lowest affinity of the nickel complexes for this particular tetramolecular
quadruplex. This is the reverse of what was found when the binding of the
complexes to D2 was examined, and (4) was found to bind the most extensively.
Therefore, these results seem to indicate that the presence of a large planar
aromatic moiety in a Schiff base ligand does not result in greater binding to this
qDNA molecule.
The spectrum in Figure 4.9 (b) contains ions of high abundance at m/z
1884.4 and 2263.5, which correspond to [Q4(5G) + 2(2) + 4NH4+ -14H]6- and
[Q4(5G) + 2(2) + 4NH4+ - 13H]5-, respectively. Both ions arise from non-covalent
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complexes in which two molecules of (2) are bound to Q4(5G), which may be
represented as “{Q4(5G) + 2(2)}”. In addition, ions of low abundance are present
at m/z 1989.2 and 2390.3, which are attributable to {Q4(5G) + 3(2)}. None of the
other spectra in Figure 4.9 show ions corresponding to non-covalent complexes
in which three nickel molecules are bound to Q4(5G). This observation, together
with the greater proportion of ions from non-covalent complexes in which two
nickel molecules are bound to Q4(5G) in the case of complex (2), indicates that it
has the highest affinity of the nickel complexes studied for this tetramolecular
qDNA.
Figure 4.9 (d) and (e) both show ions of medium to high abundance
corresponding to non-covalent complexes containing one or two nickel
molecules bound to Q4(5G). However, the ions at m/z 1868.3 and 2244.1 in
Figure 4.9 (e), attributable to {Q4(5G) + 2(8)}, have slightly greater relative
abundances than the corresponding ions from {Q4(5G) + 2(6)} in Figure 4.9 (d),
at m/z 1919.3 and 2305.6. This suggests that (8) has a slightly greater affinity
for Q4(5G) than (6), and the overall order of binding affinity of these four
complexes is: (2) > (8) > (6) > (4). This is a very different order to that obtained
for binding to the dsDNA molecule D2, where a large, aromatic moiety in the
“top” of the ligand strongly favoured binding. This indicates that other structural
factors are important in determining a molecule’s ability to bind to
tetramolecular qDNA molecules such as Q4(5G).
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It is also important to highlight the significant difference in binding
affinity of (6) for Q4(5G) compared with D2. Figure 4.10 compares the relative
abundances of ions from free DNA and different non-covalent complexes in
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solutions containing a 1:3 ratio of either D2 or Q4(5G), and (6).
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Figure 4.10 – Relative abundances of ions from free DNA and non-covalent
complexes in spectra of solutions containing a 1:3 ratio of either D2 or Q4(5G)
and (6).

At this ratio the solution containing D2 and (6) was comprised almost
exclusively of free DNA, indicating this nickel complex has little ability to bind.
This is in sharp contrast to what is seen with Q4(5G), where ions from {Q4(5G) +
(6)} account for approximately 65 % of all the species observed in the spectrum,
and the remaining 35 % is chiefly attributable to {Q4(5G) + 2(6)}. These results
show that the non-coplanar arrangement of aromatic ring systems in this
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complex confers a degree of binding selectivity in favour of tetramolecular
quadruplex DNA structures over dsDNA.
In order to explore further whether (6) does exhibit selective binding
interactions with tetramolecular qDNA, a further series of ESI mass spectra were
obtained of solutions containing a 1:3 ratio of a different tetramolecular qDNA
molecule, and each of the nickel complexes. This new qDNA molecule, hereafter
referred to as Q4(4G), contains one less guanine tetrad than Q4(5G), but still
forms a tetramolecular, parallel quadruplex structure. The ESI mass spectra
obtained are presented in Figure 4.11. The spectrum of Q4(4G) alone (Figure
4.11 (a)) contained ions at m/z 1452.7, 1743.2, and 2179.5, which are
attributable to [Q4(4G) + 3NH4+- 9H]6-, [Q4(4G) + 3NH4+ - 8H]5- and [Q4(4G) +
3NH4+ - 7H]4-, respectively. The number of ammonium ions in this molecule is
one less than observed for Q4(5G), which is to be expected owing to the
difference of one guanine tetrad between the two qDNA molecules.
Comparison of Figure 4.9 and Figure 4.11 reveals a number of similarities
in how the four nickel complexes bind to these closely related tetramolecular
quadruplexes. For example, complexes (2) and (8) showed the greatest binding
affinity for both qDNA molecules. In Figure 4.11 (b) and (e), the most abundant
ions are those from non-covalent complexes containing two molecules of either
(2) or (8) bound to Q4(4G). However, the spectrum of the solution containing
(2) and Q4(4G) also contains ions of high abundance attributable to non-covalent
complexes in which one nickel molecule is bound to DNA. In contrast, in Figure
4.11 (e) the corresponding ions are only of low abundance. These observations
suggest that the affinity of (8) towards Q4(4G) is slightly greater than that
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exhibited by (2), which is the opposite of what was found in the corresponding
study involving Q4(5G).
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Figure 4.11 – Negative ion ESI mass spectra of solutions containing Q4(4G) and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q4(4G); (b) Q4(4G)
+ (2); (c) Q4(4G) + (4); (d) Q4(4G) + (6); (e) Q4(4G) + (8).  = free Q4(4G);  =
{Q4(4G) + (Ni)};  = {Q4(4G) + 2(Ni)};  = {Q4(4G) + 3(Ni)}.
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The spectrum of a solution containing (6) and Q4(4G) (Figure 4.11 (d)) is
very similar to that of the corresponding solution containing the same nickel
complex and Q4(5G) (Figure 4.9 (d)). In both cases ions from free DNA are
either absent or of very low abundance.

Ions attributable to non-covalent

complexes containing a single nickel molecule bound to DNA are the dominant
features of both spectra, which also show ions attributable to qDNA structures
with two bound nickel molecules. This provides further evidence that (6), which
contains a non-planar meso-1,2-diphenylethylenediamine moiety, shows a clear
preference for binding to tetramolecular qDNA molecules over dsDNA.
Complex (4), containing the large phenanthrene moiety, showed a very
limited ability to bind to Q4(4G). This is reflected in the spectrum of a solution
containing (4) and Q4(4G) (Figure 4.11 (c)) being dominated by ions at m/z
1743.5 from free DNA. Ions of very low abundance at m/z 1889.2 are also
present, which are attributable to {Q4(4G) + (4)}. Complex (4) therefore clearly
has the lowest binding affinity of the four nickel complexes for Q4(4G). This was
also true in the case of Q4(5G), although addition of complex (4) did result in the
formation of ions of high abundance from non-covalent complexes containing
one nickel molecule bound to DNA. Since Q4(4G) contains one less guanine
tetrad than Q4(5G), not only will the DNA molecule itself be slightly shorter, but
the size of grooves along the side of the molecule will also be different. Such
subtle differences in DNA structure may account for the slight differences in
binding affinity exhibited by the nickel complexes for these two tetramolecular
G-quadruplexes.
The most important observation made during the studies with both
tetramolecular quadruplexes was the ability of complex (6) to bind, as this nickel
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molecule had been shown earlier to have little tendency to interact with the
dsDNA molecule D2. For the three remaining nickel complexes (2), (4) and (8),
the order of increasing binding affinity towards the two tetramolecular
quadruplexes was very different to that for D2. This shows that the structural
aspects of ligands and metal complexes traditionally sought after for effective
dsDNA binding, may be detrimental for binding to some qDNA molecules.
CD spectra were subsequently obtained of solutions containing the four
nickel complexes and the tetramolecular quadruplex Q4(5G), so that the binding
results obtained using ESI-MS could be compared with those obtained using a
second technique. As discussed previously, CD spectroscopy is widely used to
identify the conformation of qDNA molecules. The spectrum of Q4(5G) alone
(Figure 4.12) shows a positive CD signal with maximum ellipticity at 260 nm, and
a negative CD signal with maximum, negative ellipticity at 240 nm. These CD
features are indicative of a parallel quadruplex.47,105,249,259-262 Addition of the
nickel complexes resulted in small changes to the position of these two CD
signals (Table 4-3). In contrast, the ellipticity of the positive CD band decreased
to widely differing extents in response to the addition of increasing amounts of
the nickel complexes (Table 4-3).
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Figure 4.12 - Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q4(5G). (a) Q4(5G) + (2); (b)
Q4(5G) + (4); (c) Q4(5G) + (6); and (d) Q4(5G) + (8).

Table 4-3 - Effect on the CD spectrum of Q4(5G) of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
0.7
11.6
0.6
0.44
(4)
0.0
0.82
-0.9
0.62
(6)
-1.4
6.5
-1.5
3.1
(8)
-1.3
2.0
-0.9
1.7
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:7. Negative ∆λ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

If the magnitude of the change in ellipticity of the positive CD signal is
taken as a measure of the extent of nickel binding to DNA,46,105,259,263 then the
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results presented in Figure 4.12 suggest a similar order of relative binding
affinities for the nickel complexes to that deduced from the ESI-MS results
presented earlier. For example, the complex which caused the greatest decrease
in ellipticity of the positive CD signal was (2) (Table 4-3). This is consistent with
the observation that the mass spectrum of a solution containing (2) and Q4(5G)
contained ions attributable to non-covalent complexes containing one or two
molecules of (2) bound to Q4(5G), which were of higher abundance than those of
the corresponding ions in mass spectra of solutions containing any of the other
nickel complexes and Q4(5G) at the same DNA:Ni ratio. In contrast, addition of
seven equivalents of (4) to Q4(5G) resulted in an almost imperceptible (< 1
mdeg) decrease in ellipticity of the positive CD band. This is consistent with the
observation that solutions containing Q4(5G) and (4) were the only ones to give
ESI mass spectra that contained peaks from free DNA. Of the remaining two
nickel complexes, (6) exhibited the most surprising results in the CD study. Not
only did addition of (6) result in the second largest decrease in ellipticity of the
positive CD signal, but it also resulted in a much larger change to the negative CD
signal than that caused by the other three nickel complexes. Together, these
observations hint at complex (6) being able to bind more extensively to Q4(5G)
than previously thought. Alternatively, the very different structure of (6) may
enable it to employ different qDNA binding modes to the other complexes. These
interactions may not be sufficiently strong to withstand ionisation within the
mass spectrometer, but are able to produce significant changes to the
conformation of the qDNA molecule, and therefore its CD spectrum.
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Overall, the DNA binding results obtained by CD spectroscopy and ESI-MS
for solutions containing the nickel complexes and either D2 or Q4(5G) are very
similar.

For example, both techniques indicated that the order of relative

binding affinity of the nickel complexes is not the same for the two types of DNA.
For dsDNA, the presence of a large aromatic moiety in the “top” of the Schiff base
ligand in complex (4) resulted in greater perturbation of the positive CD signal,
and more extensive non-covalent adduct formation in ESI mass spectra. Both
these observations suggest a greater level of interaction with the DNA.

In

contrast, complex (4) showed little ability to form non-covalent complexes with
Q4(5G), and had an almost negligible effect on its CD spectrum.
Another important conclusion stemming from the CD and ESI-MS studies
concerns

the

effect

of

incorporating

the

non-planar

meso-1,2-

diphenylethylenediamine moiety into a nickel Schiff base complex on its affinity
towards different types of DNA. When complex (6) was added to D2, there was
only a small change to its CD spectrum, and an almost complete absence of ions
from non-covalent complexes in ESI mass spectra. The opposite was true for
solutions containing (6) and Q4(5G), indicating that while the above structural
unit may prohibit binding to dsDNA, other modes of interaction are possible with
at least one type of quadruplex DNA.
In order to provide additional support for these conclusions, further CD
studies were carried out using the four nickel complexes and the shorter
tetramolecular qDNA molecule, Q4(4G) (Figure 4.13). Like Q4(5G), it forms a
parallel, tetramolecular structure, confirmed by the large positive band at 260
nm and the negative band at 240 nm in its CD spectrum. Overall, the results of
nickel binding experiments performed with Q4(4G), which are summarised in
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Table 4-4, were very similar to those presented earlier for Q4(5G). For example,
addition of up to nine equivalents of (4) once again had a negligible effect on the
CD spectrum of the nucleic acid. Furthermore, addition of (8) resulted in only
minor changes to the CD spectrum of Q4(4G), whilst (2) and (6) produced the
greatest perturbations to the spectrum. These observations suggest that the
latter complexes again had the biggest effect on the conformation of this type of
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Figure 4.13 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q4(4G). (a) Q4(4G) + (2); (b)
Q4(4G) + (4); (c) Q4(4G) + (6); and (d) Q4(4G) + (8). Data for Q4(4G) and (2)
does not include the spectrum obtained for a 1:9 ratio, as precipitation occurred
in this solution.

Addition of up to six equivalents of (2) and (6) caused very similar
changes to the position and ellipticity of both the positive and negative CD
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signals of Q4(4G). However, increasing the amount of (6) in solution so that the
ratio of Q4(4G):(6) was 1:9, resulted in no significant further changes to the CD
spectrum. This indicates that this nickel complex could not bind any more
extensively to Q4(4G). In contrast, the CD spectrum of a solution containing a 1:9
ratio of Q4(4G) and (2) had a totally different appearance to that of all the other
spectra, as a result of a precipitate having formed due to further interactions
between the metal complex and DNA.

Therefore this CD spectrum is not

included in Figure 4.13 (a).

Table 4-4 – Effect on the CD spectrum of Q4(4G) of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
0.7
8.1
3.9
2.3
(4)
0.3
0.58
2.9
1.0
(6)
1.8
9.4
5.1
2.9
(8)
-0.5
1.9
-1.9
1.1
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:9, except for
complex (2), where a solutions with a DNA:Ni ratio of 1:6 was used. Negative ∆λ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

Addition of (6) to a solution of Q4(4G) resulted in major changes to its CD
spectrum, suggesting that this nickel complex interacts strongly and/or
extensively with this tetramolecular quadruplex. Therefore all the ESI-MS and
CD results indicate that (6) interacts with this type of DNA, in contrast to what
was observed in experiments with dsDNA. It is also noteworthy that complex
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(8), which resulted in the most extensive formation of non-covalent complexes
with Q4(4G) in the ESI-MS study, had a relatively minor effect on the CD
spectrum of this nucleic acid molecule. Comparison of the structure of (8) to that
of the other three nickel complexes reveals it has at least one less aromatic ring.
Therefore the binding interactions of this complex with Q4(4G) are less likely to
involve π-π stacking with the terminal G-tetrad of the quadruplex. Instead, (8)
may bind to Q4(4G) through a mixture of groove binding and simple electrostatic
interactions.

However, other techniques (e.g. NMR spectroscopy and X-ray

crystallography) would be required to determine the exact nature of the DNAbinding interactions of this complex.

4. 4 DNA binding experiments using unimolecular qDNA
A series of DNA binding experiments were also carried out to examine the
effect of varying the structure of the nickel complexes on their affinity towards
the unimolecular qDNA molecule Q1 (Table 2-1). In our hands, the specific
buffer and annealing conditions used as outlined in section 2.3.3 resulted in a
parallel conformation, and this was confirmed using CD spectroscopy. The exact
conditions which were determined to result in a parallel conformation of Q1 are
further discussed below in this section.
Figure 4.14 shows a representative series of ESI mass spectra of Q1 with
the four nickel complexes, which were all obtained using solutions containing a
DNA:Ni ratio of 1:3. Under these conditions, ions at m/z 1330.9 and 1662.7,
attributable to [Q1 - 6H]6- and [Q1 – 5H]5-, respectively, were present in medium
to high abundance in all spectra except that of the solution containing (2) and
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Q1, where they were still of medium abundance. This suggests that the affinity of
the nickel complexes towards Q1 is generally less than that they exhibited
towards both tetramolecular quadruplexes.
The nickel complex which showed the greatest binding was (2), as Figure
4.14 (b) contains ions of high abundance at m/z 1455.5, attributable to {Q1 +
(2)}, as well as ions of medium abundance at m/z 1581.0, which corresponds to
{Q1 + 2(2)}. At higher ratios of Q1:(2), the abundance of ions from free DNA
decreased, while that of ions from the above non-covalent complexes remained
approximately the same.
The spectrum of a solution containing (8) and Q1 (Figure 4.14 (e)) also
contains ions from non-covalent complexes consisting of one and two nickel
molecules bound to DNA, although their relative abundances are much lower
than that of the corresponding ions in the spectrum of a solution containing (2)
and Q1. This indicates that (2) has greater binding affinity for this parallel,
unimolecular qDNA molecule, than that exhibited by (8). The only difference
between the two structures of these molecules is that (8) possesses one less
aromatic ring than (2), which suggests that the additional aromatic ring
facilitates binding to this DNA molecule.
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Figure 4.14 – Negative ion ESI mass spectra of solutions containing Q1 and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q1; (b) Q1 + (2); (c)
Q1 + (4); (d) Q1 + (6); (e) Q1 + (8).  = free Q1;  = {Q1 + (Ni)};  = Q1 + 2(Ni)}.

Increasing the number of aromatic rings in the “top” of the molecule,
however, proved detrimental to DNA binding ability. This is demonstrated by
the observation only of ions of low abundance from {Q1 + (4)} in the ESI mass
spectrum of a solution containing this nickel complex and Q1 (Figure 4.14 (c)).
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These results indicate that the presence of the large phenanthrene moiety in (4),
as opposed to the single aromatic ring in (2), or the simple ethylenediamine unit
in (8), inhibits binding to this particular qDNA structure. This may result from
steric hindrance between the phenanthrene group in (4) and the loops of this
qDNA molecule, which limits the approach of the nickel complex. These results
are consistent with what was seen for the two tetramolecular qDNA molecules
Q4(5G) and Q4(4G), both of which also demonstrated limited binding to (4).
The remaining nickel complex, (6), showed no evidence of binding to Q1
(Figure 4.14 (d)). This result is notable as (6) was shown previously to bind to
both tetramolecular quadruplexes examined. This observation highlights the
role which the loops that are only found on unimolecular or bimolecular qDNA
molecules may have on the binding of small molecules. The ESI mass spectrum
of a solution containing DNA:(6) in the ratio of 1:9 (data not shown) showed
some evidence of binding, with the abundance of ions corresponding to {Q1 +
(6)} making up 20 % of the total abundance of all ions in the spectrum.
Nevertheless, (6) still exhibited the lowest binding ability of all nickel complexes
for Q1 in ESI MS experiments. The final binding affinity series for Q1 therefore
is: (2) > (8) > (4) > (6).
Examination of the mass spectral data reveals that (2) and (8) clearly
showed a greater ability to bind to all three DNA quadruplexes than (4) and (6).
However, nickel complex (6), which contains the non-planar meso-1,2diphenylethylenediamine moiety, exhibited the most notable degree of DNAbinding selectivity. This nickel complex formed non-covalent complexes with
both types of tetramolecular quadruplexes examined, but showed essentially no
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ability to interact with either dsDNA or unimolecular qDNA in mass
spectrometry studies.
As outlined previously, the CD spectrum of qDNA molecules is
characteristic of their secondary structure. This is extremely useful, as there are
many instances where a single oligonucleotide sequence can form different types
of quadruplexes, such as parallel, antiparallel, or mixed conformation, depending
on what buffer and annealing conditions are used.249,262 In view of this issue,
prior to using CD spectroscopy to examine the binding of the nickel complexes to
Q1, an investigation was undertaken to determine, in our hands (in ammonium
acetate) what annealing conditions were required to reproducibly form a
quadruplex structure with a specific conformation. It was hoped that conditions
would be obtained for forming a parallel quadruplex structure, so that the results
of metal binding studies could be more readily compared to those obtained using
the parallel quadruplexes Q4(5G) and Q4(4G). These preliminary investigations
were carried out using solutions of Q1 dissolved in aqueous NH4OAc, so that the
results of nickel binding studies could be directly compared to those obtained by
ESI-MS. Figure 4.15 shows the effect of annealing 1 mM solutions of Q1 under
different conditions on its CD spectrum.

172

14

12
10

CD (mdeg)

8

6
4

2
0
-2
-4

200

250

300

350

400

Wavelength (nm)

Figure 4.15 – CD spectra of Q1, annealed under different conditions:
pH 7.4,
15 min at 90 °C, cool overnight;
pH 7.0, 15 min at 95 °C, cool overnight;
_____ pH 7.4, 15 min at 90 °C, iced immediately;
pH 7.0, 15 min at 95 °C,
cooled at a rate of 10 °C/h;
pH 7.4, 15 min at 95 °C, cooled at a rate of 10
°C/h. Times refer to the length of time held at the specified temperature.
Concentration of Q1 for obtaining the final CD spectrum was 20 µM from a 1 mM
annealed stock, and NH4OAc was 150 mM.

The CD spectra obtained show how the secondary structure of this Gquadruplex varies depending on the annealing conditions. Ideally, for drug/DNA
binding experiments, one single topology should be present in solution.
However, several of the spectra suggest that a mixture of different quadruplex
conformations were present, as they exhibit positive CD signals with maxima at
both 260 and 290 nm. For example, the spectrum of a pH 7.4 solution of Q1
annealed at 90 °C for 15 min, and then allowed to cool slowly overnight, shows
both CD signals are present and of roughly equal ellipticity. In contrast, the
spectrum of a pH 7.4 solution also annealed at 90 °C for 15 min, but then
immediately placed in ice, suggests that there is either two types of quadruplex
present, or alternatively that the quadruplex formed is of a mixed conformation.
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These results show that the rate at which a solution is cooled can significantly
affect what type of quadruplex structure is formed. The DNA sequence and
buffer conditions also affect the conformation of the quadruplex.116,249,259-260,262
For example, Paramasivian et al. prepared two unimolecular qDNA molecules by
heating the sample to 90 °C, and subsequently cooling to room temperature over
a period of 8 h. This resulted in either an antiparallel or mixed conformation,
depending on the specific DNA sequence used, even when the same buffer
solutions were present.259 Furthermore, one additional unimolecular sequence
was shown to form either a parallel or antiparallel conformation depending on
whether a sodium or potassium buffer was used. In another study, Renciuk et al.
prepared their qDNA samples by heating to 90 °C for 3 min, but in this instance
cooling to room temperature over a period of 4 h. Once more, there was a wide
variety of conformations observed, which depended on the base sequence of the
quadruplex as well as the buffer conditions.116
When a pH 7.0 solution of Q1 was annealed at 95 °C for 15 min, and
allowed to cool overnight, significantly more parallel qDNA was present, as
shown by the prominence of the CD signal at 260 nm. This result suggested that
a slower rate of cooling favours formation of a parallel quadruplex conformation,
although the presence of a single topology was still not achieved. A crystal
structure of a similar sequence, d(AG3(TTAGGG)3), in K+ solution shows all
strands in parallel orientations with the three TTA regions forming three
propeller loops.117 It was therefore decided to examine the effect of slowing the
rate of cooling even further. A solution was prepared which was allowed to cool
at just 10 °C / h, after it was initially heated at 95 °C for 15 min. Samples with an
initial pH of 7.4 and 7.0 were treated in this manner, and both were found to give
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CD spectra which still indicated that a small amount of a second DNA
conformation was present, together with the dominant parallel conformation.
Repeating the annealing and cooling process at both pH levels yielded samples
which gave the spectra in Figure 4.15, which indicated that now only the parallel
topology was present. As the pH 7.4 sample gave a spectrum where the signal at
260 nm had twice the ellipticity, it was decided to use this pH in all future
annealing procedures involving Q1. This also meant that the pH of DNA binding
studies with Q1 were identical with those involving Q4(4G) and Q4(5G).
The effect of adding the four nickel Schiff base complexes on the CD
spectrum of Q1 is shown in Figure 4.16, while Table 4-5 summarises the
maximum changes to the position and ellipticity of the CD signals. The overall
trends closely resemble what was seen with the two tetramolecular qDNA
molecules. Two of the most noteworthy results were the spectra obtained after
either (2) or (6) had been added (Figure 4.16 (a) and (c), respectively). Both of
these complexes caused significant decreases in ellipticity of both the positive CD
band at 260 nm and the negative CD signal. In addition, significant asymmetry
was present on the right hand side of the positive CD band when large amounts
of (6) had been added. This suggests a change in conformation of the DNA may
have occurred.262
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Figure 4.16 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q1: (a) Q1 + (2); (b) Q1 + (4);
(c) Q1 + (6); and (d) Q1 + (8).

The data in Table 4-5 provide further insight into the changes to the CD
spectrum of Q1 caused by addition of the nickel Schiff base complexes. Each of
the four complexes affected the spectrum in different ways, indicating that they
interact with Q1 through subtly different binding modes, owing to the
differences in their structures. For example, the complex which caused the
largest decrease in ellipticity of the positive CD band was (2), followed by (6), yet
the reverse is true for the negative CD band. In view of these results, it is
perhaps surprising that these two nickel complexes did not also cause the
greatest shift in position of either CD band. For the positive CD signal, complex
(8) had the biggest effect, resulting in a blue shift of 4.3 nm. The second largest
shift in position of this CD signal occurred when (2) was added, however this
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resulted in the band moving to longer wavelengths by 2.8 nm. In the case of the
negative CD band, complex (6) produced the biggest shift in its position, followed
by complex (4).

Table 4-5 – Effect on the CD spectrum of Q1 of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
2.8
7.0
0.9
1.9
(4)
0.9
0.13
-1.5
0.46
(6)
-1.6
5.5
-4.3
3.3
(8)
-4.3
1.9
-0.7
0.99
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:7. Negative ∆λ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

Finally, it is also worth reflecting on the observation that complexes (2)
and (6) produced significant, but opposite, effects on the position of the positive
CD band of Q1. This suggests that these complexes employ different binding
modes when interacting with this DNA molecule. In addition, the ESI-MS results
obtained for solutions containing the nickel complexes and Q1 indicated only
limited binding of (6), while interactions with (2) occurred to a much greater
extent. These observations contrast with those based on results obtained from
the CD experiments. This may reflect the different sensitivities of ESI-MS and CD
spectroscopy to the strength and mechanism of metal/DNA interactions.
The results shown in Figure 4.16, and presented in Table 4-5, again
suggest that the presence of the non-planar meso-1,2-diphenylethylenediamine
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moiety in (6) is able to confer binding selectivity in favour of parallel Gquadruplexes over dsDNA. In addition, it appears that the large phenanthrene
group in (4) prohibits significant interaction with qDNA, as opposed to
increasing binding affinity, which was observed with dsDNA. Overall, on the
basis of the CD results presented here and in earlier sections of this chapter,
complex (2) appears to interact to the greatest extent of all four nickel Schiff
base complexes with the different types of G-quadruplex DNA.
The ability of three of the nickel complexes to stabilise F21T, a 21mer
unimolecular qDNA structure (Table 2-6), was also examined using FRET. The
nickel complex (4) was not available at the time these experiments were
performed in the laboratory of Dr. Jean-Louis Mergny. F21T is identical to Q1 in
its sequence, with the only difference being the presence of the FAM- and
TAMRA-tagged ends of the oligonucleotide. These experiments were carried out
in the Mergny laboratory under conditions previously described,240-241 which
involved the use of buffers containing sodium ions.

Previously, NMR

experiments have shown that under these conditions, F21T may form a mainly
antiparallel conformation.241-242
The FRET melting curves obtained with F21T and increasing
concentrations of (6) are shown in Figure 4.17. The melting curves shifted to
higher temperatures with increasing nickel complex concentration.

At the

highest concentration of nickel complex (10 µM), there was evidence for at least
two melting events. This may be due to different binding modes being used by
the nickel molecule at the highest concentration, which is equivalent to a DNA:Ni
ratio of 1:50, and possible heterogeneity of the qDNA present in the solution.
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In general, the ∆Tm values obtained with this DNA molecule and each of
the nickel complexes were much greater than what was observed in the
corresponding investigations involving the dsDNA, FdxT. This indicates that the
nickel complexes stabilise the qDNA molecule more than dsDNA. Table 4-6
shows that as the concentration of each nickel complex was increased, so did the
values of ΔTm. It is also apparent from Table 4-6 that complex (2) had a greater
ability to stabilise F21T than the other two nickel complexes, at each
concentration studied. This suggests that (2) had the greatest affinity for F21T
of the three nickel complexes examined. As for complexes (6) and (8), their ∆Tm
values were very similar to each other at most concentrations. Therefore, these
two nickel complexes had a similar ability to stabilise F21T, presumably because
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they interact with this DNA molecule to a similar extent.
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Figure 4.17 – Effect of increasing concentrations of (6) on the FRET melting
curve for F21T.
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Table 4-6 – Values of ΔTm derived from FRET melting experiments performed
using solutions containing different concentration of nickel complexes and F21T
(0.2 μM, Tm = 50.0 ± 0.2 °C).
1 µM
2 µM
(2)
3.0 ± 0.7
9.4 ± 0.7
(6)
0.8 ± 0.4
2.9 ± 0.2
(8)
1.8 ± 0.2
3.4 ± 0.5
Error values are standard errors.

∆ Tm (°C)
4 µM
14.0 ± 0.5
5.7 ± 0.7
5.0 ± 0.4

5 µM
13.3 ± 2.1
3.4 ± 0.7
6.5 ± 0.5

10 µM
24.4 ± 0.4
10.4 ± 2.2
10.2 ± 0.5

Overall, the results of ESI-MS and CD experiments performed using
solutions containing (2), (6) or (8) and Q1 indicated that all were able to interact
with this parallel, unimolecular qDNA molecule. Both techniques indicated that
complex (2) interacted to the greatest extent, whilst (6) and (8) interacted with
Q1 to different extents, depending on which of the two techniques was used.
Since the F21T used in the FRET experiments discussed above has a different
structure to Q1, this may account for some of the different trends in binding
affinity observed.
The binding interactions of (2) with F21T have been previously examined
using FRET melting assays.149-150 In the literature work, the ∆Tm obtained was
significantly larger than the value reported here. One possible reason for this
variation is that the previous study was performed using F21T dissolved in a
different buffer solution to that employed in the current experiments.
Furthermore, it has been previously shown that Tm values derived from
experiments performed in buffers containing sodium ions (e.g. those described
in this thesis) are often lower than those obtained from investigations carried
out in buffers containing potassium ions.241 Given these reported differences, it
is also reasonable to expect differences in orders of binding affinity determined
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from the ESI-MS and CD experiments carried out in ammonium acetate, and the
FRET experiments carried out in sodium-containing buffer.
FRET competition experiments were also carried out, in which the effect
of increasing concentrations of a dsDNA molecule (ds26, Table 2-6; no
fluorescent tag) on the Tm value derived from solutions containing F21T
(fluorescently tagged qDNA) and the nickel complexes was explored.

The

premise of these experiments was that if the nickel molecules do not exhibit a
high degree of selectivity in their binding interactions in favour of the qDNA,
then addition of the competitor dsDNA will result in a decrease in ΔTm. The
results obtained from experiments performed with the three nickel Schiff base
complexes (one concentration only shown, 5 µM) are presented in Figure 4.18.
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no competitor

5 µM (6)
3 µM ds26
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Figure 4.18 – Effect of increasing concentration of ds26 on ΔTm derived from
FRET melting assays performed with solutions containing 5 µM nickel Schiff base
complex and 0.2 µM F21T. Error bars are standard errors.

181

The results presented in Figure 4.18

indicate that all three nickel

complexes display a degree of binding selectivity in favour of the qDNA F21T
over the competitor dsDNA molecule. That is, in each case, the presence of a
much higher concentration of ds26 made only small differences, given the error
in the experiments, to the ΔTm caused by the addition of (2), (6) or (8) to the
qDNA, F21T. For example, when the concentration of ds26 was 3 µM, the values
of ∆Tm obtained for each of the three nickel complexes were within experimental
error of the results obtained from the control experiments. Variability was
associated with some of the data obtained, particularly in the experiments
involving (2) with 10 µM ds26. Increasing the concentration of ds 26 up to 10
µM in experiments involving (8) had only a small effect on ΔTm, supporting the
conclusion that this nickel complex exhibits a significant degree of binding
selectivity. This complex was found to display similar selectivity in favour of
qDNA over dsDNA in a previous study.150
Another method for quantifying the binding selectivity for F21T over
ds26 is to use

FRETS,

calculated as described by Equation 1.264-265 The closer a

value of FRETS value is to 1, the more selective a small molecule is for F21T.

FRETS =

Therefore, the values of

FRETS

Equation 1

presented in Table 4-7 indicate that the nickel

complex exhibiting the greatest selectivity for F21T was (8), as it gave a value of
0.85. This FRETS value is similar to those obtained for some copper and platinum
terpyridine-based complexes (0.84 and 0.80, respectively).266 The

FRETS

values

determined for complexes (2) and (6) suggest that these molecules also exhibit a
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degree of binding selectivity in favour of the qDNA molecule; as they are similar
to values obtained for some cyclophane macrocyclic ligands considered to be
selective binders, which were in the range of 0.62-0.71.265

Table 4-7 – FRETS values for nickel Schiff base complexes calculated using ΔTm
values from FRET competition assays and Equation 1.
Nickel Complex
(2)
(6)
(8)

FRETS

0.72
0.70
0.85

4. 5 Summary
The aim of the work presented in this chapter was to use a combination of
approaches to explore the effect of varying the structure of the nickel Schiff base
complexes, by altering the diamine used in its preparation, on their binding
affinity towards different types of DNA molecules.
Binding studies conducted using the dsDNA molecule D2 showed that
nickel complexes synthesised using a diamine which contained at least one
aromatic ring exhibited the most extensive degree of interactions.

This is

highlighted by the results of ESI-MS, CD spectroscopy, and DNA melting studies,
all indicating that complex (4), prepared using 9,10-diaminophenanthrene,
showed the greatest degree of binding with D2. In contrast, complex (6), which
was

prepared

using

the

non-planar

meso-1,2-diphenylethylenediamine,

consistently showed extremely poor binding, possibly owing to steric hindrance,
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which prevented this complex from being able to intercalate between the base
pairs of D2.
Comparison of the results obtained from binding studies conducted using
the two tetramolecular qDNA molecules Q4(5G) and Q4(4G), with those obtained
from experiments performed with D2, revealed that the structure/binding
relationships determined for dsDNA did not hold true for these quadruplexes.
For example, introduction of additional aromatic rings into the structure of the
Schiff base ligand did not enhance overall affinity for the tetramolecular
quadruplexes. Although complex (6) showed little or no evidence of binding to
D2, both ESI-MS and CD studies indicated it was able to do so with the two
tetramolecular quaduplexes. There were some small differences in the extent of
interactions between (6) and Q4(5G) or Q4(4G), but these were insignificant in
comparison to the almost complete lack of interaction with D2.
Overall, complex (2) appeared to have the greatest affinity for both Q1
and F21T. The affinity of (6) and (8) for these two qDNA molecules was shown
to be significantly lower using ESI-MS and FRET melting studies. However, the
CD signal of Q1 was significantly perturbed by the addition of (6). This situation
is reminiscent of that found for solutions containing complex (6) and the dsDNA
D2, where ESI-MS indicated an almost complete absence of any non-covalent
complexes, despite perturbations of the CD spectrum of the nucleic acid. This
may reflect the CD signals of different types of DNA being particularly sensitive
to changes in nucleic acid conformation, caused by relatively fragile interactions
with small molecules. Overall, however, there was broad agreement between
orders of binding affinity derived using different techniques for the nickel
complexes with a specific DNA sequence.
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CHAPTER 5 - DNA-BINDING PROPERTIES OF
NICKEL SCHIFF BASE COMPLEXES: EFFECT OF
VARYING THE PENDANT SIDE CHAINS
5. 1 Introduction and scope of the chapter
The “salphen” type complexes whose DNA-binding properties were
originally studied by Vilar and co-workers contained ethylpiperidine moieties
appended to the rings derived from 2,4-dihydroxysalicylaldehyde.193

These

groups were incorporated to provide additional binding interactions with
functional groups in the grooves of qDNA structures. In addition, since the
nitrogen atoms of the piperidine moieties become positively charged in aqueous
solutions with a pH near 7, the solubility of the complex is increased, and their
ability to participate in electrostatic interactions with the negatively charged
phosphate backbone of DNA is enhanced.
This chapter explores the effect of replacing both ethylpiperidine moieties
in complexes (2), (6) and (8) with other substituents on the ability of the nickel
complexes to bind to dsDNA and different types of qDNA. Two different types of
alternate substituents were examined: ethylmorpholine and propylpiperidine
moieties.

The DNA binding chemistry of some nickel “salphen” complexes

bearing these substituents has been reported previously.149-150,193
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5. 2 Longer chain piperidine complexes
The synthesis and characterisation of (12) and (13) was presented in
sections 3.2 and 3.3.2.

These complexes feature propyl, rather than ethyl,

connectors between the piperidine and Schiff base units. The structures of these
complexes are displayed in Figure 5.1. The DNA binding properties of complex
(12) have been partially explored previously.150 However, complex (13) is novel,
and as such its DNA binding properties are described here for the first time.
With the exception of FRET melting assays performed using F21T, each of the
experiments described in this chapter were performed using different types of
DNA molecules to those examined in the earlier study involving complex (12).150
This includes the first investigation of the ability of these compounds to bind to a
tetramolecular quadruplex DNA.

Figure 5.1 - Structures of the nickel Schiff base complexes (12) and (13), both
containing piperidine units linked to the rest of the molecule by propyl chains.
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5.2.1 Binding experiments involving duplex DNA
Initially, ESI-MS was used to compare the ability of (12) and (13) to bind
to the dsDNA molecule D2, with that of the analogous complexes, (2) and (6),
containing shorter alkyl groups. The results of these experiments, which were
performed using solutions containing a 1:3 DNA:metal complex ratio, are shown
in Figure 5.2. The spectra in Figure 5.2 (b) and (c) were previously shown in
Figure 4.3, but are reproduced here to facilitate comparison.
The spectrum of a solution containing only D2 (Figure 5.2 (a)) displayed
ions of high abundance at m/z 1627.0 and ions of lower abundance at m/z
1952.5. These ions are also present in the spectra of solutions containing nickel
complexes and D2. Comparison of Figure 5.2 (b) and (c) shows that replacing
the ethyl linkers in complex (2) by propyl groups in (12) had a significant impact
on the spectrum obtained. When complex (2) was present in solution, the most
abundant ions observed were from non-covalent complexes containing one
nickel molecule bound to DNA (Figure 5.2 (b)). In addition, there were also ions
attributable to {D2 + 2(2)}. In contrast, the most abundant ions in the spectrum
of the solution containing (12) and D2 (Figure 5.2 (c)) were from D2 alone, with
only a small proportion of ions attributable to {D2 + (12)}. The much lower
relative abundance of ions from {D2 + (12)} in Figure 5.2 (c), compared to that of
{D2 + (2)} in Figure 5.2 (b), suggests that the presence of the longer alkyl chain
has inhibited binding of (12) to D2. An earlier FRET study using a different
dsDNA molecule showed that (12) had a greater stabilising effect than (2).150
This is likely the result of different experimental conditions. However, it should
be noted that the increase in dsDNA melting temperature caused by addition of
either (2) or (12) in these FRET experiments was very small. Increasing the
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D2:(12) ratio to 1:9 still afforded a spectrum in which ions attributable to free
DNA were the most abundant.
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Figure 5.2 - Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:3 ratio. (a) free D2; (b) D2 + (2); (c)
D2 + (12); (d) D2 + (6); (e) D2 + (13).  = free D2;  = {D2 + (Ni)};  = {D2 +
2(Ni)}.
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The spectra in Figure 5.2 (d) and (e) are of solutions containing D2 in a
1:3 ratio with either (6) or (13), respectively. Both of these complexes contain
the non-planar meso-1,2-diphenylethylenediamine moiety. In each spectrum, the
most abundant ions are those attributable to [D2 – 6H]6-, followed by [D2 – 5H]5-.
The only other ions present appear in Figure 5.2 (d), and are of very low
abundance and attributable to {D2 + (6)}. The very limited ability of (6) to bind
to D2 was noted in section 4.2 (see Figure 4.3). This was attributed to the nonplanar phenyl units in the diamine moiety, which prohibits intercalation as a
binding mechanism. Figure 5.2 shows that the presence of the longer, propyl
linking groups in (13) has no beneficial effect on binding to dsDNA.

This

parallels the results observed when the binding of (2) and (12) were compared.
Once again it appears that the presence of the meso-1,2-diphenylethylenediamine moiety (this time in (13)) strongly inhibits binding of the nickel
Schiff base complexes to dsDNA. In an attempt to obtain more evidence for this
conclusion, as well as to compare the different binding affinities of (12) and (13)
with their shorter chain analogues (2) and (6), respectively, UV melting curves
were obtained of solutions containing either a 1:3 or 1:6 ratio of D2 and the
nickel complexes. Representative melting curves are illustrated in Figure 5.3,
whilst the melting temperatures (Tm) obtained from these data are presented in
Table 5-1. Also shown are the ∆Tm values, which are the differences between the
melting temperature of a solution containing the specific nickel complex and D2
at a designated ratio, and the melting temperature of a solution containing D2
alone. The values of Tm and ΔTm for complexes (2) and (6) were first reported in
section 4.2 (Figure 4.7).
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Figure 5.3 – DNA melting curves obtained using solutions containing a 1:3 or 1:6
ratio of D2 with either (12) or (13).

Table 5-1 – DNA melting temperatures (Tm) obtained for solutions containing D2
and nickel Schiff base complexes, at a DNA:metal complex ratio of either 1:3 or
1:6.
Nickel
Tm (1:3)
∆Tm (°C)
Tm (1:6)
Complex
(2)
64.5 ± 0.6
+ 4.4
65.2 ± 0.2
(12)
64.5 ± 0.2
+ 4.4
64.2 ± 0.2
(6)
60.9 ± 0.2
+ 0.8
59.7 ± 0.5
(13)
60.4 ± 0.9
+ 0.3
60.1 ± 0.0
The Tm of D2 was 60.1 ± 0.3 °C. Error values are standard error.

∆Tm (°C)
+ 5.1
+ 4.1
- 0.5
0.0

The magnitude of ΔTm reflects the ability of the nickel complexes to
stabilise D2 against separation of its constituent strands. The two complexes
containing a phenylenediamine moiety ((2) and (12)), show much larger values
of ΔTm at both DNA:metal complex ratios than the two nickel complexes
containing the meso-1,2-diphenylethylenediamine moiety ((6) and (13)).
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Furthermore, the results presented here for complexes (12) and (13) parallel
those reported earlier in section 4.2 for their analogues (2) and (6). Specifically,
the complex retaining the planar phenylenediamine unit, (12), is able to
significantly stabilise the dsDNA molecule, most likely as a result of intercalation,
and thereby increase its Tm by more than 4 °C. In contrast, complex (13),
containing the meso-1,2-diphenylethylenediamine moiety, showed essentially no
ability to increase the Tm of D2, most likely as a result of its inability to act as an
intercalator. It is worth noting that the values of ΔTm for both complexes (2) and
(12) are, for example, smaller than that obtained for [Ru(phen)2(dppz)]2+ (dppz
= dipyrido[3,2,a:2′,3′-c]phenazine, ΔTm = 9.3 ± 0.5 °C) with a similar 16mer
dsDNA molecule.239 This is not surprising as the phenylenediamine moiety in (2)
and (12) cannot function as effectively as an intercalating moiety as the extended
dppz ligand present in the ruthenium complex.
Inspection of the ΔTm values in Table 5-1 also shows that the presence of
the longer, propyl linking groups in (12) and (13) did not increase the ability of
the nickel complexes to stabilise D2, relative to complexes (2) and (6). The
results obtained from the DNA melting temperature experiments are therefore
generally consistent with those obtained by ESI-MS.

For example, both

techniques showed that complexes (6) and (13) have very little affinity for this
particular dsDNA molecule. It is somewhat surprising, however, that the extent
of non-covalent complex formation in solutions containing (12) and D2 was so
much less than in solutions containing (2), as both nickel complexes produced
similar values of ΔTm. Therefore, in an attempt to shed further light on the
binding interactions in these systems, CD spectroscopy was used to compare the
effect of addition of (2), (6), (12) and (13) on the CD spectrum of D2 (Figure 5.4).
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The spectra shown in Figure 5.4 (a) and (b) were previously shown in Figure 4.5,
but are reproduced here to facilitate comparison.
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Figure 5.4 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and D2: (a) D2 + (2); (b) D2 + (6);
(c) D2 + (12); (d) D2 + (13).

Visual inspection of the CD spectra suggests that addition of (12) and (13)
produced larger perturbations to the CD spectrum of D2 than their analogues
containing the shorter ethyl linking groups, complexes (2) and (6). While this
could be interpreted as being due to (12) and (13) binding more extensively to
D2, it may also be explained by postulating that the type of interactions that
occur between (12) or (13) and D2 are different in nature, and result in more
substantial changes to the conformation of D2. Of all four nickel complexes, (13)
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produced the biggest changes to the initial CD spectrum of the nucleic acid.
Although the ellipticity of the positive CD band at 280 nm did not change
significantly, this CD signal split into two separate bands, one with a maximum at
290 nm and the other at 277 nm. There was also a large decrease in ellipticity of
the negative CD signal at 250 nm. Table 5-2 shows that the magnitude of this
change was greater than that caused by any of the other three nickel complexes.
Figure 5.4 (d) also shows that a new, positive CD signal appeared in the 300 –
350 nm region, the origin of which is at present unknown. These results suggest
that (13) causes significant perturbation to the secondary structure of the
nucleic acid. This is not what would have been predicted from the ESI-MS
results, which suggested that very little of this complex binds to D2. However, if
(13) binds in such a manner that the resulting non-covalent complex(es) does
not have a high degree of stability, it is entirely possible that in the more
energetic environment of the mass spectrometer that they do not persist and are
not detected. This hypothesis is supported by the results of UV-Vis melting
studies presented in Table 5-1, which indicate that the binding of (13) does not
significantly stabilise D2.
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Table 5-2 – Effect on the CD spectrum of D2 of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 279 nm
Negative CD band at 247 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
-1.9
0.36
-0.1
2.5
(12)
-2.7
1.6
-1.1
2.3
(6)
0.8
1.6
-0.7
2.0
a
(13)
9.7
-2.8
0.48
1.5
3.9
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:9, except where
otherwise noted. Negative Δλ values indicate a blue shift; positive values
indicate a red shift. ∆ε values are the difference between ε at this wavelength for
the solution containing no metal complex, and ε at the wavelength of maximum
ellipticity for the solution with the highest DNA:metal complex ratio.
a Given that λmax splits at this point, the ∆ε here is calculated as the difference in
ellipticity at the same wavelength, rather than at the shifted wavelength.

Another possible reason for the large changes to the CD spectra shown in
Figure

5.4

(d)

is

that

complex

(13),

owing

to

the

meso-1,2-

diphenylethylenediamine moiety, may exhibit a significant CD spectrum of its
own. To test this hypothesis, CD spectra were obtained of solutions containing
the same concentrations of (13) as in those used to obtain the spectra in Figure
5.4 (d). The results obtained (Figure 5.5), showed that (13) does not have a
significant CD signal in the region investigated. Therefore, the changes to the
spectra in Figure 5.4 (d) result solely from the effects complex (13) has on the
conformation of D2, although it still is possible that in particular signals in the
300-400 nm range of the spectrum may be an induced circular dichroism (ICD)
band, arising from subtle changes to the nickel molecule caused by interactions
between the complex and the DNA.
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Figure 5.5 – CD spectra of solutions containing different concentrations of (13) in
100 mM NH4OAc.

Inspection of the changes in position and ellipticity of the CD signals
compiled in Table 5-2 shows that complex (13) had the largest effects, followed
by (12). Further scrutiny of the data reveals that the nickel complexes affected
the initial CD spectrum in different ways. For example, addition of (2) or (12)
resulted in blue shifts for the positive CD signal at 280 nm, as opposed to the red
shift caused by (6). Furthermore, complexes (2), (6) and (12) all resulted in
small blue shifts for the negative CD signal, whereas (13) produced a red shift.
What is clear from these results is that the nickel complexes are capable of
interacting with D2 in slightly different ways. Furthermore, the two nickel
complexes containing the longer alkyl linking groups produced the greatest
changes to the CD spectrum of D2.
Finally, fluorescence resonance energy transfer (FRET) experiments were
performed in order to compare the effects of complexes (12) and (13) on a
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dsDNA molecule, with that of (2) and (6). Figure 5.6 shows normalised FRET
melting curves obtained using solutions containing varying amounts of (12) or
(13) and the fluorescently-labelled 10mer DNA molecule FdxT, which has a
duplex structure. As the concentration of either nickel complex was increased,
the sigmoidal melting curve shifted to higher temperatures. These experiments
were carried out using sodium-containing buffer solutions, compared to

Normalised Absorbance

ammonium acetate which was used for ESI-MS and CD studies.
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Figure 5.6 – Normalised FRET melting curves obtained using solutions
containing 0.2 µM FdxT and different concentrations of: (a) (12); and (b) (13).

196

Values of ∆Tm determined for solutions containing FdxT and increasing
amounts of (12) or (13) are presented in Table 5-3, and compared to the
corresponding values obtained for solutions containing (2) or (6), and FdxT,
previously discussed in section 4.1. In general, the values of ΔTm obtained with
each nickel complex are relatively low.

Table 5-3 shows that as the

concentration of nickel complex was increased, so did the values of ΔTm. It is
also apparent from that data that the complexes containing the propyl linking
groups ((12) and (13)) consistently had greater ∆Tm values than the
corresponding nickel molecules containing the shorter, ethyl alkyl groups ((2)
and (6)). A surprising result was that the two non-planar nickel complexes
containing the meso-1,2-diphenylethylenediamine moiety ((6) and (13)) gave
slightly larger ∆Tm values than their analogues containing the phenylenediamine
unit ((2) and (12)). These findings suggest that the former molecules interact
more strongly with this dsDNA molecule. This is a different conclusion to that
reached on the basis of ESI-MS studies or UV-Vis melting curve measurements
performed using solutions containing D2. These discrepancies may be due to
differences in structure between the two DNA molecules used in FRET and UV
melting experiments. In particular, the short FdxT oligonucleotide is unlikely to
form as extensive a region of dsDNA as the 16mer D2, and has a higher
percentage of AT base pairs.

It is worth noting that FRET experiments

performed previously using solutions containing 1 µM (2) or (12) and calf
thymus DNA gave very small values of ΔTm (0.1 and 0.0 °C, respectively).150
These results also suggest that there may be some unique interactions occurring
between the nickel complexes and FdxT.
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Table 5-3 – Values of ΔTm derived from FRET melting experiments performed
using solutions containing different concentrations of nickel complexes and FdxT
(0.2 μM, Tm = 63.5 ± 1.2 °C).
∆ Tm (°C)
4 µM
1.8 ± 0.1
2.7 ± 1.1
2.4 ± 0.2
3.2 ± 1.2

1 µM
2 µM
(2)
1.0 ± 0.5
1.4 ± 0.7
(12)
2.0 ± 0.9
2.3 ± 0.9
(6)
1.3 ± 0.8
1.5 ± 0.6
(13)
2.1 ± 1.1
3.0 ± 0.9
Error values are standard error.

5 µM
1.9 ± 0.5
4.7 ± 0.4
1.8 ± 0.4
3.9 ± 1.0

10 µM
4.0 ± 0.9
7.2 ± 0.7
4.5 ± 0.5
9.3 ± 0.6

5.2.2 Binding experiments involving tetramolecular qDNA
ESI mass spectrometry was first used to compare the ability of complexes
(2) and (6) to bind to the tetramolecular quadruplex Q4(5G), with that of their
analogues (12) and (13).

Figure 5.7 shows the mass spectra of solutions

containing a 1:3 ratio of Q4(5G) with these four nickel complexes. The spectra of
solutions containing Q4(5G) and either (2) or (6) were first shown in Figure 4.9,
and are reproduced here for comparison.
There is very little difference between the spectra of solutions containing
(2) or (12) and Q4(5G) (Figure 5.7 (b) and (c)), indicating that their overall
binding affinities towards this G4-DNA are not very different. Ions from free
Q4(5G) were not apparent in either spectrum, while ions from {Q4(5G) + 2(2)}
and {Q4(5G) + 2(12)} were the predominant features in both cases. Ions from
non-covalent complexes consisting of three nickel molecules bound to Q4(5G)
were also evident in both spectra, and perhaps of slightly greater abundance in
the spectrum of the solution containing (2). Therefore, with this qDNA molecule,
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there appears to be only a very small difference in binding affinity, if any,
between complexes (2) and (12).
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Figure 5.7 – Negative ion ESI mass spectra of solutions containing Q4(5G) and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q4(5G); (b) Q4(5G)
+ (2); (c) Q4(5G) + (12); (d) Q4(5G) + (6); (e) Q4(5G) + (13).  = free Q4(5G); 
= {Q4(5G) + (Ni)};  = {Q4(5G) + 2(Ni)};  = {Q4(5G) + 3(Ni)}.

The results presented in section 5.2.1 showed that complex (13) which,
like its direct analogue (6), contains the non-planar meso-1,2-diphenylethylenediamine unit, exhibited little binding to dsDNA. It was therefore of great
interest to see if complex (13) was capable of binding to Q4(5G), as this would
make it another example, along with (6), of a qDNA selective reagent. Inspection
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of Figure 5.7 (e) shows that (13) did give rise to a significant abundance of ions
from {Q4(5G) + (13)}, confirming its DNA-binding selectivity.

However,

comparison of Figure 5.7 (d) and (e) suggests that the affinity of (13) for Q4(5G)
is essentially the same as that of its analogue (6), and therefore the replacement
of the ethyl linker groups in the latter complex by propyl chains had no
significant impact on DNA binding ability. This is supported by the observation
of ions of very low abundance from free DNA in both spectra, as well as that ions
from {Q4(5G) + (6)} and {Q4(5G) + (13)} were of high and similar abundance in
both cases. The spectra of solutions containing a 1:6 ratio of Q4(5G) and either
(6) or (13) were also similar (Figure 5.8), although the relative abundances of
ions from {Q4(5G) + 2(Ni)} appear to be slightly greater in the case of the
solution containing (13). This would suggest that (13) has a slightly higher
binding affinity, although the relatively poor signal:noise ratio of the spectrum in
Figure 5.8 (b), owing to the high concentration of nickel complex in solution,
makes this only a tentative conclusion.

Overall, therefore, it appears that

changing the length of the moiety linking the Schiff base to the piperidine units
has a negligible impact upon overall affinity towards Q4(5G).

The most

important conclusion to be drawn from the spectra in Figure 5.7 and Figure 5.8 is
that complex (13) has a significant ability to form non-covalent complexes with
tetramolecular qDNA, in contrast to its behaviour with the dsDNA D2.
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Figure 5.8 – Negative ion ESI mass spectra of solutions containing Q4(5G) and
different nickel Schiff base complexes at a 1:6 ratio. (a) Q4(5G) + (6); (b) Q4(5G)
+ (13).  = {Q4(5G) + (Ni)};  = {Q4(5G) + 2(Ni)}.

Inspection of Figure 5.7 also enables comparison of the affinity of
complexes (12) and (13) for Q4(5G); both nickel complexes feature the same
propyl linker between the Schiff base and piperidine units. In Figure 5.7 (c), the
abundance of ions from {Q4(5G) + 2(12)} was very high, whilst the analogous
ions containing (13) were absent from the spectrum in Figure 5.7 (e). Therefore,
it appears once again, that if all other aspects of the structure of a nickel Schiff
base complex are kept constant, a phenylenediamine moiety ((2) or (12)) will
exhibit greater affinity towards Q4(5G) than those containing the meso-1,2diphenylethylenediamine group ((6) or (13)).
In order to confirm the above conclusions regarding the effect of changing
the ‘linking’ group, ESI mass spectra were also obtained of solutions containing a
1:3 ratio of the slightly shorter qDNA molecule Q4(4G) and one of (2), (6), (12)
or (13). These results are shown in Figure 5.9. The spectra of Q4(4G) in the
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presence of either (2) or (6) were first shown in Figure 4.11, and are reproduced
here to facilitate comparison.
Figure 5.9 (a) is a spectrum of a solution containing Q4(4G) alone, and
shows ions at m/z 1452.8, 1743.8 and 2179.3, attributable to [Q4(4G) + 3NH4+ 9H]6-, [Q4(4G) + 3NH4+ - 8H]5- and [Q4(4G) + 3NH4+ - 7H]4-, respectively, with the
most abundant of these being that at m/z 1743.8. Ions from free Q4(4G) were
either absent or present in very low abundance in all spectra of solutions
containing a 1:3 ratio of DNA:nickel complex. This indicates that each of these
nickel complexes is able to bind effectively to this qDNA molecule to form noncovalent complexes. In all spectra, the most abundant ions from non-covalent
complexes were those with a 5- overall charge.
The most abundant ions in the spectrum of a solution containing (12) and
Q4(4G) (Figure 5.9 (c)) consist of two nickel molecules bound to the nucleic acid.
This spectrum also contains ions of low abundance from non-covalent complexes
containing either one or three bound nickel molecules. Overall, (12) appears to
have a greater propensity to form non-covalent complexes with Q4(4G) than any
of the other three nickel complexes, including (2). The latter result is somewhat
surprising as (2) and (12) showed very similar abilities to form non-covalent
complexes with Q4(5G). It is also noteworthy that (12) is able to bind at least as
extensively to Q4(4G) as it does to Q4(5G), despite the former tetramolecular
qDNA having one less G-quartet.
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Figure 5.9 – Negative ion ESI mass spectra of solutions containing Q4(4G) and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q4(4G); (b) Q4(4G)
+ (2); (c) Q4(4G) + (12); (d) Q4(4G) + (6); (e) Q4(4G) + (13).  = free Q4(4G); 
= {Q4(4G) + (Ni)};  = {Q4(4G) + 2(Ni)};  = {Q4(4G) + 3(Ni)}.

Ions corresponding to non-covalent complexes consisting of two nickel
molecules bound to qDNA were of high abundance in a number of the
nickel/qDNA systems examined. In contrast, ions from more heavily adducted
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non-covalent complexes were not observed, or of very low abundance, even in
solutions containing a 1:6 DNA:Ni ratio. These observations are consistent with
the hypothesis that “end-stacking” is the primary means of interaction in these
systems. This binding mode involves drug molecules stacking onto the ends of a
DNA quadruplex.81,86,129,267 Xu and co-workers used ESI-MS to investigate the
binding of alkaloids to d(TGGGGT)4, which is a tetramolecular qDNA molecule
very similar to Q4(4G), and found that no more than two of the organic
molecules were bound to the nucleic acid in the spectra of solutions containing a
1:4 qDNA:drug ratio.268 These workers used MS/MS experiments to provide
evidence for end-stacking in these systems, although some drug molecules also
acted as groove binders. Therefore, the possibility remains that the nickel Schiff
base complexes may participate in other types of binding modes than endstacking with Q4(4G) and Q4(5G).
Comparison of Figure 5.9 (d) and (e) suggests that the nickel complex
having the longer linking group, (13), may have a slightly higher affinity for
Q4(4G) than the otherwise identical complex (6). However, when solutions
containing a 1:6 ratio of Q4(4G) and either (6) or (13) were examined (data not
shown), there was little difference between the spectra obtained. Therefore,
there appears to be little overall difference in binding affinity towards this DNA
molecule between (6) and (13).
Comparison of the spectra in Figure 5.9 allows a clear order of relative
binding affinities for the four nickel complexes to be determined. The two
complexes containing a phenylenediamine moiety, (2) and (12), bind with
greater affinity to Q4(4G) than the complexes containing the non-planar meso1,2-diphenylethylenediamine moiety, (6) and (13). Furthermore, for both sets of
204

nickel complexes, those containing the longer, propyl linking group ((12) and
(13)) show a slightly greater ability to form non-covalent complexes with the
tetramolecular G-quadruplexes. This contrasts slightly with what was found for
solutions containing Q4(5G), where (6) and (13) showed very similar abilities to
form non-covalent complexes to each other, as did (2) and (12).
Overall, the results of the ESI-MS experiments performed with both types
of tetramolecular quadruplexes demonstrated that the nickel complexes
containing the phenylenediamine group have a higher binding affinity. These
studies also highlighted the ability of nickel complexes containing the meso-1,2diphenylethylenediamine group to bind to qDNA molecules, in stark contrast to
what was observed with a dsDNA molecule.
In order to seek further evidence in support of these findings, CD
spectroscopy was employed to further probe these nickel/qDNA systems. Figure
5.10 compares the effects of addition of complexes (2), (6), (12) and (13) on the
CD spectrum of Q4(5G), while Table 5-4 summarises the observed effects on the
positions and ellipticities of the CD signals. The effects of addition of (2) or (6)
on the CD spectrum of Q4(5G) were first shown in Figure 4.12. Spectra have
been reproduced here to facilitate comparison with the changes observed when
either (12) or (13) was added to the same qDNA molecule.
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Figure 5.10 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q4(5G): (a) Q4(5G) + (2); (b)
Q4(5G) + (6); (c) Q4(5G) + (12); (d) Q4(5G) +(13).

Table 5-4 - Effect on the CD spectrum of Q4(5G) of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
0.7
12
0.6
0.44
(12)
0
15
-0.1
7.6
(6)
-1.4
6.5
-1.5
3.1
(13)
0.1
18
0.8
5.2
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:7. Negative Δλ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.
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The most obvious difference between the spectra shown in Figure 5.10 is
that addition of the two nickel complexes containing the longer linker groups,
(12) and (13), induced much larger decreases in ellipticity of the positive CD
band at 260 nm than the analogues (2) and (6). For example, addition of 7
equivalents of (13) produced a decrease of 18 mdeg, compared to just 6.5 mdeg
for its analogue, complex (6). Significant decreases in ellipticity of the negative
CD band were also observed, and were again more pronounced when either (12)
or (13) was added to Q4(5G). Whilst each of the nickel complexes caused
notable changes to the ellipticities of all CD signals, the positions of the bands
themselves did not change greatly. Complex (6) had the biggest effect, but still
only resulted in a shift of ≤ 1.5 nm for both the positive and negative CD signals.
The significant changes to the CD spectrum of Q4(5G) observed upon
addition of (13) and, to a lesser extent (6), provide further support for the
conclusion reached previously on the basis of ESI-MS results, that these
complexes show a significant ability to bind to tetramolecular G-quadruplexes. It
is also tempting to conclude on the basis of the results shown in Figure 5.10 that
the two complexes containing the longer linking groups, (12) and (13), show a
greater ability to bind to Q4(5G) than (2) and (6). However, this conclusion
would be in contrast to what is suggested by the results of the ESI-MS
experiments (Figure 5.7 and Figure 5.8), where complexes (12) and (13) showed
only comparable levels of formation of non-covalent complexes compared to the
two analogues containing the shorter linker groups. This dichotomy of relative
binding affinities, based on the two instrumental techniques, was also noted
earlier in studies involving D2 presented in section 5.2.1. In order to understand
these differences it is important to consider the various aspects of drug/DNA
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binding that each technique examines.

For example, ESI-MS provides

information regarding the number of small molecules which can remain bound
to a DNA molecule in an energetic, ionised environment, but, unlike CD
spectroscopy, does not afford clues regarding how these small molecules interact
with the DNA, or change its secondary structure.
In order to explore whether the results presented in Figure 5.10 are
typical of nickel Schiff base complex/tetramolecular qDNA systems, an additional
series of experiments were performed. This time, CD spectra were obtained of
solutions containing different ratios of Q4(4G) and the four nickel complexes.
The results obtained are presented in Figure 5.11, while the effects on the
position and ellipticity of the CD bands are summarised in Table 5-5. The effects
of addition of each nickel complex on the CD spectrum of Q4(4G) are more
dramatic than what was observed previously with Q4(5G). This is in general
agreement with observations made during ESI-MS experiments, which suggested
that most nickel molecules exhibited an ability to form non-covalent complexes
with Q4(4G) that was at least comparable to, or even greater than, what they
displayed with Q4(5G).
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Figure 5.11 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q4(4G): (a) Q4(4G) + (2); (b)
Q4(4G) + (6); (c) Q4(4G) + (12); (d) Q4(4G) + (13). Data for Q4(4G) and (2)
does not include the spectrum obtained for a 1:9 ratio, as precipitation occurred
in this solution.

Table 5-5 – Effect on the CD spectrum of addition of nickel Schiff base complexes
to a solution containing Q4(4G).
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
CD ∆λ (nm)
∆ε λmin (mdeg)
a
a
a
(2)
0.7
8.2
3.9
2.3a
(12)
7.7
14
6.8
3.5
(6)
1.8
9.4
5.1
2.9
(13)
0.3
9.6
2.9
2.2
All Δλ and Δε values are the differences between the values for free DNA and
those for a solution containing a DNA:nickel complex ratio of 1:9, except where
otherwise noted. Negative Δλ values indicate a blue shift; positive values
indicate a red shift. ∆ε values are the difference between ε at this wavelength for
the solution containing no metal complex, and ε at the wavelength of maximum
ellipticity for the solution with the highest DNA:metal complex ratio.
a The significant change of the CD spectrum at a 1:9 ratio means that it has
deviated so much from the original, it is not possible to calculate a shift in
wavelength or change in ellipticity. Therefore, values are calculated here using
the spectrum of a 1:6 DNA:metal complex ratio.
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The effects of addition of (13) upon the CD spectrum of Q4(4G) are
particularly striking. Addition of small amounts of (13) resulted in similar
decreases in ellipticity of the positive and negative CD signals to those elicited by
addition of the other nickel complexes. However, at high DNA:nickel ratios, an
additional positive CD signal appeared with a maximum at 320 nm. These
changes indicate that a significant alteration to the conformation of Q4(4G) had
taken place. None of the other nickel complexes had a similar effect, and (13) did
not affect the CD spectrum of Q4(5G) as profoundly. This suggests that complex
(13), containing the meso-1,2-diphenylethylenediamine moiety, is able to
interact very strongly with Q4(4G). Consistent with this, ESI mass spectra of
solutions containing (13) and Q4(4G) showed ions of high abundance from
{Q4(4G) + 2(13)} (Figure 5.9), whereas the corresponding ions were absent from
spectra of solutions containing (13) and Q4(5G) (Figure 5.7).

5.2.3 Binding experiments involving unimolecular qDNA
Since both CD spectroscopy and ESI-MS suggested that complexes (12)
and (13) were able to bind to tetramolecular G-quadruplexes to a similar extent
to that of the analogues (2) and (6), it was of interest to see if this was also true
for unimolecular G-quadruplexes. ESI mass spectra were therefore obtained of
solutions containing different ratios of Q1 and the four nickel complexes (Figure
5.12). The spectra in Figure 5.12 (b) and (d) were previously shown in Figure
4.14, but are reproduced here to facilitate comparison.
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Figure 5.12 – Negative ion ESI mass spectra of solutions containing Q1 and
different nickel Schiff base complexes at a 1:3 ratio. (a) free Q1; (b) Q1 + (2); (c)
Q1 + (12); (d) Q1 + (6); (e) Q1 + (13).  = free Q1;  = {Q1 + (Ni)};  = {Q1 +
2(Ni)}.

Ions at m/z 1329.9 and 1662.6 in these spectra correspond to free Q1 in
the 6- and 5- charge states, respectively. These ions are of medium to high
abundance in all spectra, except that shown in Figure 5.12 (c), where only the 6211

ion appears, and is of low abundance. This is because of extensive formation of
non-covalent complexes between Q1 and (12), with the ions of greatest
abundance in the spectrum (at m/z 1592.3) corresponding to {Q1 + 2(12)}. Ions
attributable to {Q1 + (2)} are of high abundance in the spectrum shown in Figure
5.12 (b), which also contains ions of medium abundance from {Q1 + 2(2)}.
Comparison of these two spectra therefore suggests that the nickel molecule
containing the longer linker group shows a greater ability to bind to this
particular qDNA molecule.
The spectra of solutions containing Q1 with either (6) or (13) (Figure
5.12 (d) and (e), respectively), show little evidence of formation of non-covalent
complexes. The dominant ions in both spectra are those corresponding to free
Q1. The only other ions present are of low abundance in Figure 5.12 (e), at m/z
1482.0, and correspond to {Q1 + (13)}. The inability of (6) and (13) to form noncovalent complexes with Q1 parallels results presented earlier for solutions
containing these nickel complexes and D2, and contrasts with what was
observed in the corresponding studies involving tetramolecular G-quadruplexes.
This suggests that (6) and (13) may exhibit binding selectivity in favour of the
latter type of G-quadruplex over both dsDNA and unimolecular qDNA. ESI mass
spectra were also obtained of solutions containing lower and higher ratios of Q1
and either (6) or (13). The relative abundances of ions from free DNA and
various non-covalent complexes observed in these spectra are presented
graphically in Figure 5.13. The results presented in Figure 5.13 (a) confirm that
(6) has essentially no ability to form non-covalent complexes with Q1, except in
solutions with very high Q1:Ni ratios. In contrast, the results presented in Figure
5.13 (b) show that (13) can form non-covalent complexes with this DNA
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molecule if added in sufficient quantities. This suggests that the presence of the
longer linker groups may have had a beneficial effect on quadruplex DNA
binding. A further conclusion to be drawn from the results presented in Figure
5.13 is that complex (6) appears to be the nickel complex most likely to act as a
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selective binding reagent for tetramolecular G-quadruplexes.
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Figure 5.13 – Relative abundances of ions from free DNA and different noncovalent complexes observed in ESI mass spectra of solutions containing Q1 and:
(a) (6); or (b) (13).
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The binding of the four nickel complexes to the unimolecular quadruplex
Q1 was also examined using CD spectroscopy, affording the results shown in
Figure 5.14. The DNA was annealed under the conditions described in section
4.4, to ensure that it was present in a parallel conformation. The series of CD
spectra presented in Figure 5.14 (a) and (b) were originally shown in Figure
4.16, and discussed in section 4.4, but are reproduced here to facilitate
comparison with the results obtained using the other nickel complexes
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Figure 5.14 – Circular dichroism (200 – 400 nm) of solutions containing different
ratios of nickel Schiff base complexes and Q1: (a) Q1 + (2); (b) Q1 + (6); (c) Q1 +
(12); (d) Q1 + (13).

Inspection of the CD spectra shows that addition of all nickel complexes
resulted in decreases in ellipticity of both the positive CD signal at 260 nm and
negative CD signal at approximately 240 nm. The extent of these decreases, and
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the changes in position of these two CD signals are compiled in Table 5-6.
Comparison of the CD spectra shows that addition of (2) and (12), which both
contain the phenylenediamine moiety, caused greater decreases in ellipticity of
the positive CD signal than addition of (6) or (13), which contain the non-planar
meso-1,2-diphenyl-ethylenediamine group.

Furthermore, of these two

complexes (6) had the greater effect on both the position and ellipticity of the
positive CD band of Q1. This is surprising in view of the absence of ions from
species such as {Q1 + (6)} in the ESI mass spectra of solutions containing both
binding partners (Figure 5.12 (d)). Therefore, this appears to be yet another
example where interactions between the metal complex and nucleic acid can
significantly alter the conformation of the latter, but are not sufficiently stable to
survive the ESI process.

Table 5-6 – Effect on the CD spectrum of Q1 of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
2.8
7.0
0.9
1.9
(12)
9.8
8.6
2.0
1.8
(6)
-1.6
5.5
-4.3
3.3
(13)
0.3
3.7
-1.8
2.0
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:7. Negative Δλ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

Whilst the decreases in ellipticity are the most notable effect that all four
nickel complexes had on the CD spectrum of Q1, (2) and (12) also shifted the
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position of the positive CD signal to lower energy to a significant extent. In the
case of (12), this red shift amounted to almost 10 nm. In contrast, addition of
complex (6) produced a small blue shift, whereas the presence of (13) had
virtually no effect. These different effects on the CD spectrum of Q1 indicate that
the two types of nickel complex, which vary in the identity of the head group, are
able to interact in different ways with Q1. Further examination of Figure 5.14
suggests that, overall, varying the linker connecting the Schiff base ligand to the
piperidine moieties has only a minor effect on the manner with which the nickel
complex binds to the DNA, or the extent of binding. Comparison of either the
values of Δλ or Δε for the positive CD signals leads to the following order of
relative binding affinities: (12) > (2) > (6) > (13). This order is very similar to
the ability of the nickel complexes to form non-covalent complexes with Q1 using
ESI-MS, and might ordinarily support the conclusion that both techniques are
providing results that accurately reflect the degree of interaction between the
binding partners. However, the almost complete absence of ions from noncovalent complexes in ESI mass spectra of solutions containing Q1 and either (6)
or (13) is, as noted above, inconsistent with the significant changes to the CD
spectrum of Q1 apparent in Figure 5.14 (b) and (d).
FRET melting assays were therefore conducted using the same four nickel
complexes and the unimolecular qDNA molecule F21T. The ∆Tm values derived
from these experiments are listed in Table 5-7 and are presented graphically in
Figure 5.15, alongside values obtained from experiments performed with the
same nickel complexes and the dsDNA FdxT, which was first discussed in section
5.2.1. The values of ΔTm obtained for the unimolecular qDNA were much larger
than those obtained with the dsDNA molecule, and also showed greater
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sensitivity to changes in the concentration of the nickel complex. Complexes
(12) and (13), which contain the longer linking groups, gave greater ∆Tm values
for F21T than their analogues (2) and (6), respectively. Complex (12) was
shown previously to more extensively form non-covalent complexes with Q1
than (2), and also had a pronounced effect in general on the CD spectrum of this
unimolecular qDNA. Therefore, the FRET melting assay results obtained with
F21T are consistent with the conclusion that replacing the ethyl linking groups in
(2) by the longer, propyl chains, enhances binding affinity towards unimolecular
qDNA molecules. A similar conclusion cannot be reached unequivocally for
complexes (6) and (13).

Although the FRET results obtained with these

complexes and F21T support the conclusion that the longer linker groups
enhance binding affinity, the opposite trend was observed in the CD study with
Q1, and neither complex showed evidence of a significant ability to form noncovalent complexes in the ESI-MS study. However, as discussed previously in
section 4.4, the different buffer conditions used for FRET as opposed to ESI-MS
or CD studies, or the presence of the fluorescent labels, may have an effect on the
results obtained.

Table 5-7 – Values of ΔTm derived from FRET melting experiments performed
using solutions containing different concentrations of nickel complexes and F21T
(0.2 μM, Tm = 50.0 ± 0.2 °C).
∆ Tm (°C)
4 µM
14.0 ± 0.5
23.7 ± 0.9
5.7 ± 0.7
7.0 ± 1.5

1 µM
2 µM
(2)
3.0 ± 0.7
9.4 ± 0.7
(12)
7.6 ± 1.1
12.2 ± 1.0
(6)
0.8 ± 0.4
2.9 ± 0.2
(13)
1.1 ± 0.6
5.3 ± 0.6
Error values are standard errors.
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5 µM
13.3 ± 2.1
30.4 ± 0.4
3.4 ± 0.7
7.6 ± 1.9

10 µM
24.4 ± 0.4
36.6 ± 0.3
10.4 ± 2.2
15.8 ± 3.6
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Figure 5.15 – Effect of increasing concentration of nickel complexes on the value
of ΔTm derived from FRET melting assays for experiments performed with: (a)
F21T; and (b) FdxT. Error bars are standard errors.

The complexes containing the planar phenylenediamine moiety ((2) and
(12)) had greater effects on ∆Tm than the non-planar complexes (6) and (13).
This result is consistent with those obtained from binding studies performed
using Q1 and both ESI-MS and CD. The order of binding affinity of the four nickel
complexes towards F21T, based on the results presented in Table 5-7, is: (12) >
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(2) > (13) > (6). This order is identical to that obtained from ESI-MS binding
studies involving Q1 and Q4(4G), and that based on the decreases in ellipticity
observed for the positive CD band of this qDNA. Overall, the FRET results lend
further support to the notion that complex (6) exhibits the greatest degree of
selectivity in its DNA-binding behaviour by virtue of showing little tendency to
interact with F21T. This parallels results obtained with the other unimolecular
qDNA Q1, and the dsDNA D2, and contrasts with its ability to bind to
tetramolecular G-quadruplexes.
It should be noted that the binding of both (2) and (12) to F21T has been
previously examined using FRET melting assays.149-150 At a 1 µM concentration
of metal complex, the ∆Tm values reported for (2) and (12) were greater than
those obtained in the current work.

However, the F21T was prepared in

different buffer solutions for the two different sets of experiments, and it has
been previously shown that Tm values obtained in sodium-containing buffer (this
thesis) are often lower than those derived from measurements performed in
potassium buffer (literature results).241
When the ∆Tm results derived from experiments performed with both
FdxT and F21T are directly compared, as in Figure 5.15, the differences in
binding affinity of the nickel complexes towards the two DNA molecules
becomes very apparent. What is most evident is that the nickel complexes show
a much greater ability to stabilise the unimolecular qDNA F21T than the dsDNA
FdxT, indicating a much higher degree of affinity towards the former type of
DNA.
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In order to further explore the degree of selectivity exhibited by the nickel
complexes, FRET competition assays were carried out. These were analogous to
the competition assay described in section 4.4, and for which results were
presented in Figure 4.18. The FRET competition assay results obtained with the
four nickel complexes are presented in Figure 5.16. ΔTm values for complexes
(2) and (6) were previously reported and discussed in section 4.4, but are
reproduced here to facilitate comparison.
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Figure 5.16 – Effect of increasing concentration of dsDNA competitor molecule
ds26, on the ΔTm obtained from solutions containing 5 µM nickel complex and
0.2 µM F21T.

For most of the nickel complexes, increasing the concentration of ds26
from 0-10 μM resulted in small decreases in ΔTm, although these were generally
within the error of the experiments. The only exception to this was for (2),
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which showed a decrease in ΔTm of 5 °C at the highest concentration of
competitor dsDNA used. Therefore, it appears that complex (2) may interact to a
small extent with ds26 in solutions with relatively high concentrations of the
latter. Overall, however, the small decreases in ΔTm caused by addition of much
greater concentrations of ds26 is consistent with the conclusion that each of the
nickel complexes exhibits a preference for binding to the unimolecular qDNA
molecule over the dsDNA.
In previous competition FRET assays performed using platinum(II)
phenanthroline-imidazole derivatives, heptamethincyanine dyes, substituted
macrocycles and cyclophanes, ΔTm was found to be decreased by up to 8 °C,
which is greater than the effects observed here. These molecules were still
considered to be qDNA selective, or to be strong qDNA binders and weak dsDNA
binding agents.176,264-265,269 As previously described in Equation 1 in section 4.4,
values of

FRETS

were calculated using the results of the competition assay.264-265

For the nickel complexes examined here, FRETS varied from 0.71-0.97 (Table 5-8),
with the value for complex (12) the highest. As discussed previously in section
4.4, the range of FRETS values for a small molecule considered to be selective for
qDNA is 0.62-0.84.265-266

Table 5-8 – Values of FRETS for different nickel complexes.
Nickel Complex
(2)
(12)
(6)
(13)
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FRETS

0.72
0.97
0.70
0.71

Overall, the FRET melting and competition assays confirm that the four
nickel complexes can interact significantly with unimolecular qDNA, and show a
degree of selectivity for qDNA over dsDNA. The results also suggest that the
nickel complexes with the longer alkyl groups connecting to the piperidine
moieties exhibit greater stabilisation of qDNA, presumably as a result of stronger
binding interactions.
Each of the previous techniques used to investigate the binding of nickel
complexes to various DNA molecules mainly provided qualitative information
about the extent of binding interactions, and their effects on the conformation of
the nucleic acid molecules. In an attempt to obtain information about what
specific regions of an intramolecular qDNA molecule the nickel complexes prefer
to interact with, a series of 1H-NMR experiments was performed using the
antiparallel qDNA molecule 22AG1 in 100 mM sodium ions (10 mM sodium
phosphate, 90 mM sodium chloride), the solution structure of which has been
previously characterised in this buffer.242 Initially, the chemical shifts of the
imino protons of the guanine residues of 22AG alone were measured and
assigned, and then the solution containing the nucleic acid was titrated with
different nickel complexes, and the effect on the chemical shifts of the above
protons measured. This process was repeated several times with solutions
containing different DNA:nickel ratios. Since the imino region of the 1H-NMR
spectrum is well resolved, it was possible to observe small changes in chemical

1

The usage of an antiparallel qDNA molecule in this instance was a matter of practicality: these NMR
experiments were conducted in an overseas laboratory, using qDNA molecules that were available and
for which the NMR parameters had already been optimised.
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shifts caused by interactions with drug molecules close to the binding site. 105
The titrations were stopped once precipitation in the solution was observed.
The 1H-NMR spectra of solutions containing different ratios of 22AG with
either (2) or (12) are shown in Figure 5.17. Addition of increasing amounts of
(2) resulted in the appearance of a broad signal underneath all of the imino
resonances from 22AG, as well as broadening of the resonances themselves. In
addition, the signal at 11.12 ppm was observed to split into two signals, at 11.12
and 11.09 ppm.

These results indicate that there was a greater degree of

interaction between this nickel complex and the DNA molecule than in solutions
containing 22AG and (12), where only a small amount of signal broadening was
seen.

Whilst the order of binding affinity for these two nickel complexes

therefore appears to be opposite to that obtained with most of the other
techniques used to investigate interactions with qDNA, it must be remembered
that 22AG is known to adopt an antiparallel conformation under these
conditions.242 This is different to the conformation adopted by the various
unimolecular qDNA molecules used in binding studies described earlier in this
thesis. Therefore, it is possible that complexes (2) and (12) exhibit different
binding preferences towards different unimolecular DNA quadruplexes.
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Figure 5.17 – Effect of addition of increasing amounts of nickel complexes on the
imino region of the 1H-NMR spectrum of 22AG: (a) solutions containing (2) and
22AG; and (b) solutions containing (12) and 22AG.
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The effects on the 1H-NMR spectrum of 22AG caused by the addition of
(6) or (13) were much greater than observed for previous two nickel complexes,

[rel]

and are shown in Figure 5.18 and Figure 5.19, respectively.
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Figure 5.18 – Effect of increasing amounts of (6) on the imino region of the 1HNMR spectrum of a solution containing 22AG. Lines have been placed across the
spectra in order to track the shifts of the imino protons.

This is reflected partially in the observation that the chemical shifts of the
imino protons for most of the guanine residues were affected by the addition of
(6) or (13), whereas the presence of (2) or (12) generally had only a minor
effect. The maximum changes in chemical shift are compiled in Table 5-9.
Addition of (13) resulted only in upfield shifts, while for (6) most shifts were

225

upfield, although the G8 and G20 imino protons experienced downfield shifts.

1.0 [rel]

These two imino protons were not affected by the addition of (13).
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Figure 5.19 – Effect of increasing amounts of (13) on the imino region of the 1HNMR spectrum of a solution containing 22AG. Lines have been placed across the
spectra in order to track the shifts of the imino protons.
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Table 5-9 – Maximum change in chemical shift of the imino protons of 22AG
caused by addition of (6) or (13).
Residue
(6)
(13)
G2
0.02
0.02
G3
0.01
0.02
G4
0.04
0.03
G8
-0.02
0
G9
0.01
0.01
G10
0.02
0.03
G14
0.01
0.02
G15
0.01
0.02
G16
0.02
0.02
G20
-0.01
0
G21
0.01
0.02
G22
0
0
Negative values reflect a downfield shift, positive values an upfield shift.

A schematic illustration of the structure of 22AG, indicating the position
of each guanine residue, is presented in Figure 5.20. The structure shows the
DNA molecule in an antiparallel conformation it is known to adopt in solution
under similar buffer conditions.242 Each rectangular panel has a colour that
reflects the size of the maximum change in chemical shift of the imino proton of
that guanine residue. Changes in chemical shift greater than or equal to 0.03
ppm are illustrated as red rectangular panels, while changes in chemical shift of
0.02 ppm are denoted by orange panels. Smaller changes in chemical shift (0.01
ppm) are presented as yellow panels, whilst guanine residues whose imino
protons were unaffected by the addition of a nickel complex are depicted as
white panels.
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Figure 5.20 – A schematic illustration of 22AG, showing the maximum changes in
chemical shift resulting from the addition of (6) or (13). The schematic is
adapted from Ambrus et al.,270 and rearranged to match the structure as
presented by Wang and Patel.242

By assuming that a larger change in chemical shift for an imino proton
reflects a greater degree of binding between a nickel complex and the guanine
residue containing that imine, it is possible to draw tentative conclusions
regarding the regions of the nucleic acid where the interactions primarily occur.
Figure 5.20 shows that complex (13) interacts to a similar extent with many of
the guanine residues distributed throughout the structure of 22AG.

This

suggests that the nickel complex binds in a largely non-specific manner, and that
further changes to the structure of the metal complex are probably required to
produce a useful quadruplex-selective reagent. Interestingly, however, G8 and
G20, which are positioned adjacent to two adenine residues at the end of the
qDNA molecule with two lateral loops, remain unaffected by the binding of (13)
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to 22AG. This may indicate that this molecule is unable to access these residues,
possibly because of the position of the loops. Furthermore, the chemical shifts
observed for the residues in the middle guanine tetrad may be a result of the
lengthened alkyl chain on this complex, which would permit the piperidine units
to access the grooves of this DNA molecule. In contrast, complex (6), shows a
noticeable preference for residues on the ends of 22AG, in particular on the end
with the two lateral loops, although the overall maximum chemical shifts caused
by binding of this complex to 22AG are less than observed for binding of (13).
This suggests that (6) may participate to a significant extent in an end-stacking
mode of binding with 22AG, but that the shorter alkyl chains do not probe as far
into the residues, thereby resulting in smaller changes being induced in the
chemical shifts of the imino protons.

5.2.4 Summary
A variety of techniques was used to examine the effects of modifying the
length of the alkyl chains connecting pendant piperidine groups to the rest of
four nickel Schiff base molecules, on their DNA binding affinities. In most cases,
nickel molecules with longer alkyl chains showed slightly higher binding
affinities, while in the case of (12) enhanced selectivity for both tetramolecular
and unimolecular qDNA over dsDNA was observed.
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5. 3 Morpholine complexes
In this section the effect on DNA binding properties of replacing the
piperidine groups in complexes (2), (6) and (8) by morpholine rings was
explored. The synthesis and characterisation of the morpholine complexes (9),
(10) and (11) were described in section 3.2, and the structure of these
complexes is shown in Figure 5.21.

Figure 5.21 - Structures of nickel Schiff base complexes containing pendant
morpholine groups.
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The interactions of (9) with F21T and a human telomeric qDNA molecule
have been previously investigated.149-150 However, complexes (10) and (11), to
the best of our knowledge, are reported here for the first time, as are the results
of DNA-binding studies involving all three compounds and the dsDNA, D2, the
tetramolecular qDNA, Q4(5G), and the unimolecular qDNA, Q1.

5.3.1 DNA binding experiments involving duplex DNA
ESI-MS was first used to examine the ability of (9), (10) and (11) to bind
to the dsDNA D2.

Figure 5.22 shows the spectra obtained using solutions

containing a 1:3 ratio of D2 and one of these three nickel complexes. None of the
solutions containing nickel complexes and D2 gave spectra containing ions
attributable to non-covalent complexes. This was not surprising in the case of
(10), as it contains the meso-1,2-diphenylethylenediamine moiety which was
shown in section 4.2 to inhibit interactions between nickel Schiff base complexes
and dsDNA molecules such as D2. The lack of evidence for interaction between
either (9) or (11) and D2 was, however, unexpected. ESI mass spectra of
solutions containing the analogous complexes featuring pendant piperidine
groups instead of morpholines ((2) and (8)) both showed ions from noncovalent complexes with the general formula {D2 + (Ni)} and {D2 + 2(Ni)}
(Figure 4.3).

The spectra in Figure 5.22 therefore strongly suggest that

modifying the structure of the nickel Schiff base complexes to contain
morpholine units has a major inhibitory effect on their affinity towards dsDNA.
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Figure 5.22 - Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:3 ratio: (a) free D2; (b) D2 + (9); (c)
D2 + (10); (d) D2 + (11).  = free DNA.

In order to test this hypothesis, CD spectra were obtained of solutions
containing D2 and increasing amounts of (9), (10) and (11) (Figure 5.23).
Addition of (10) and (11) resulted in no significant change to the CD spectrum of
the nucleic acid, while (9) only produced very small changes in ellipticity (< 2
mdeg) for the negative CD signal and the positive CD signal at ~220 nm. These
results are therefore in accordance with those obtained by ESI-MS for the same
systems, as well as a previous study where (9) was shown by FRET melting to
exhibit no stabilisation of a t-loop duplex DNA molecule.150
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Figure 5.23 – Circular dichroism spectra (200-400 nm) for solutions containing
different ratios of nickel Schiff base complexes and D2: (a) D2 + (9); (b) D2 +
(10); (c) D2 + (11).

It must be noted that the changes to the CD spectrum of D2 caused by the
piperidine-containing analogues of these three nickel complexes were also small,
although complexes (2) and (8) were shown by ESI-MS to form non-covalent
complexes with this dsDNA (Figure 4.3). Therefore the small changes to the CD
spectrum of D2 caused by the morpholine-containing complexes is not
necessarily indicative of a lack of binding. However, the absence of any ions of
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significant abundance in the mass spectra of solutions containing (9), (10), or
(11), and D2, combined with the absence of any notable changes to the CD
spectrum of the latter upon addition of these metal complexes, provides strong
evidence for the absence of significant binding interactions in these systems.
This was a very surprising result, as the only difference between complexes (9),
(10) and (11), and their piperidine-containing analogues, is the presence of two
oxygen atoms in place of two methylene groups. Introduction of the electronrich oxygen atoms therefore appears to create unfavourable interactions, at least
with this particular dsDNA molecule. Since the ultimate aim of this project was
to create nickel complexes that bind strongly to one or more types of qDNA
structures, but not dsDNA, the results presented in Figure 5.22 and Figure 5.23
do not prohibit the possibility that morpholine-containing nickel complexes
might prove useful as qDNA-selective agents. Attention was therefore turned to
examining the interactions of complexes (9) – (11) with different qDNA
structures.

5.3.2 DNA binding experiments involving quadruplex DNA
Figure 5.24 compares the ESI mass spectra of solutions containing (9),
(10) or (11), and either the tetramolecular qDNA molecule Q4(5G) or the
unimolecular Q1.
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Figure 5.24 - Negative ion ESI mass spectra of solutions containing either Q4(5G)
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Ions attributable to non-covalent complexes are either absent or present
in very low abundance in all of the spectra, except that of the solution containing
Q4(5G) and (11) (Figure 5.24 (c)). This suggests that the lack of interaction
these morpholine-containing complexes exhibited towards D2 may be a more
general phenomenon. If this is the case, then the observation of ions of high
abundance from {Q4(5G) + (11) in Figure 5.24 (c), along with ions of low
abundance from {Q4(5G) + 2(11)}, is surprising. Although (11) clearly is able to
form non-covalent complexes with Q4(5G), it does so to a lesser extent than its
piperidine-containing analogue (8).

This conclusion is supported by the

observation that the ESI mass spectrum of a solution containing a 1:3 ratio of
Q4(5G) and (8) (Figure 4.9) showed no ions attributable to free DNA, unlike the
spectrum in Figure 5.24 (c).

Furthermore, the spectrum of the solution

comprising Q4(5G) and (8) contained ions of high abundance from {Q4(5G) +
2(8)}. The analogous ions were of low abundance in the spectrum of the solution
containing (11) and Q4(5G).
The above results therefore suggest that replacement of both piperidine
groups by morpholine units generally has a detrimental effect on the affinity of
the nickel complex for all types of DNA studied. This was a surprising result,
given the simple difference in structure between these two ring systems. It is,
however, consistent with a report that (9) exhibited a much poorer ability than
(2) to stabilise F21T.150
In order to further explore the ability of the morpholine-containing nickel
complexes to bind to quadruplex DNA, CD spectra were obtained of solutions
containing these nickel complexes and Q4(5G). These spectra are presented in
Figure 5.25, and show that the three morpholine-containing complexes have a
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negligible effect on the conformation of Q4(5G).

This suggests that these

complexes bind to only a limited extent to this qDNA molecule, and is consistent
with the conclusions based on the results of ESI mass spectra of solutions
containing (9) or (10) and Q4(5G), which were presented in Figure 5.24. In
contrast, the CD spectrum of a solution containing (11) and Q4(5G) provides
little evidence of binding interactions between the two, which is inconsistent
with the observation of ions of high abundance attributable to non-covalent
complexes in the mass spectrum of a similar solution (Figure 5.24 (c)).
The changes to the CD spectrum of Q4(5G) caused by addition of (9), (10)
and (11) are generally smaller than those observed when the corresponding
complexes containing two piperidine groups were added (Figure 4.12). This is
most readily apparent through comparing the effect of two related complexes on
the ellipticity of the positive band at 260 nm in the CD spectrum of the nucleic
acid. For example, addition of 7 equivalents of (2) resulted in a decrease in
ellipticity of this CD band of 11.6 mdeg (Figure 4.12 and Table 4-3).

This is

almost an order of magnitude greater than the effect of its morpholinecontaining counterpart (9). Similarly, addition of (6) to a solution containing
Q4(5G) resulted in a decrease in ellipticity of the positive CD band that was more
than three times as large as that caused by the presence of an equivalent amount
of the morpholine analogue (10).
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Figure 5.25 – Circular dichroism spectra (200-400 nm) of solutions containing
Q4(5G) and different ratios of nickel Schiff base complexes; (a) Q4(5G) + (9); (b)
Q4(5G) + (10); (c) Q4(5G) + (11).

CD spectra were also obtained of solutions containing one of the
morpholine-containing complexes (9), (10) or (11) and Q1 (Figure 5.26). In a
similar manner to what was observed for CD experiments involving Q4(5G),
there were only minor changes observed to both the positive and negative CD
bands of Q1 upon addition of the nickel complexes. Furthermore, the changes in
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ellipticity of these bands was significantly less than those observed in CD spectra
of solutions containing Q1 and the piperidine-containing analogues (2), (6) and
(8) (Figure 4.16).
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Figure 5.26 – Circular dichroism spectra (200-400 nm) of solutions containing
Q1 and different ratios of nickel Schiff base complexes; (a) Q1 + (9); (b) Q1 +
(10); (c) Q1 + (11)
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These results suggest that the presence of the morpholine unit in these
nickel complexes has an inhibitory effect upon binding to a unimolecular qDNA
molecule such as Q1.

5.3.3 Summary
ESI-MS and CD spectroscopy were used to examine the binding of three
nickel Schiff base complexes containing two pendant morpholine moieties to
duplex DNA, as well as to tetramolecular and unimolecular G-quadruplex DNA.
Overall, each of the three complexes (9), (10) and (11) displayed a lower DNAbinding ability than the analogous complexes (2), (6) and (8), which contain two
pendant piperidine moieties in place of the morpholine groups. Only complex
(11) which also contains an ethylenediamine unit was shown to bind to Q4(5G)
through the use of ESI-MS. However, the extent of binding was still far less than
what was observed with its piperidine analogue (8). Therefore there appears to
be little benefit to be gained by replacing the piperidine moieties in the initial
Schiff base complexes studied with morpholine groups, in terms of enhancing the
affinity or selectivity of these metal complexes for any type of DNA.
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CHAPTER 6 - DNA-BINDING PROPERTIES OF
NICKEL SCHIFF BASE COMPLEXES: EFFECT OF
INTRODUCING ASYMMETRY
6. 1 Introduction and scope of this chapter
The final aim of this project was to investigate the effects of replacing one
of the salicylaldehyde moieties in the nickel Schiff base complex (2) with a
naphthaldehyde unit, on the DNA binding properties of the resulting asymmetric
complex. It was hoped that introducing a larger aromatic ring system into the
molecule might confer enhanced binding interactions with quadruplex DNA
molecules, as it would facilitate additional π-π stacking interactions with a
terminal G-quartet.

As it was not possible to obtain 2,4-dihydroxy-

naphthaldehyde from a commercial supplier, the synthesis of asymmetric nickel
Schiff base complexes was performed using 2-hydroxy-1-naphthaldehyde,
leading eventually to complexes containing only one pendant alkyl group (Figure
6.1). A structurally related version of these complexes was recently reported,207
however it contained a different diamine component, and lacked the piperidine
or morpholine side chains. To date, there has not been an investigation into the
DNA binding properties, or more generally the biological properties (such as cell
toxicity), of this sub-class of nickel Schiff base complexes.
Two different asymmetric nickel Schiff base complexes were synthesised,
where the linking alkyl group was either an ethyl or a propyl chain (section
3.3.3).

This added another dimension to DNA binding investigations, as it
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allowed not only the effect of changing the aromatic group to be examined, but
also the effect of different spacer lengths. The following sections present the
results of DNA binding studies involving complexes (15) and (16), and a range of
different DNA molecules.

Figure 6.1 – Structures of asymmetric nickel Schiff base complexes used in DNA
binding studies.

6. 2 Binding experiments involving duplex DNA
The binding of the two asymmetric nickel Schiff base complexes to the
dsDNA D2 was first investigated using ESI-MS. Since complexes (15) and (16)
both contain the phenylenediamine moiety, it was considered most appropriate
to compare their DNA-binding properties to that of the symmetrical analogue
(2), which was first discussed in section 4.2. Figure 6.2 shows the ESI mass
spectra of solutions containing a 1:3 ratio of D2 and (2), (15) or (16). Inspection
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of these spectra suggests that unlike (2), both of the asymmetric nickel
complexes lack the ability to bind to this dsDNA to form non-covalent complexes.
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Figure 6.2 – Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:3 ratio. (a) free D2; (b) D2 + (2); (c)
D2 + (15); (d) D2 + (16).  = free D2;  = {D2 + (Ni)};  = {D2 + 2(Ni)}.

When solutions containing higher DNA:metal complex ratios were
examined (data not shown), the ESI mass spectra still showed that there was
limited binding of (15) to D2, whereas (16) failed to show any evidence for
formation of non-covalent complexes. Therefore, the presence of the additional
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aromatic rings in both (15) and (16) had a very detrimental effect on the ability
of the nickel Schiff base complexes to bind to dsDNA. In order to test this
hypothesis, CD spectra were obtained of solutions containing different ratios of
D2 and either (15) or (16). Figure 6.3 compares the CD spectra obtained of
these systems, with those of identical solutions containing the corresponding
“symmetric” complexes (2) and (12). The latter spectra were first shown in
Figure 4.5 and Figure 5.4, respectively. Comparison of the spectra in Figure 6.3
(c) with those in Figure 6.3 (a) shows that the asymmetric complex produces
much smaller changes in position and ellipticity of all CD signals. This indicates
that (15) has a lesser effect than (2) on the conformation of D2. This suggests
that it interacts to a lesser extent with the dsDNA, a conclusion consistent with
the results of the ESI-MS investigation.

Similarly, addition of (16) to D2

appeared to have a smaller effect on the CD spectrum of the latter than addition
of (12), which also contains a propylene linker, suggesting once again that
incorporating additional aromatic ring systems into this class of nickel
complexes does not enhance affinity for dsDNA.
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Figure 6.3 – Circular dichroism spectra (200 – 400 nm) of solutions containing
different ratios of nickel Schiff base complexes and D2: (a) D2 + (2); (b) D2 +
(12); (c) D2 + (15); (d) D2 + (16).

This view was reinforced by the results of DNA melting studies performed
using solutions containing (15) or (16) and D2, which were conducted by
absorption spectrophotometry. The Tm and ΔTm values obtained are presented
in Table 6-1, along with the corresponding values obtained from analogous
experiments performed with (2) and (12), for comparison. Inspection of the
data supports the view that (15) does not interact extensively with D2, as it
produced an increase in Tm of only ~0.8 °C. Whilst addition of (16) resulted in a
larger increase (3.2 °C), this was still less than that induced by addition of (2) or
(12). These results therefore further support the conclusion that the asymmetric
complexes display little tendency to interact with D2. This suggests that the
presence of the additional aromatic ring system in these complexes does not
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facilitate binding, such as through greater opportunity for intercalation with D2.
In contrast, it appears that interactions with the dsDNA have been curtailed to an
extent as a result of the change in structure. One possible explanation for this is
that electrostatic interactions, as opposed to intercalation, play a significant role
in determining the overall strength of the interactions in these systems. Since
the asymmetric complexes have only one piperidine group that can be
protonated, this might be expected to reduce their ability to bind strongly to D2
via an electrostatic mechanism. This possibility could be explored in future work
by examining the effect of varying the ionic strength (by changing the
ammonium acetate concentration) on the appearance of both CD and ESI mass
spectra.

A second possible explanation for the lack of binding of these

asymmetric complexes is that the naphthaldehyde unit may hinder the approach
of the nickel Schiff base molecules to the dsDNA, thereby inhibiting electrostatic
binding.

Finally, it is worth noting that while most effective intercalators

typically have several fused aromatic rings in their structures to facilitate
intercalative interactions, complexes (15) and (16) only have two rings joined
together, which may not be sufficient for this binding mode.

Table 6-1 –DNA melting temperatures (Tm) obtained for solutions containing a
1:3 ratio of D2 and selected nickel Schiff base complexes.
Nickel Complex
Tm (°C)
∆ Tm (°C)
(2)
64.5 ± 0.6
+ 4.4
(12)
64.5 ± 0.2
+ 4.4
(15)
60.9 ± 0.2
+ 0.8
(16)
63.3 ± 0.5
+ 3.2
The Tm of D2 was 60.1 ± 0.3 °C. Error values are standard errors.
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Of the three techniques used, only the measurement of DNA melting points
provided evidence that suggested the presence of the longer linking group in
(16) might endow this complex with some dsDNA binding capacity.

This

hypothesis is not, however, supported by the results of the ESI-MS and CD
studies. Therefore, it appears that the additional methylene group in (16) may
only have a marginal effect, if any, on affinity towards dsDNA molecules.

6. 3 Binding experiments involving quadruplex DNA
The experiments in the previous section suggest that (15) and (16)
interact only to a limited extent with dsDNA. Therefore, if these molecules bind
extensively to one or more types of quadruplex DNA, they could be useful as
selective probes of the latter type of nucleic acid. To investigate this possibility,
ESI-MS was used to investigate solutions containing a 1:3 ratio of Q4(5G) and
one of the asymmetric complexes. The spectra obtained are shown in Figure 6.4,
along with those of solutions containing a 1:3 ratio of the same DNA molecule
and either (2) or (12), for comparison. The spectra of the latter two complexes
and Q4(5G) were previously shown in Figure 4.9 and Figure 5.7, respectively.
Although ions attributable to free Q4(5G) were the dominant features of
spectra of solutions containing the asymmetric complexes (Figure 6.4 (d) and
(e)), there were also ions of low abundance attributable to non-covalent
complexes containing one or two nickel molecules bound to DNA.

The

asymmetric complexes therefore showed greater affinity for Q4(5G) than D2,
however the extent of binding to Q4(5G) was significantly less than that
observed with the two symmetrical nickel complexes (2) and (12).
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different nickel Schiff base complexes at a 1:3 ratio. (a) free Q4(5G); (b) Q4(5G)
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Therefore, based on the results of the ESI-MS study only, it does not
appear likely that either (15) or (16) have the requisite affinity for Q4(5G) to
make them useful as qDNA-selective reagents.
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To explore this further, CD

spectra were obtained of solutions containing Q4(5G) and increasing amounts of
(15) or (16) (Figure 6.5).
The observed changes to the CD spectrum of Q4(5G) were very small,
especially compared to those observed when either (2) or (12) was added to
solutions containing Q4(5G) (Figure 5.10). Overall, the results of the CD study
are consistent with those obtained in the ESI-MS investigation, and strongly
suggest that the introduction of the additional aromatic ring systems to form
complexes (15) and (16) had a detrimental effect on affinity towards the
tetramolecular qDNA.
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Figure 6.5 – Circular dichroism spectra (200–400 nm) of solutions containing
different ratios of nickel Schiff base complexes and Q4(5G): (a) Q4(5G) + (15);
(b) Q4(5G) +(16).

To see if the asymmetric complexes showed any significant binding
affinity towards unimolecular qDNA, ESI mass spectra were obtained of solutions
containing a 1:3 ratio of Q1 and either (15) or (16). These spectra are shown in
Figure 6.6, together with those of the corresponding solutions containing the
symmetric nickel molecules (2) and (12), which were discussed in section 5.2.3.
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Inspection of the spectra suggests that the asymmetric complexes lack
any ability to bind to this type of qDNA, in contrast to (2) and (12). The only
evidence obtained for any binding interaction was found in the spectrum of a
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solution containing a 1:9 ratio of Q1 and (15) (data not shown), which contained
ions of low abundance corresponding to one nickel molecule bound to the DNA.
This is a similar extent of binding to what was observed in solutions containing
D2 and (15) at high DNA:nickel ratios. Therefore, given that ESI mass spectra of
solutions containing either of the symmetrical analogues (2) and (12), and Q1,
displayed ions attributable to non-covalent complexes consisting of one or two
nickel molecules bound to the DNA, the results support the conclusion that the
addition of the extra aromatic ring failed to improve binding to this DNA
molecule.
To investigate this further, CD spectra were obtained of solutions
containing increasing amounts of (15) or (16) and Q1 (Figure 6.7).

Also

included are the CD spectra obtained when identical amounts of the symmetric
analogues (2) and (12) were added to Q1. These spectra were presented earlier
in this thesis (Figure 4.16 and Figure 5.14), but are included again here to
facilitate comparison with the effects of adding (15) or (16) on the CD spectrum
of Q1. Upon titration of Q1 with either (15) or (16), the ellipticity of the CD
signal at 260 nm decreased significantly, although not to the extent elicited by
the addition of the same amount of the symmetrical complexes (Table 6-2). This
was also true for the changes in ellipticity of the negative CD signal. A further
noteworthy aspect of the spectra in Figure 6.7 is that the addition of large
amounts of (16) resulted in the appearance of a distinct shoulder on the low
energy side of the positive CD signal, at 290 nm. This new CD band is close to the
area where one expects to see a signal for antiparallel qDNA, which is typically
around 290 nm.260,262 Therefore, it is possible that whilst the overall strength of
the binding interaction between the normally parallel Q1 and (16) may not be
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sufficient to survive ESI-MS conditions, it may still result in significant
conformational changes to a percentage of the qDNA molecules. This may imply
that (16) interacts with Q1 in a manner slightly different to most of the other
nickel Schiff base complexes investigated, or alternatively that an ICD band has
resulted owing to small changes to the nickel complex induced upon binding to
the qDNA molecule. Furthermore, whilst the overall changes in ellipticity and
position of the CD bands of Q1 induced by (15) and (16) are modest in
comparison to those elicited by (2) and (12), the nature of the interactions in
these systems may be profoundly different.
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Table 6-2 – Effect on the CD spectrum of Q1 of addition of nickel Schiff base
complexes.
Nickel Complex

Positive CD band at 260 nm
Negative CD band at 240 nm
∆λ (nm)
∆ε (mdeg)
∆λ (nm)
∆ε (mdeg)
(2)
2.8
7.0
0.9
1.9
(12)
9.8
8.6
2.0
1.8
(15)
1.4
1.8
-1.4
0.57
(16)
0.6
0.29
0.5
0.17
All Δλ and Δε values are the difference between the values for free DNA and
those for a solution containing a DNA:metal complex ratio of 1:7. Negative ∆λ
values indicate a blue shift; positive values indicate a red shift. ∆ε values are the
difference between ε at this wavelength for the solution containing no metal
complex, and ε at the wavelength of maximum ellipticity for the solution with the
highest DNA:metal complex ratio.

6. 4 Summary
The results of ESI-MS studies involving the two asymmetric complexes
showed that the addition of an additional aromatic moiety to complex (2) or (12)
did not improve binding affinity for any of the various DNA structures examined.
Instead, this structural change resulted in significant decreases in ability to form
non-covalent complexes with DNA. This was somewhat unexpected for the
dsDNA binding studies, where the presence of an extra fused aromatic ring on
the Schiff base ligand was expected to enhance prospects for binding via an
intercalative mechanism. One reason this may have not occurred is because
complexes (15) and (16) only possess one piperidine group which can protonate
in aqueous solution, thus reducing their ability to engage in electrostatic binding.
It should also be noted that increasing the size of the aromatic moiety on the
Schiff base ligand may not enhance binding to G-quadruplexes, as intercalation
may not be the primary mode of interaction with these types of DNA molecules.
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The results of the CD binding studies also indicated that the addition of an
extra aromatic ring to (2) and (12), to form (15) and (16), respectively,
decreased affinity for each of the three types of DNA molecules. In addition, the
slightly longer alkyl chain in (16) did not result in significantly greater binding to
any of the three types of DNA examined, compared to what was observed with
complex (15). However, addition of (15) and, in particular (16), to solutions of
DNA did result in some instances in some surprising changes to CD spectra,
which suggested that they may participate in alternative binding interactions
compared to what was observed with their symmetrical analogues. Of most note
in this context were the changes to the CD spectrum of the unimolecular qDNA
molecule Q1 in the presence of excess (16), which indicated that some significant
changes to the conformation of this DNA molecule had occurred.
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CHAPTER 7 - CONCLUSIONS AND FUTURE
DIRECTIONS
7. 1 Conclusions
The overall aim of this thesis was to investigate the interactions of a
range of structurally diverse nickel Schiff base complexes with several different
types of DNA molecules. Given the potential of quadruplex DNA as a target for
anticancer therapies, the development of an understanding of how changes to
the structure of these metal complexes can lead to new molecules which
interact with higher affinity and selectivity for qDNA is extremely important. In
order to achieve this goal, eleven different alkylated nickel Schiff base
complexes were synthesised in high purity, and characterised using NMR
spectroscopy, ESI-MS and microanalysis. In addition, the solid state structures
of five nickel complexes were determined using X-ray crystallographic methods.
The synthesis of complexes (2) and (12) (Figure 1.42), both of which
contain a 1,2-phenylenediamine moiety, had been previously reported, along
with the results of a DNA binding investigation.150,193 As these prior studies
indicated that (2) and (12) were capable of binding to qDNA structures with a
degree of selectivity, they were chosen as the “lead” complexes for the present
investigation. Initially, it was decided to explore the effect of replacing the 1,2phenylenediamine group with other diamine moieties in the Schiff base, on the
DNA-binding properties of the resulting nickel complexes.
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One of the most significant sets of binding results was obtained with
complex (6) (Figure 1.42), which contains the non-planar, meso-1,2diphenylethylenediamine structural moiety. The results of DNA-binding studies
performed using ESI-MS or a UV melting temperature method, and D2,
suggested that (6) has essentially no affinity for this typical dsDNA molecule.
Addition of complex (6) did affect the principle, positive CD band of D2.
However, the changes to the CD spectrum were still relatively small in
magnitude, and therefore consistent with the conclusion that (6) has only a very
limited affinity towards typical duplex DNA structures. This is most likely
attributable to steric hindrance caused by the non-planar meso-1,2diphenylethylenediamine unit, which would prevent the nickel Schiff base
complex from being able to intercalate between the base pairs of D2, and
perhaps more generally hinder the approach of the nickel complex to the DNA.
In contrast to the above results, both ESI-MS and CD spectroscopy provided
evidence of formation of non-covalent complexes with two different
tetramolecular qDNA molecules. These observations suggest that complex (6)
exhibits a degree of selectivity in its binding interactions, in favour of the latter
type of qDNA over dsDNA.
Experiments aimed at determining whether this selectivity also extended
to unimolecular qDNA molecules, however, were inconclusive. ESI-MS
measurements on solutions containing (6) and the parallel, unimolecular qDNA,
Q1, revealed the absence of any ions attributable to non-covalent complexes. In
contrast, CD spectra showed the metal complex was able to affect the
conformation of the nucleic acid to a greater extent than many other nickel
Schiff base complexes. This proved to be the first of several occasions when
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addition of nickel complexes produced changes to the CD spectrum of a qDNA
molecule, despite ESI-MS showing little evidence for non-covalent complex
formation. This apparent contradiction can be explained by either proposing
that non-covalent complexes are formed between the two binding partners, but
are insufficiently stable to withstand the conditions in the mass spectrometer,
and/or that CD spectroscopy is especially sensitive to small changes in
conformation of the nucleic acid occasioned by very weak binding interactions.
Of these two possible explanations, it would appear that the former is less likely,
owing to the prevalence of non-covalent complexes in spectra of most
nickel/DNA systems examined in this thesis, and general similarity in structure
between the nickel Schiff base complexes. Irrespective of the cause of the
apparent difference in binding affinities for complex (6) towards Q1 obtained
using the two techniques, this observation highlights the need for additional
spectroscopic and other methods to be used to investigate these systems in
future, in order to fully understand the precise nature and extent of the binding
interactions present.
With this in mind, an investigation of the binding of several nickel
complexes, including (6), to a similar, but fluorescently-labelled unimolecular
qDNA molecule, F21T, was performed using FRET. The results of a standard
FRET experiment performed using this qDNA, which has predominantly an
antiparallel conformation, showed that (6) did not interact as extensively as the
lead complex (2).

When a competition FRET study was performed using

solutions containing (6), F21T and a dsDNA sequence, the presence of the latter
was not found to greatly affect the binding of complex (6) to the qDNA molecule.
These results therefore support the view that (6) shows a degree of binding
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selectivity in favour of tetramolecular qDNA, over both dsDNA and unimolecular
qDNA.
Of all four complexes involved in the initial investigation into the effects
of varying the diamine moiety on DNA-binding properties, it was complex (4)
(Figure 1.42) which proved to have the highest affinity towards the dsDNA
molecule D2. ESI mass spectrometry, CD spectroscopy and UV melting studies
all supported this conclusion, which suggests that the presence of the 9,10diaminophenanthrene moiety is favourable for binding to duplex DNA.

In

contrast, complex (8) (Figure 1.42), which was the only one of the four
complexes prepared using a non-aromatic diamine, showed limited ability to
bind to or stabilise D2. The larger 9,10-diaminophenanthrene moiety of (4)
proved to be detrimental when it came to qDNA binding, with both
tetramolecular and unimolecular qDNA binding studies showing that this
complex had very limited ability to interact with a range of qDNA molecules. In
these experiments, the lead complex (2) was found to have the greatest affinity
for the various qDNA molecules.

All of the above results highlight the

importance of the number, size and configuration of the aromatic rings in a
metal complex when it comes to determining its overall DNA-binding
properties.
In a second set of experiments, the effect of changing the length of the
alkyl linkers connecting the piperidine groups to the rest of the Schiff base
ligand, on DNA-binding properties was explored. In general, the longer alkyl
linker chains in (12) and (13) (Figure 1.42) resulted in improved binding ability
towards qDNA, but a decreased level of binding to dsDNA. The results obtained
using ESI-MS, CD spectroscopy, UV-Vis thermal melting studies and FRET
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indicated that (12), in particular, had slightly enhanced qDNA selectivity as a
result of the longer alkyl chain. Since (13) contained the non-planar meso-1,2diphenylethylenediamine moiety, it too showed qDNA selectivity as it had little
ability to bind to dsDNA. Since these pendant groups have been shown in both
molecular modelling and X-ray crystallographic studies to interact with the
grooves of qDNA molecules,149,193 it is possible that the extra methylene groups
in (12) and (13) allow the piperidine units to either reach further into the
groove in order to bind more tightly, or alternatively that they are positioned in
more optimal locations than what is permitted by the ethylene linker groups.
Changing the piperidine groups in several metal complexes to
morpholines resulted in significant inhibition of binding to dsDNA, Q4(5G) and
Q1. ESI mass spectrometry and CD spectroscopy showed little evidence of
interaction between morpholine-containing complexes and any of the three
types of DNA examined. Therefore there appears to be little or no enhancement
in DNA-binding properties to be gained from this specific type of substitution.
The asymmetric complexes (15) and (16) (Figure 1.42) provided some
unexpected results when used in DNA-binding studies. It was anticipated that
they would produce greater evidence of binding to dsDNA than the lead
complex (2), owing to the presence of the additional aromatic ring within the
naphthyl moiety, increasing the intercalative ability of the complexes. However,
there was limited binding to dsDNA observed in ESI-MS, CD spectroscopy and
UV-Vis DNA melting studies. The asymmetric complex containing the longer
alkyl linker group, (16), did provide some improvement in binding relative to
that exhibited by (15), but it was still less than that displayed by both the
symmetrical complexes (2) and (12).
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Binding studies involving (15) or (16) and both types of qDNA also
generally indicated that the extra aromatic ring in (15) and (16) did not
improve affinity or selectivity for qDNA. This may be because the presence of
the additional aromatic ring inhibits these molecules from being able to
orientate themselves so as to interact optimally with the G-quartets of either a
unimolecular or tetramolecular qDNA molecule. Surprisingly, CD spectra of
solutions containing (15) or (16), and Q1, showed spectral changes which
indicated that the conformation of this DNA molecule was being significantly
affected, especially in the case of (16) and Q1, despite ESI mass spectra showing
little evidence of formation of non-covalent complexes.
One additional reason that binding of the asymmetric complexes to either
dsDNA or qDNA may have been limited is that they possess only one
protonatable piperidine group. This would mean that the complexes can only
have a maximum of one positive charge in solutions with a pH ~ 7, and
therefore they would not be able to interact with any type of DNA by an
electrostatic mechanism as strongly as any of the doubly alkylated symmetrical
nickel complexes.

7. 2 Future Directions
The results presented in this thesis raise some interesting questions
regarding the interactions of nickel Schiff base complexes with qDNA structures,
and as such warrant further studies into the structure-activity relationships
between the two types of molecules. The qDNA-binding selectivity exhibited by
nickel complexes containing the non-planar meso-1,2-diphenylethylenediamine
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moiety was one of the most significant observations made during the course of
this work. The meso isomer of this diamine is just one of three diastereoisomers.
Already another student in our laboratory has prepared the two isomers of (6)
using either R,R- or S,S-1,2-diphenylethylenediamine in place of the meso
isomer, and carried out a preliminary investigation of the binding of these two
complexes to both D2 and Q4(5G), using ESI-MS and CD spectroscopy.271
However, the binding interactions in these systems are yet to be explored using
other methods such as FRET, and studies including unimolecular qDNA
molecules have not yet commenced. In addition, it may be profitable to explore
the DNA binding chemistry of nickel complexes containing other non-planar
structural moieties. In this context, nickel complexes of Schiff base ligands
prepared using the isomers of 1,2-diaminocyclohexane may also show a lack of
binding to dsDNA, but could perhaps exhibit improved binding to one or more
types of qDNA molecules.
Some results obtained during the course of this thesis yielded results
which raise further questions and lines of investigation. For example, the NMR
binding studies of (13) with 22AG (discussed in section 5.2.3) showed that two
of the guanine residues on the terminal ends of this quadruplex molecule
remained unaffected by the binding of this complex, bases which would
typically be expected to to be involved in a classic binding event. Further NMR
solution structure studies of these types of systems would allow confirmation of
these results, as well as obtaining an explanation for this phenomenon.
Additionally, obtaining binding constants for the interactions of the nickel Schiff
base complexes investigated during the course of this thesis would allow for
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further quantification and comparison of the complexes and their interactions
with various DNA structures.
Changing the identity of the alkyl groups attached to the Schiff base ligand
was shown in some instances to significantly affect the binding of the nickel
complexes to the various DNA molecules. However, the effect of varying the
position of these alkyl groups on DNA binding was not explored. This could be
readily achieved in future work, by preparing the nickel Schiff base complexes
using either 2,3- or 2,5-dihydroxybenzaldehyde, instead of the 2,4- isomer.
Alkylation of the resulting complexes would yield a range of new materials
whose DNA-binding ability could significantly differ from those reported in this
thesis, by virtue of being able to more favourably position the alkyl groups in
the grooves of qDNA molecules.
Whilst studies carried out as part of this thesis investigated the ability of
nickel complexes to bind to or stabilise various DNA molecules, the techniques
employed were not appropriate for providing information regarding the exact
nature of the binding interactions. A number of future investigations directed at
determining the base pair(s) on dsDNA or qDNA molecules that are involved in
binding to nickel complexes, or the mechanisms of binding, are logical
extensions of the results presented in this thesis. For example, complex (4) was
shown by a variety of methods to interact with D2 to a greater extent than any
other nickel complex examined. Whilst it is tempting to attribute this to a much
greater ability of (4) to act as an intercalator, by virtue of its 9,10diaminophenanthrene moiety, this needs to be confirmed using viscosity
measurements, or by applying techniques such as X-ray crystallography and
NMR spectroscopy. The latter methods, as well as computational chemistry
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techniques, could also be used in future to answer a number of other questions
that arise from the work completed to date. These include why replacing the
piperidines in the pendant chains by morpholine groups had such a negative
influence on binding interactions with all three types of DNA examined. In
addition, the above techniques could be used to address why the asymmetric
complexes did not bind more avidly to some of the DNA molecules, particularly
as it was expected that the presence of the additional aromatic ring might
facilitate stacking interactions with some qDNA molecules. Finally, it is only
solution NMR techniques that will likely shed light on the reasons why some
nickel complexes were able to significantly perturb the CD spectrum of a DNA
molecule, despite ESI-MS studies indicating that there was little evidence of
non-covalent complex formation between the two binding partners. Uncovering
answers to these questions will further enhance future efforts directed towards
preparing nickel Schiff base complexes with greater affinity and selectivity
towards specific types of DNA structures.
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